{
  "usdmVersion": "4.0",
  "generatedAt": "2026-01-23T04:22:59.451190",
  "generator": "Protocol2USDM v6.5.0",
  "study": {
    "id": "cc623ce3-0bdd-4cdb-a0df-df4b514419bd",
    "instanceType": "Study",
    "versions": [
      {
        "id": "50f877ed-2608-442b-95c9-f029b8971a66",
        "instanceType": "StudyVersion",
        "versionIdentifier": "1.0",
        "studyDesigns": [
          {
            "id": "721d04c1-9c49-41b8-b159-092b40460d0d",
            "name": "Study Design",
            "rationale": "Protocol-defined study design for investigating efficacy and safety",
            "instanceType": "InterventionalStudyDesign",
            "blindingSchema": {
              "id": "d4800012-7e8a-431c-b7e5-9bfa05ab139a",
              "standardCode": {
                "id": "81acbca2-169f-4c3a-a3cf-c407e151584b",
                "code": "Open Label",
                "codeSystem": "http://www.cdisc.org",
                "codeSystemVersion": "2024-09-27",
                "decode": "Open Label",
                "instanceType": "Code"
              },
              "instanceType": "AliasCode"
            },
            "randomizationType": {
              "code": "Randomized"
            },
            "arms": [
              {
                "id": "8e1be536-29af-44e2-ab1a-2fa4aec373c6",
                "name": "LY3298176 5 mg",
                "instanceType": "StudyArm",
                "dataOriginDescription": "Collected",
                "description": "Participants receive LY3298176 once weekly with dose titration to a maintenance dose of 5 mg",
                "type": {
                  "id": "C174266",
                  "code": "C174266",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Investigational Arm",
                  "instanceType": "Code"
                },
                "dataOriginType": {
                  "id": "232130f3-c5a5-4305-a1e7-3c87798d7c2a",
                  "code": "C70793",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Collected",
                  "instanceType": "Code"
                }
              },
              {
                "id": "d6df18e7-a054-4d46-8fd1-6cd7e68ff7a6",
                "name": "LY3298176 10 mg",
                "instanceType": "StudyArm",
                "dataOriginDescription": "Collected",
                "description": "Participants receive LY3298176 once weekly with dose titration to a maintenance dose of 10 mg",
                "type": {
                  "id": "C174266",
                  "code": "C174266",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Investigational Arm",
                  "instanceType": "Code"
                },
                "dataOriginType": {
                  "id": "9eebe00b-65ea-4553-b67a-53e54bafe85c",
                  "code": "C70793",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Collected",
                  "instanceType": "Code"
                }
              },
              {
                "id": "932b29b6-2ae5-484c-803b-5d67f4f0604f",
                "name": "LY3298176 15 mg",
                "instanceType": "StudyArm",
                "dataOriginDescription": "Collected",
                "description": "Participants receive LY3298176 once weekly with dose titration to a maintenance dose of 15 mg",
                "type": {
                  "id": "C174266",
                  "code": "C174266",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Investigational Arm",
                  "instanceType": "Code"
                },
                "dataOriginType": {
                  "id": "58e7684b-ebd8-4c42-90cf-0470f7abbf18",
                  "code": "C70793",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Collected",
                  "instanceType": "Code"
                }
              },
              {
                "id": "2ba2fb50-39c6-425f-9dd0-7e9dea6a2626",
                "name": "Insulin Glargine",
                "instanceType": "StudyArm",
                "dataOriginDescription": "Collected",
                "description": "Starting dose of 10 IU/day at bedtime, titrated to a fasting blood glucose <100 mg/dL following a treat-to-target algorithm",
                "type": {
                  "id": "C174267",
                  "code": "C174267",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.12e",
                  "decode": "Active Comparator Arm",
                  "instanceType": "Code"
                },
                "dataOriginType": {
                  "id": "1e95bcb7-1424-4fa3-88e8-314c145ace37",
                  "code": "C70793",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Collected",
                  "instanceType": "Code"
                }
              }
            ],
            "studyCohorts": [],
            "studyCells": [
              {
                "id": "bdbd9cde-e354-4eb2-b1f5-2c9a28be31b4",
                "armId": "8e1be536-29af-44e2-ab1a-2fa4aec373c6",
                "epochId": "38f89303-7b16-408d-b45a-60e38a3bf61c",
                "elementIds": [
                  "5da24f69-8774-4c1b-ba36-88026bd5d9ba"
                ],
                "instanceType": "StudyCell"
              },
              {
                "id": "81e9f724-f483-48fb-9a82-089d835f0a1d",
                "armId": "8e1be536-29af-44e2-ab1a-2fa4aec373c6",
                "epochId": "7cd400af-071d-4c0d-ac31-146e94963378",
                "elementIds": [
                  "edebb53d-b37f-4ca8-b00c-007353b0b7ec"
                ],
                "instanceType": "StudyCell"
              },
              {
                "id": "85cf8235-faab-4e60-b9ec-f3bb950074f2",
                "armId": "8e1be536-29af-44e2-ab1a-2fa4aec373c6",
                "epochId": "b3ce9d66-4927-47d5-b494-3333d89f8438",
                "elementIds": [
                  "a19d7d2e-a80e-4c50-aa81-314c8b4563be"
                ],
                "instanceType": "StudyCell"
              },
              {
                "id": "9d56dfd1-157e-4da4-9607-fb57d71608e9",
                "armId": "8e1be536-29af-44e2-ab1a-2fa4aec373c6",
                "epochId": "f188cb50-86bc-4641-9f26-2d2c65b77eae",
                "elementIds": [
                  "443e3199-53cd-4c3e-973c-0e474a4601cb"
                ],
                "instanceType": "StudyCell"
              },
              {
                "id": "b7e5bd49-c617-4e8d-a4bb-5e536c51d5ec",
                "armId": "d6df18e7-a054-4d46-8fd1-6cd7e68ff7a6",
                "epochId": "38f89303-7b16-408d-b45a-60e38a3bf61c",
                "elementIds": [
                  "1321b27a-5610-463f-b69e-303164bb27c5"
                ],
                "instanceType": "StudyCell"
              },
              {
                "id": "cb35a087-f559-455d-97e2-65276eead122",
                "armId": "d6df18e7-a054-4d46-8fd1-6cd7e68ff7a6",
                "epochId": "7cd400af-071d-4c0d-ac31-146e94963378",
                "elementIds": [
                  "7a1c6d1c-c5c2-474a-be87-a179231629c4"
                ],
                "instanceType": "StudyCell"
              },
              {
                "id": "f4c1c162-4271-4d7b-bf6f-96ddb6d3ac7c",
                "armId": "d6df18e7-a054-4d46-8fd1-6cd7e68ff7a6",
                "epochId": "b3ce9d66-4927-47d5-b494-3333d89f8438",
                "elementIds": [
                  "5877770e-15f5-4ce6-87b8-c5af3aab6c4e"
                ],
                "instanceType": "StudyCell"
              },
              {
                "id": "dbf2200d-2a69-429e-84a6-76728425898a",
                "armId": "d6df18e7-a054-4d46-8fd1-6cd7e68ff7a6",
                "epochId": "f188cb50-86bc-4641-9f26-2d2c65b77eae",
                "elementIds": [
                  "a7fbebab-fe53-4c60-90d3-b365623cb012"
                ],
                "instanceType": "StudyCell"
              },
              {
                "id": "e08c1e48-1205-4f88-bdb8-bbedac2d1c85",
                "armId": "932b29b6-2ae5-484c-803b-5d67f4f0604f",
                "epochId": "38f89303-7b16-408d-b45a-60e38a3bf61c",
                "elementIds": [
                  "d369997c-38b6-422d-9ba1-4ade33253da0"
                ],
                "instanceType": "StudyCell"
              },
              {
                "id": "17c90435-65bd-4b64-aec2-0c46bf280037",
                "armId": "932b29b6-2ae5-484c-803b-5d67f4f0604f",
                "epochId": "7cd400af-071d-4c0d-ac31-146e94963378",
                "elementIds": [
                  "39777f33-76db-4f7e-b2bd-ca1f2c32d9b9"
                ],
                "instanceType": "StudyCell"
              },
              {
                "id": "6a8829f6-a75b-46b0-84a7-5e7c8a9d3bbb",
                "armId": "932b29b6-2ae5-484c-803b-5d67f4f0604f",
                "epochId": "b3ce9d66-4927-47d5-b494-3333d89f8438",
                "elementIds": [
                  "690469c6-1a7f-48bf-a172-a85667989f61"
                ],
                "instanceType": "StudyCell"
              },
              {
                "id": "bce77434-bd83-4dfa-9f1d-c5f8a8be4dec",
                "armId": "932b29b6-2ae5-484c-803b-5d67f4f0604f",
                "epochId": "f188cb50-86bc-4641-9f26-2d2c65b77eae",
                "elementIds": [
                  "5fc7e4fb-f6a1-441d-9507-d1c921b9b9f2"
                ],
                "instanceType": "StudyCell"
              },
              {
                "id": "46e3c2b9-76e7-4ca9-b24e-6040c2eb0366",
                "armId": "2ba2fb50-39c6-425f-9dd0-7e9dea6a2626",
                "epochId": "38f89303-7b16-408d-b45a-60e38a3bf61c",
                "elementIds": [
                  "9168b1bc-f9ce-4bec-a9f6-06695ff45e74"
                ],
                "instanceType": "StudyCell"
              },
              {
                "id": "48a479aa-c193-467c-b404-2e1ed9793a3b",
                "armId": "2ba2fb50-39c6-425f-9dd0-7e9dea6a2626",
                "epochId": "7cd400af-071d-4c0d-ac31-146e94963378",
                "elementIds": [
                  "e6876e84-9585-49e0-85f6-b740c66d15c6"
                ],
                "instanceType": "StudyCell"
              },
              {
                "id": "c7cf819e-7f84-4f61-85e8-cd6408d58741",
                "armId": "2ba2fb50-39c6-425f-9dd0-7e9dea6a2626",
                "epochId": "b3ce9d66-4927-47d5-b494-3333d89f8438",
                "elementIds": [
                  "5d5754e8-928c-4a53-9e70-75889018d79e"
                ],
                "instanceType": "StudyCell"
              },
              {
                "id": "a3358e2a-5816-4db8-ba9c-dcae553fd9fc",
                "armId": "2ba2fb50-39c6-425f-9dd0-7e9dea6a2626",
                "epochId": "f188cb50-86bc-4641-9f26-2d2c65b77eae",
                "elementIds": [
                  "5dbc082b-1682-4610-acee-7182661d7dcf"
                ],
                "instanceType": "StudyCell"
              }
            ],
            "studyElements": [
              {
                "id": "5da24f69-8774-4c1b-ba36-88026bd5d9ba",
                "name": "LY3298176 5 mg - Study Period I: Screening Lead-in",
                "instanceType": "StudyElement",
                "description": "Treatment period for LY3298176 5 mg during Study Period I: Screening Lead-in"
              },
              {
                "id": "edebb53d-b37f-4ca8-b00c-007353b0b7ec",
                "name": "LY3298176 5 mg - Study Period II: 52-Week Treatment Period",
                "instanceType": "StudyElement",
                "description": "Treatment period for LY3298176 5 mg during Study Period II: 52-Week Treatment Period"
              },
              {
                "id": "a19d7d2e-a80e-4c50-aa81-314c8b4563be",
                "name": "LY3298176 5 mg - Study Period III: Variable Treatment Period",
                "instanceType": "StudyElement",
                "description": "Treatment period for LY3298176 5 mg during Study Period III: Variable Treatment Period"
              },
              {
                "id": "443e3199-53cd-4c3e-973c-0e474a4601cb",
                "name": "LY3298176 5 mg - Study Period IV: Safety Follow-up",
                "instanceType": "StudyElement",
                "description": "Treatment period for LY3298176 5 mg during Study Period IV: Safety Follow-up"
              },
              {
                "id": "1321b27a-5610-463f-b69e-303164bb27c5",
                "name": "LY3298176 10 mg - Study Period I: Screening Lead-in",
                "instanceType": "StudyElement",
                "description": "Treatment period for LY3298176 10 mg during Study Period I: Screening Lead-in"
              },
              {
                "id": "7a1c6d1c-c5c2-474a-be87-a179231629c4",
                "name": "LY3298176 10 mg - Study Period II: 52-Week Treatment Period",
                "instanceType": "StudyElement",
                "description": "Treatment period for LY3298176 10 mg during Study Period II: 52-Week Treatment Period"
              },
              {
                "id": "5877770e-15f5-4ce6-87b8-c5af3aab6c4e",
                "name": "LY3298176 10 mg - Study Period III: Variable Treatment Period",
                "instanceType": "StudyElement",
                "description": "Treatment period for LY3298176 10 mg during Study Period III: Variable Treatment Period"
              },
              {
                "id": "a7fbebab-fe53-4c60-90d3-b365623cb012",
                "name": "LY3298176 10 mg - Study Period IV: Safety Follow-up",
                "instanceType": "StudyElement",
                "description": "Treatment period for LY3298176 10 mg during Study Period IV: Safety Follow-up"
              },
              {
                "id": "d369997c-38b6-422d-9ba1-4ade33253da0",
                "name": "LY3298176 15 mg - Study Period I: Screening Lead-in",
                "instanceType": "StudyElement",
                "description": "Treatment period for LY3298176 15 mg during Study Period I: Screening Lead-in"
              },
              {
                "id": "39777f33-76db-4f7e-b2bd-ca1f2c32d9b9",
                "name": "LY3298176 15 mg - Study Period II: 52-Week Treatment Period",
                "instanceType": "StudyElement",
                "description": "Treatment period for LY3298176 15 mg during Study Period II: 52-Week Treatment Period"
              },
              {
                "id": "690469c6-1a7f-48bf-a172-a85667989f61",
                "name": "LY3298176 15 mg - Study Period III: Variable Treatment Period",
                "instanceType": "StudyElement",
                "description": "Treatment period for LY3298176 15 mg during Study Period III: Variable Treatment Period"
              },
              {
                "id": "5fc7e4fb-f6a1-441d-9507-d1c921b9b9f2",
                "name": "LY3298176 15 mg - Study Period IV: Safety Follow-up",
                "instanceType": "StudyElement",
                "description": "Treatment period for LY3298176 15 mg during Study Period IV: Safety Follow-up"
              },
              {
                "id": "9168b1bc-f9ce-4bec-a9f6-06695ff45e74",
                "name": "Insulin Glargine - Study Period I: Screening Lead-in",
                "instanceType": "StudyElement",
                "description": "Treatment period for Insulin Glargine during Study Period I: Screening Lead-in"
              },
              {
                "id": "e6876e84-9585-49e0-85f6-b740c66d15c6",
                "name": "Insulin Glargine - Study Period II: 52-Week Treatment Period",
                "instanceType": "StudyElement",
                "description": "Treatment period for Insulin Glargine during Study Period II: 52-Week Treatment Period"
              },
              {
                "id": "5d5754e8-928c-4a53-9e70-75889018d79e",
                "name": "Insulin Glargine - Study Period III: Variable Treatment Period",
                "instanceType": "StudyElement",
                "description": "Treatment period for Insulin Glargine during Study Period III: Variable Treatment Period"
              },
              {
                "id": "5dbc082b-1682-4610-acee-7182661d7dcf",
                "name": "Insulin Glargine - Study Period IV: Safety Follow-up",
                "instanceType": "StudyElement",
                "description": "Treatment period for Insulin Glargine during Study Period IV: Safety Follow-up"
              }
            ],
            "maskingRoles": [
              {
                "id": "269be1ff-c8fc-4a5e-a66d-f9c2061fe8dd",
                "text": "This is an Open Label study with no masking",
                "isMasked": false,
                "instanceType": "Masking"
              }
            ],
            "eligibilityCriteria": [
              {
                "id": "6c21993e-79b9-4ebb-8d37-9e7cb2c104bb",
                "identifier": "1",
                "category": {
                  "id": "C25532",
                  "code": "C25532",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Inclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "58cce86d-0d0d-4f25-b3fe-040e65804d5c",
                "instanceType": "EligibilityCriterion",
                "name": "T2DM Diagnosis",
                "nextId": "37c7565e-899d-432e-bca3-d8f3424b91bc"
              },
              {
                "id": "37c7565e-899d-432e-bca3-d8f3424b91bc",
                "identifier": "2",
                "category": {
                  "id": "C25532",
                  "code": "C25532",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Inclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "e760185b-8629-43cc-b6c5-9e76eba2b158",
                "instanceType": "EligibilityCriterion",
                "name": "HbA1c Range",
                "previousId": "6c21993e-79b9-4ebb-8d37-9e7cb2c104bb",
                "nextId": "a9ddd87c-4eb5-4b12-ba20-a8304598f22b"
              },
              {
                "id": "a9ddd87c-4eb5-4b12-ba20-a8304598f22b",
                "identifier": "3",
                "category": {
                  "id": "C25532",
                  "code": "C25532",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Inclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "1388a367-9835-4502-bf2c-ae7abe53453b",
                "instanceType": "EligibilityCriterion",
                "name": "Stable Oral Antihyperglycemic Treatment",
                "previousId": "37c7565e-899d-432e-bca3-d8f3424b91bc",
                "nextId": "78bf7321-739e-428b-a51f-777f6dc3b1b2"
              },
              {
                "id": "78bf7321-739e-428b-a51f-777f6dc3b1b2",
                "identifier": "4",
                "category": {
                  "id": "C25532",
                  "code": "C25532",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Inclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "71e9f429-c7d3-4eb5-95dd-168e71f044f8",
                "instanceType": "EligibilityCriterion",
                "name": "Increased CV Risk",
                "previousId": "a9ddd87c-4eb5-4b12-ba20-a8304598f22b",
                "nextId": "76f74dd5-96ae-4129-9480-16f1a4b02584"
              },
              {
                "id": "76f74dd5-96ae-4129-9480-16f1a4b02584",
                "identifier": "5",
                "category": {
                  "id": "C25532",
                  "code": "C25532",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Inclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "84b43ed5-e1f7-4787-8bbb-ac509ec7a4ed",
                "instanceType": "EligibilityCriterion",
                "name": "Stable Weight",
                "previousId": "78bf7321-739e-428b-a51f-777f6dc3b1b2",
                "nextId": "b2fffc67-a6ff-46f3-a29f-4204544e2d01"
              },
              {
                "id": "b2fffc67-a6ff-46f3-a29f-4204544e2d01",
                "identifier": "6",
                "category": {
                  "id": "C25532",
                  "code": "C25532",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Inclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "1a0e26db-a667-4f66-9c62-ab090639aaa7",
                "instanceType": "EligibilityCriterion",
                "name": "BMI Requirement",
                "previousId": "76f74dd5-96ae-4129-9480-16f1a4b02584",
                "nextId": "3dd2865f-f647-48c6-9918-c341185973c0"
              },
              {
                "id": "3dd2865f-f647-48c6-9918-c341185973c0",
                "identifier": "7",
                "category": {
                  "id": "C25532",
                  "code": "C25532",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Inclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "171265aa-1314-4d2a-8f04-968c18666e51",
                "instanceType": "EligibilityCriterion",
                "name": "Age and Contraception",
                "previousId": "b2fffc67-a6ff-46f3-a29f-4204544e2d01",
                "nextId": "6ddeba4d-4a2e-49b3-baf4-e71511419a46"
              },
              {
                "id": "6ddeba4d-4a2e-49b3-baf4-e71511419a46",
                "identifier": "8",
                "category": {
                  "id": "C25532",
                  "code": "C25532",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Inclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "62df65e3-64c4-4172-b670-8a07d9240f11",
                "instanceType": "EligibilityCriterion",
                "name": "Motivation and Capability",
                "previousId": "3dd2865f-f647-48c6-9918-c341185973c0",
                "nextId": "a12c5bb8-1dd6-42a6-8947-0cbdd1d178b3"
              },
              {
                "id": "a12c5bb8-1dd6-42a6-8947-0cbdd1d178b3",
                "identifier": "9",
                "category": {
                  "id": "C25532",
                  "code": "C25532",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Inclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "14f04edb-492f-47e3-987c-af24d8a5a9e4",
                "instanceType": "EligibilityCriterion",
                "name": "Informed Consent",
                "previousId": "6ddeba4d-4a2e-49b3-baf4-e71511419a46"
              },
              {
                "id": "2cfe5482-0f3f-4ae4-8f1e-812c8a3936fc",
                "identifier": "10",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "24eb1727-a242-44d4-840f-8c22153d028a",
                "instanceType": "EligibilityCriterion",
                "name": "Type 1 Diabetes",
                "nextId": "e223d596-1de0-466b-b1fb-48fbf55c922d"
              },
              {
                "id": "e223d596-1de0-466b-b1fb-48fbf55c922d",
                "identifier": "11",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "ba70b236-862b-4423-9636-8f2a683ec588",
                "instanceType": "EligibilityCriterion",
                "name": "Pancreatitis History",
                "previousId": "2cfe5482-0f3f-4ae4-8f1e-812c8a3936fc",
                "nextId": "4906a74a-f063-43a0-a257-b954b92018f5"
              },
              {
                "id": "4906a74a-f063-43a0-a257-b954b92018f5",
                "identifier": "12",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "c5d36a39-be5c-438c-8436-1d9f218a0ab9",
                "instanceType": "EligibilityCriterion",
                "name": "Diabetic Retinopathy",
                "previousId": "e223d596-1de0-466b-b1fb-48fbf55c922d",
                "nextId": "5c42344c-bd3a-40b2-8114-f75939c5c6db"
              },
              {
                "id": "5c42344c-bd3a-40b2-8114-f75939c5c6db",
                "identifier": "13",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "ea949626-9d26-4daa-9cf6-f6e51ccc1e8e",
                "instanceType": "EligibilityCriterion",
                "name": "Ketoacidosis History",
                "previousId": "4906a74a-f063-43a0-a257-b954b92018f5",
                "nextId": "cb04f741-df13-4569-81ba-f3fab4a3b5ca"
              },
              {
                "id": "cb04f741-df13-4569-81ba-f3fab4a3b5ca",
                "identifier": "14",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "4bae81cf-13ba-4cdd-b0fb-c90c6e51bdfe",
                "instanceType": "EligibilityCriterion",
                "name": "Severe Hypoglycemia",
                "previousId": "5c42344c-bd3a-40b2-8114-f75939c5c6db",
                "nextId": "aba45f57-6739-4112-964a-79840cad29e9"
              },
              {
                "id": "aba45f57-6739-4112-964a-79840cad29e9",
                "identifier": "15",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "2b590e10-8e33-487d-92d2-6110f3119c72",
                "instanceType": "EligibilityCriterion",
                "name": "Gastric Emptying Abnormality",
                "previousId": "cb04f741-df13-4569-81ba-f3fab4a3b5ca",
                "nextId": "d33c9b4d-5500-4dff-a88f-276dbedcc818"
              },
              {
                "id": "d33c9b4d-5500-4dff-a88f-276dbedcc818",
                "identifier": "16",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "66ce6876-09c0-451b-895a-ba4863db6b76",
                "instanceType": "EligibilityCriterion",
                "name": "NYHA Class IV CHF",
                "previousId": "aba45f57-6739-4112-964a-79840cad29e9",
                "nextId": "4963fc3c-af7c-4182-84a7-03ffadf54683"
              },
              {
                "id": "4963fc3c-af7c-4182-84a7-03ffadf54683",
                "identifier": "17",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "8d62c56a-3ef5-4368-8f41-8be06879d19b",
                "instanceType": "EligibilityCriterion",
                "name": "Recent CV Conditions",
                "previousId": "d33c9b4d-5500-4dff-a88f-276dbedcc818",
                "nextId": "0a0fcfc9-4e22-4256-834d-c32b23afea5f"
              },
              {
                "id": "0a0fcfc9-4e22-4256-834d-c32b23afea5f",
                "identifier": "18",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "40f6f06b-bbab-4ba3-aeae-97abd274f3f4",
                "instanceType": "EligibilityCriterion",
                "name": "Liver Disease",
                "previousId": "4963fc3c-af7c-4182-84a7-03ffadf54683",
                "nextId": "8d7e769a-3a17-41f4-8de6-a700dbdcfcee"
              },
              {
                "id": "8d7e769a-3a17-41f4-8de6-a700dbdcfcee",
                "identifier": "19",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "91363638-3d45-4f70-ae3f-859737a37b6b",
                "instanceType": "EligibilityCriterion",
                "name": "Endocrine Abnormality",
                "previousId": "0a0fcfc9-4e22-4256-834d-c32b23afea5f",
                "nextId": "f1538764-1092-43e8-b0a7-ac353424cce1"
              },
              {
                "id": "f1538764-1092-43e8-b0a7-ac353424cce1",
                "identifier": "20",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "dfe93147-ca4a-4a70-ab96-644f3f9e9e38",
                "instanceType": "EligibilityCriterion",
                "name": "Thyroid Carcinoma History",
                "previousId": "8d7e769a-3a17-41f4-8de6-a700dbdcfcee",
                "nextId": "2c0698cb-a1ca-47bb-ac6a-5f1062a16f07"
              },
              {
                "id": "2c0698cb-a1ca-47bb-ac6a-5f1062a16f07",
                "identifier": "21",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "80db5d26-57f8-49cf-b599-54febea34e52",
                "instanceType": "EligibilityCriterion",
                "name": "Serum Calcitonin Level",
                "previousId": "f1538764-1092-43e8-b0a7-ac353424cce1",
                "nextId": "6db95687-a143-4310-906e-ef24d9470c60"
              },
              {
                "id": "6db95687-a143-4310-906e-ef24d9470c60",
                "identifier": "22",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "3f80df5d-91b1-4f7f-9068-03888ad8fb33",
                "instanceType": "EligibilityCriterion",
                "name": "Autoimmune Abnormality",
                "previousId": "2c0698cb-a1ca-47bb-ac6a-5f1062a16f07",
                "nextId": "84a1dcc0-9984-45a1-a6a9-5a28f5a7bba3"
              },
              {
                "id": "84a1dcc0-9984-45a1-a6a9-5a28f5a7bba3",
                "identifier": "23",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "53e409dd-812a-47a1-9152-c0f9d3bdc1d2",
                "instanceType": "EligibilityCriterion",
                "name": "Product Hypersensitivity",
                "previousId": "6db95687-a143-4310-906e-ef24d9470c60",
                "nextId": "e9a4c3ce-36c4-4fdb-89bd-40f68a108f8d"
              },
              {
                "id": "e9a4c3ce-36c4-4fdb-89bd-40f68a108f8d",
                "identifier": "24",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "9acfd639-ad05-4e5e-a7bc-a865b88e65c1",
                "instanceType": "EligibilityCriterion",
                "name": "Insulin Glargine Hypersensitivity",
                "previousId": "84a1dcc0-9984-45a1-a6a9-5a28f5a7bba3",
                "nextId": "9490bbe6-5d10-42df-9e7b-188420ff2d56"
              },
              {
                "id": "9490bbe6-5d10-42df-9e7b-188420ff2d56",
                "identifier": "25",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "d1b31a4d-37e9-42c8-b5f9-3fd7af3e38e0",
                "instanceType": "EligibilityCriterion",
                "name": "Organ Transplant",
                "previousId": "e9a4c3ce-36c4-4fdb-89bd-40f68a108f8d",
                "nextId": "4ff3aec6-df8e-4b80-8676-5a1c054f6619"
              },
              {
                "id": "4ff3aec6-df8e-4b80-8676-5a1c054f6619",
                "identifier": "26",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "03987741-4427-4da6-b663-1d7fe36a6343",
                "instanceType": "EligibilityCriterion",
                "name": "Malignancy History",
                "previousId": "9490bbe6-5d10-42df-9e7b-188420ff2d56",
                "nextId": "2029d8a7-3358-4a5a-ad38-454902765dc2"
              },
              {
                "id": "2029d8a7-3358-4a5a-ad38-454902765dc2",
                "identifier": "27",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "15b7bc28-dd0e-41b0-bee7-fe19fa9cdece",
                "instanceType": "EligibilityCriterion",
                "name": "Other Conditions",
                "previousId": "4ff3aec6-df8e-4b80-8676-5a1c054f6619",
                "nextId": "f6d6f979-0434-4c06-aa84-6ebea83a4ada"
              },
              {
                "id": "f6d6f979-0434-4c06-aa84-6ebea83a4ada",
                "identifier": "28",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "293a802c-815e-47e2-bc60-92b49372d398",
                "instanceType": "EligibilityCriterion",
                "name": "Hematological Condition",
                "previousId": "2029d8a7-3358-4a5a-ad38-454902765dc2",
                "nextId": "7ec93a50-decc-4fff-9897-6f07dce323f3"
              },
              {
                "id": "7ec93a50-decc-4fff-9897-6f07dce323f3",
                "identifier": "29",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "ed396ee4-4e6f-4d04-b8bb-bed6d6df2dc6",
                "instanceType": "EligibilityCriterion",
                "name": "Insulin Therapy History",
                "previousId": "f6d6f979-0434-4c06-aa84-6ebea83a4ada",
                "nextId": "93e2a53d-aff6-47e8-8697-ec4b70cd9ebb"
              },
              {
                "id": "93e2a53d-aff6-47e8-8697-ec4b70cd9ebb",
                "identifier": "30",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "0010d932-dc87-4058-847c-e692e492bc10",
                "instanceType": "EligibilityCriterion",
                "name": "Other Glucose-Lowering Agents",
                "previousId": "7ec93a50-decc-4fff-9897-6f07dce323f3",
                "nextId": "0f5a271a-a30b-4d59-8a74-9849d9dd07f3"
              },
              {
                "id": "0f5a271a-a30b-4d59-8a74-9849d9dd07f3",
                "identifier": "31",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "4609541e-379e-41f2-b236-ba8b58c84761",
                "instanceType": "EligibilityCriterion",
                "name": "Glucocorticoid Therapy",
                "previousId": "93e2a53d-aff6-47e8-8697-ec4b70cd9ebb",
                "nextId": "2e6cc1d9-39e2-4446-a0a8-58951dec668d"
              },
              {
                "id": "2e6cc1d9-39e2-4446-a0a8-58951dec668d",
                "identifier": "32",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "881f84c1-0f7e-4338-9f0a-1760bc422c91",
                "instanceType": "EligibilityCriterion",
                "name": "Weight Loss Drugs",
                "previousId": "0f5a271a-a30b-4d59-8a74-9849d9dd07f3",
                "nextId": "1e89d275-ea6e-4ca0-b905-662d3642a15a"
              },
              {
                "id": "1e89d275-ea6e-4ca0-b905-662d3642a15a",
                "identifier": "33",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "793e55c4-952e-4be9-adde-d90a83b09459",
                "instanceType": "EligibilityCriterion",
                "name": "Concurrent Clinical Study",
                "previousId": "2e6cc1d9-39e2-4446-a0a8-58951dec668d",
                "nextId": "908411bc-0e04-4eb2-9684-1c3f22221c00"
              },
              {
                "id": "908411bc-0e04-4eb2-9684-1c3f22221c00",
                "identifier": "34",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "3ec2019c-611f-43bb-a113-ea40a44da437",
                "instanceType": "EligibilityCriterion",
                "name": "Recent Investigational Product",
                "previousId": "1e89d275-ea6e-4ca0-b905-662d3642a15a",
                "nextId": "6cf58c2d-b1ba-41a2-9895-e49ce54f2ad4"
              },
              {
                "id": "6cf58c2d-b1ba-41a2-9895-e49ce54f2ad4",
                "identifier": "35",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "67fe5218-1fca-4dbe-8a74-7642030f89e0",
                "instanceType": "EligibilityCriterion",
                "name": "Previous LY3298176 Study",
                "previousId": "908411bc-0e04-4eb2-9684-1c3f22221c00",
                "nextId": "f570a023-2864-4b3b-b257-6f3819aaa2a8"
              },
              {
                "id": "f570a023-2864-4b3b-b257-6f3819aaa2a8",
                "identifier": "36",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "9921029b-36c6-4e21-ae4d-5cecd7268b07",
                "instanceType": "EligibilityCriterion",
                "name": "Site Personnel",
                "previousId": "6cf58c2d-b1ba-41a2-9895-e49ce54f2ad4",
                "nextId": "3cc4f90c-aa5c-4f74-b158-62b034df7737"
              },
              {
                "id": "3cc4f90c-aa5c-4f74-b158-62b034df7737",
                "identifier": "37",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "b8d8b132-cb97-4319-a8b9-273a52c63e4d",
                "instanceType": "EligibilityCriterion",
                "name": "Lilly Employees",
                "previousId": "f570a023-2864-4b3b-b257-6f3819aaa2a8",
                "nextId": "860d37c8-a7f0-4972-b701-8a143e8555d3"
              },
              {
                "id": "860d37c8-a7f0-4972-b701-8a143e8555d3",
                "identifier": "38",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "cb2e8f2c-fb96-4e30-9e58-fba5cf08a7ec",
                "instanceType": "EligibilityCriterion",
                "name": "Diary Compliance",
                "previousId": "3cc4f90c-aa5c-4f74-b158-62b034df7737"
              }
            ],
            "population": {
              "id": "2a45f8a7-64ca-49d3-afd3-6929cbd24249",
              "name": "Study Population",
              "includesHealthySubjects": false,
              "criterionIds": [
                "6c21993e-79b9-4ebb-8d37-9e7cb2c104bb",
                "37c7565e-899d-432e-bca3-d8f3424b91bc",
                "a9ddd87c-4eb5-4b12-ba20-a8304598f22b",
                "78bf7321-739e-428b-a51f-777f6dc3b1b2",
                "76f74dd5-96ae-4129-9480-16f1a4b02584",
                "b2fffc67-a6ff-46f3-a29f-4204544e2d01",
                "3dd2865f-f647-48c6-9918-c341185973c0",
                "6ddeba4d-4a2e-49b3-baf4-e71511419a46",
                "a12c5bb8-1dd6-42a6-8947-0cbdd1d178b3",
                "2cfe5482-0f3f-4ae4-8f1e-812c8a3936fc",
                "e223d596-1de0-466b-b1fb-48fbf55c922d",
                "4906a74a-f063-43a0-a257-b954b92018f5",
                "5c42344c-bd3a-40b2-8114-f75939c5c6db",
                "cb04f741-df13-4569-81ba-f3fab4a3b5ca",
                "aba45f57-6739-4112-964a-79840cad29e9",
                "d33c9b4d-5500-4dff-a88f-276dbedcc818",
                "4963fc3c-af7c-4182-84a7-03ffadf54683",
                "0a0fcfc9-4e22-4256-834d-c32b23afea5f",
                "8d7e769a-3a17-41f4-8de6-a700dbdcfcee",
                "f1538764-1092-43e8-b0a7-ac353424cce1",
                "2c0698cb-a1ca-47bb-ac6a-5f1062a16f07",
                "6db95687-a143-4310-906e-ef24d9470c60",
                "84a1dcc0-9984-45a1-a6a9-5a28f5a7bba3",
                "e9a4c3ce-36c4-4fdb-89bd-40f68a108f8d",
                "9490bbe6-5d10-42df-9e7b-188420ff2d56",
                "4ff3aec6-df8e-4b80-8676-5a1c054f6619",
                "2029d8a7-3358-4a5a-ad38-454902765dc2",
                "f6d6f979-0434-4c06-aa84-6ebea83a4ada",
                "7ec93a50-decc-4fff-9897-6f07dce323f3",
                "93e2a53d-aff6-47e8-8697-ec4b70cd9ebb",
                "0f5a271a-a30b-4d59-8a74-9849d9dd07f3",
                "2e6cc1d9-39e2-4446-a0a8-58951dec668d",
                "1e89d275-ea6e-4ca0-b905-662d3642a15a",
                "908411bc-0e04-4eb2-9684-1c3f22221c00",
                "6cf58c2d-b1ba-41a2-9895-e49ce54f2ad4",
                "f570a023-2864-4b3b-b257-6f3819aaa2a8",
                "3cc4f90c-aa5c-4f74-b158-62b034df7737",
                "860d37c8-a7f0-4972-b701-8a143e8555d3"
              ],
              "instanceType": "StudyDesignPopulation",
              "description": "Target population defined by eligibility criteria"
            },
            "objectives": [
              {
                "id": "223ee35e-ff38-486c-80ac-baef25a98719",
                "name": "Primary Efficacy Objective",
                "text": "To demonstrate that QW LY3298176 10 mg and/or 15 mg is noninferior to insulin glargine for change from baseline in HbA1c at 52 weeks",
                "level": {
                  "id": "C85826",
                  "code": "C85826",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Trial Primary Objective",
                  "instanceType": "Code"
                },
                "endpointIds": [
                  "c2751c57-26e3-44b6-81e4-c3b30f83f411"
                ],
                "instanceType": "Objective"
              },
              {
                "id": "217a6694-26ac-4c42-8dbc-f484b7960410",
                "name": "Key Secondary Efficacy Objective 1",
                "text": "To demonstrate that QW LY3298176 5 mg is noninferior to insulin glargine for change from baseline in HbA1c at 52 weeks",
                "level": {
                  "id": "C85827",
                  "code": "C85827",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Trial Secondary Objective",
                  "instanceType": "Code"
                },
                "endpointIds": [
                  "dd354d38-6065-4f10-951c-c3e42b57949d"
                ],
                "instanceType": "Objective"
              },
              {
                "id": "c23f64c1-3517-4294-8af0-f29295f662f8",
                "name": "Key Secondary Efficacy Objective 2",
                "text": "To demonstrate that QW LY3298176 5 mg, 10 mg, and/or 15 mg is superior to insulin glargine for change from baseline in weight at 52 weeks",
                "level": {
                  "id": "C85827",
                  "code": "C85827",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Trial Secondary Objective",
                  "instanceType": "Code"
                },
                "endpointIds": [
                  "2a91e2be-9449-4a30-8ee6-1ee722e06307"
                ],
                "instanceType": "Objective"
              },
              {
                "id": "34f7cfe1-d51c-4545-9069-3de57212fb78",
                "name": "Key Secondary Efficacy Objective 3",
                "text": "To demonstrate that QW LY3298176 5 mg, 10 mg, and/or 15 mg is superior to insulin glargine for change from baseline in HbA1c at 52 weeks",
                "level": {
                  "id": "C85827",
                  "code": "C85827",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Trial Secondary Objective",
                  "instanceType": "Code"
                },
                "endpointIds": [
                  "b19a9dc5-c807-4cbc-a87e-cd9adff9f7b2"
                ],
                "instanceType": "Objective"
              },
              {
                "id": "75d71bf4-7c6c-40e9-a80e-97f00472f22d",
                "name": "Key Secondary Efficacy Objective 4",
                "text": "To demonstrate that QW LY3298176 5 mg, 10 mg, and/or 15 mg is superior to insulin glargine for the proportion of patients with HbA1c target values of <7.0% (53 mmol/mol) at 52 weeks",
                "level": {
                  "id": "C85827",
                  "code": "C85827",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Trial Secondary Objective",
                  "instanceType": "Code"
                },
                "endpointIds": [
                  "b197a44e-1def-4887-8a71-cfbd4f689bc7"
                ],
                "instanceType": "Objective"
              },
              {
                "id": "4d7a650a-20f1-4eaa-ae15-a910212fc614",
                "name": "Additional Secondary Efficacy Objective",
                "text": "To demonstrate that QW LY3298176 5 mg, 10 mg, and/or 15 mg is superior to insulin glargine at 52 weeks",
                "level": {
                  "id": "C85827",
                  "code": "C85827",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Trial Secondary Objective",
                  "instanceType": "Code"
                },
                "endpointIds": [
                  "dc7f9c82-b566-4f21-ac72-4fbd2a7f2fe3",
                  "22bcbc5e-265a-4816-a1cd-b53b74e60adb",
                  "43f6071a-0362-4721-a833-82570ce2e60d",
                  "5db7b08f-9b98-403d-9b1e-de9a6ba312da"
                ],
                "instanceType": "Objective"
              },
              {
                "id": "e8b80c15-e126-493c-a042-33dd532081c8",
                "name": "Secondary Safety Objective",
                "text": "To compare the safety of LY3298176 5 mg, 10 mg, and 15 mg LY3298176 to insulin glargine at 52 weeks and at the end of the safety follow-up period",
                "level": {
                  "id": "C85827",
                  "code": "C85827",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Trial Secondary Objective",
                  "instanceType": "Code"
                },
                "endpointIds": [
                  "1e9bf2b4-1759-46e3-b028-51b2dbc08584",
                  "f8d1c98f-8aa4-492b-a23e-061014e0f2f7",
                  "25921c88-d3dd-46fb-a499-a633ae0b1d22",
                  "dc476cb3-ebef-41b5-8d0f-f0970f5f5f47",
                  "f2edd78b-63d3-4c7e-9fc9-dd00bfb8d725",
                  "d463d49f-5060-4fa1-b1b3-b18c4a91fb5b",
                  "c9e0baa4-a7b9-4be7-baed-6f9857a54fc2",
                  "5f250779-58ac-48e2-abaf-9caf4099fe08",
                  "ef8e697a-7403-412d-b853-261df98637ca"
                ],
                "instanceType": "Objective"
              },
              {
                "id": "a6210517-a0e0-448c-b713-81d4e298b635",
                "name": "Secondary Pharmacokinetics Objective",
                "text": "To characterize the pharmacokinetics (PK) of LY3298176 5 mg, 10 mg, and 15 mg and evaluate the relationships between LY3298176 exposure and safety, tolerability, and efficacy measures",
                "level": {
                  "id": "C85827",
                  "code": "C85827",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Trial Secondary Objective",
                  "instanceType": "Code"
                },
                "endpointIds": [
                  "d33dc577-55d5-4dcb-b000-ae0db25a389d"
                ],
                "instanceType": "Objective"
              },
              {
                "id": "bd0f252e-89f6-4e0d-89c7-a1a464947f32",
                "name": "Exploratory Glycemic Objective",
                "text": "To characterize long-term glycemic control with LY3298176 5 mg, 10 mg, and 15 mg",
                "level": {
                  "id": "C163559",
                  "code": "C163559",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Trial Exploratory Objective",
                  "instanceType": "Code"
                },
                "endpointIds": [
                  "9ad6d682-c6c6-4a98-a3f5-09a808bb1928"
                ],
                "instanceType": "Objective"
              },
              {
                "id": "47f6f9a8-571f-41cd-9ef8-09795d9aed33",
                "name": "Exploratory Comparison Objective",
                "text": "To compare LY3298176 5 mg, 10 mg, and 15 mg to insulin glargine with respect to lipids, BMI, waist circumference, biomarkers, and PROs",
                "level": {
                  "id": "C163559",
                  "code": "C163559",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Trial Exploratory Objective",
                  "instanceType": "Code"
                },
                "endpointIds": [
                  "4000f87b-7259-4090-b34b-d62be64859ca",
                  "c4efea1a-9e7a-41ec-af3d-6802fe988a75",
                  "c958996c-f9d5-4628-b2a6-3ec639eced12",
                  "54b4914e-6d3d-4900-a1ff-ab7d423033a4",
                  "e28ab95c-eab6-49eb-b1ed-c62d2cba5622"
                ],
                "instanceType": "Objective"
              }
            ],
            "endpoints": [
              {
                "id": "c2751c57-26e3-44b6-81e4-c3b30f83f411",
                "name": "Primary HbA1c Endpoint",
                "text": "Mean change in HbA1c",
                "level": {
                  "id": "C98772",
                  "code": "C98772",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Primary Outcome Measure",
                  "instanceType": "Code"
                },
                "instanceType": "Endpoint",
                "purpose": "Efficacy"
              },
              {
                "id": "dd354d38-6065-4f10-951c-c3e42b57949d",
                "name": "Key Secondary HbA1c Endpoint",
                "text": "Mean change in HbA1c",
                "level": {
                  "id": "C98781",
                  "code": "C98781",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Secondary Outcome Measure",
                  "instanceType": "Code"
                },
                "instanceType": "Endpoint",
                "purpose": "Efficacy"
              },
              {
                "id": "2a91e2be-9449-4a30-8ee6-1ee722e06307",
                "name": "Body Weight Endpoint",
                "text": "Mean change in body weight",
                "level": {
                  "id": "C98781",
                  "code": "C98781",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Secondary Outcome Measure",
                  "instanceType": "Code"
                },
                "instanceType": "Endpoint",
                "purpose": "Efficacy"
              },
              {
                "id": "b19a9dc5-c807-4cbc-a87e-cd9adff9f7b2",
                "name": "Superiority HbA1c Endpoint",
                "text": "Mean change in HbA1c",
                "level": {
                  "id": "C98781",
                  "code": "C98781",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Secondary Outcome Measure",
                  "instanceType": "Code"
                },
                "instanceType": "Endpoint",
                "purpose": "Efficacy"
              },
              {
                "id": "b197a44e-1def-4887-8a71-cfbd4f689bc7",
                "name": "HbA1c Target <7.0% Endpoint",
                "text": "HbA1c",
                "level": {
                  "id": "C98781",
                  "code": "C98781",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Secondary Outcome Measure",
                  "instanceType": "Code"
                },
                "instanceType": "Endpoint",
                "purpose": "Efficacy"
              },
              {
                "id": "dc7f9c82-b566-4f21-ac72-4fbd2a7f2fe3",
                "name": "Fasting Serum Glucose Endpoint",
                "text": "The mean change in fasting serum glucose (central laboratory) from baseline",
                "level": {
                  "id": "C98781",
                  "code": "C98781",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Secondary Outcome Measure",
                  "instanceType": "Code"
                },
                "instanceType": "Endpoint",
                "purpose": "Efficacy"
              },
              {
                "id": "22bcbc5e-265a-4816-a1cd-b53b74e60adb",
                "name": "HbA1c Target 6.5% and <5.7% Endpoint",
                "text": "The proportion of patients achieving an HbA1c target value of 6.5% (48 mmol/mol) and <5.7% (39 mmol/mol)",
                "level": {
                  "id": "C98781",
                  "code": "C98781",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Secondary Outcome Measure",
                  "instanceType": "Code"
                },
                "instanceType": "Endpoint",
                "purpose": "Efficacy"
              },
              {
                "id": "43f6071a-0362-4721-a833-82570ce2e60d",
                "name": "SMBG Profile Endpoint",
                "text": "Mean change in 7-point self-monitored blood glucose profiles from baseline",
                "level": {
                  "id": "C98781",
                  "code": "C98781",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Secondary Outcome Measure",
                  "instanceType": "Code"
                },
                "instanceType": "Endpoint",
                "purpose": "Efficacy"
              },
              {
                "id": "5db7b08f-9b98-403d-9b1e-de9a6ba312da",
                "name": "Weight Loss Percentage Endpoint",
                "text": "Proportion of patients who achieved weight loss of 5%, >10%, and >15% from baseline",
                "level": {
                  "id": "C98781",
                  "code": "C98781",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Secondary Outcome Measure",
                  "instanceType": "Code"
                },
                "instanceType": "Endpoint",
                "purpose": "Efficacy"
              },
              {
                "id": "1e9bf2b4-1759-46e3-b028-51b2dbc08584",
                "name": "TEAE Endpoint",
                "text": "Treatment-emergent adverse events (TEAEs)",
                "level": {
                  "id": "C98781",
                  "code": "C98781",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Secondary Outcome Measure",
                  "instanceType": "Code"
                },
                "instanceType": "Endpoint",
                "purpose": "Safety"
              },
              {
                "id": "f8d1c98f-8aa4-492b-a23e-061014e0f2f7",
                "name": "Discontinuation due to AE Endpoint",
                "text": "Early discontinuations of study drug due to adverse events (AEs)",
                "level": {
                  "id": "C98781",
                  "code": "C98781",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Secondary Outcome Measure",
                  "instanceType": "Code"
                },
                "instanceType": "Endpoint",
                "purpose": "Safety"
              },
              {
                "id": "25921c88-d3dd-46fb-a499-a633ae0b1d22",
                "name": "CV Events Endpoint",
                "text": "Adjudicated deaths and nonfatal major CV events",
                "level": {
                  "id": "C98781",
                  "code": "C98781",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Secondary Outcome Measure",
                  "instanceType": "Code"
                },
                "instanceType": "Endpoint",
                "purpose": "Safety"
              },
              {
                "id": "dc476cb3-ebef-41b5-8d0f-f0970f5f5f47",
                "name": "Pancreatic AE Endpoint",
                "text": "Adjudicated pancreatic AEs",
                "level": {
                  "id": "C98781",
                  "code": "C98781",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Secondary Outcome Measure",
                  "instanceType": "Code"
                },
                "instanceType": "Endpoint",
                "purpose": "Safety"
              },
              {
                "id": "f2edd78b-63d3-4c7e-9fc9-dd00bfb8d725",
                "name": "Thyroid/Calcitonin Endpoint",
                "text": "Medullary thyroid carcinoma (MTC), C-cell hyperplasia, and serum calcitonin",
                "level": {
                  "id": "C98781",
                  "code": "C98781",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Secondary Outcome Measure",
                  "instanceType": "Code"
                },
                "instanceType": "Endpoint",
                "purpose": "Safety"
              },
              {
                "id": "d463d49f-5060-4fa1-b1b3-b18c4a91fb5b",
                "name": "Immunogenicity Endpoint",
                "text": "Incidence of treatment-emergent LY3298176 anti-drug antibodies and systemic hypersensitivity reactions",
                "level": {
                  "id": "C98781",
                  "code": "C98781",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Secondary Outcome Measure",
                  "instanceType": "Code"
                },
                "instanceType": "Endpoint",
                "purpose": "Safety"
              },
              {
                "id": "c9e0baa4-a7b9-4be7-baed-6f9857a54fc2",
                "name": "Vital Signs Endpoint",
                "text": "Mean change in systolic and diastolic blood pressure and heart rate from baseline",
                "level": {
                  "id": "C98781",
                  "code": "C98781",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Secondary Outcome Measure",
                  "instanceType": "Code"
                },
                "instanceType": "Endpoint",
                "purpose": "Safety"
              },
              {
                "id": "5f250779-58ac-48e2-abaf-9caf4099fe08",
                "name": "Hypoglycemia Endpoint",
                "text": "Occurrence of hypoglycemic events",
                "level": {
                  "id": "C98781",
                  "code": "C98781",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Secondary Outcome Measure",
                  "instanceType": "Code"
                },
                "instanceType": "Endpoint",
                "purpose": "Safety"
              },
              {
                "id": "ef8e697a-7403-412d-b853-261df98637ca",
                "name": "Rescue Therapy Endpoint",
                "text": "Time to initiation of rescue therapy for severe, persistent hyperglycemia",
                "level": {
                  "id": "C98781",
                  "code": "C98781",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Secondary Outcome Measure",
                  "instanceType": "Code"
                },
                "instanceType": "Endpoint",
                "purpose": "Safety"
              },
              {
                "id": "d33dc577-55d5-4dcb-b000-ae0db25a389d",
                "name": "PK/PD Parameters Endpoint",
                "text": "Population PK and PD parameters",
                "level": {
                  "id": "C98781",
                  "code": "C98781",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Secondary Outcome Measure",
                  "instanceType": "Code"
                },
                "instanceType": "Endpoint",
                "purpose": "Pharmacokinetic"
              },
              {
                "id": "9ad6d682-c6c6-4a98-a3f5-09a808bb1928",
                "name": "Exploratory HbA1c Endpoint",
                "text": "HbA1c",
                "level": {
                  "id": "C98724",
                  "code": "C98724",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exploratory Outcome Measure",
                  "instanceType": "Code"
                },
                "instanceType": "Endpoint",
                "purpose": "Efficacy"
              },
              {
                "id": "4000f87b-7259-4090-b34b-d62be64859ca",
                "name": "Lipids Endpoint",
                "text": "Change in lipids (total cholesterol, high-density lipoproteins, low-density lipoproteins, very low-density lipoproteins, and triglycerides) from baseline",
                "level": {
                  "id": "C98724",
                  "code": "C98724",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exploratory Outcome Measure",
                  "instanceType": "Code"
                },
                "instanceType": "Endpoint",
                "purpose": "Biomarker"
              },
              {
                "id": "c4efea1a-9e7a-41ec-af3d-6802fe988a75",
                "name": "BMI Endpoint",
                "text": "Changes from baseline in mean body mass index (BMI)",
                "level": {
                  "id": "C98724",
                  "code": "C98724",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exploratory Outcome Measure",
                  "instanceType": "Code"
                },
                "instanceType": "Endpoint",
                "purpose": "Efficacy"
              },
              {
                "id": "c958996c-f9d5-4628-b2a6-3ec639eced12",
                "name": "Waist Circumference Endpoint",
                "text": "Change in waist circumference",
                "level": {
                  "id": "C98724",
                  "code": "C98724",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exploratory Outcome Measure",
                  "instanceType": "Code"
                },
                "instanceType": "Endpoint",
                "purpose": "Efficacy"
              },
              {
                "id": "54b4914e-6d3d-4900-a1ff-ab7d423033a4",
                "name": "Exploratory Biomarkers Endpoint",
                "text": "Biomarkers",
                "level": {
                  "id": "C98724",
                  "code": "C98724",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exploratory Outcome Measure",
                  "instanceType": "Code"
                },
                "instanceType": "Endpoint",
                "purpose": "Biomarker"
              },
              {
                "id": "e28ab95c-eab6-49eb-b1ed-c62d2cba5622",
                "name": "PROs Endpoint",
                "text": "Patient-Reported Outcomes (European Quality of Life  dimensions [EQ-5D-5L], Ability to Perform Physical Activities of Daily Living [APPADL], Impact of Weight on Self-Perception [IW-SP], status (s) and change (c) versions of Diabetes Treatment Satisfaction Questionnaire (DTSQ)",
                "level": {
                  "id": "C98724",
                  "code": "C98724",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exploratory Outcome Measure",
                  "instanceType": "Code"
                },
                "instanceType": "Endpoint",
                "purpose": "QualityOfLife"
              }
            ],
            "estimands": [
              {
                "id": "a7e1a6b6-30db-41eb-ba16-841a34c9725a",
                "name": "Treatment-Regimen Estimand (Primary)",
                "populationSummary": "Modified intention-to-treat (mITT) population: all randomly assigned participants exposed to at least 1 dose of study drug Summary measure: Difference in least squares means (ANCOVA).",
                "analysisPopulationId": "065e6e1e-0de0-479d-bcc5-80e1cd70761e",
                "variableOfInterestId": "c2751c57-26e3-44b6-81e4-c3b30f83f411",
                "interventionIds": [
                  "36c1e17f-d891-4ab2-a9a7-0101692fc576"
                ],
                "intercurrentEvents": [
                  {
                    "id": "f83d1c8f-3507-459e-88a2-e446823dc8da",
                    "name": "Discontinuation of study drug",
                    "text": "Participants discontinue the study drug before the 52-week visit",
                    "strategy": "Treatment Policy",
                    "instanceType": "IntercurrentEvent"
                  },
                  {
                    "id": "db559789-057d-4841-ba9d-e8f49990068c",
                    "name": "Rescue therapy",
                    "text": "Introduction of rescue therapy for persistent severe hyperglycemia",
                    "strategy": "Treatment Policy",
                    "instanceType": "IntercurrentEvent"
                  }
                ],
                "instanceType": "Estimand",
                "treatment": "LY3298176 (5 mg, 10 mg, or 15 mg) once weekly vs Insulin Glargine",
                "analysisPopulation": "Modified intention-to-treat (mITT) population: all randomly assigned participants exposed to at least 1 dose of study drug",
                "variableOfInterest": "Mean change in HbA1c from baseline to 52 weeks",
                "summaryMeasure": "Difference in least squares means (ANCOVA)"
              },
              {
                "id": "eb754804-ac41-415b-8d22-d488f5a882b5",
                "name": "Efficacy Estimand",
                "populationSummary": "Modified intention-to-treat (mITT) population: all randomly assigned participants exposed to at least 1 dose of study drug Summary measure: Difference in least squares means (MMRM).",
                "analysisPopulationId": "88b21c9a-67be-49a0-9955-38963291b33e",
                "variableOfInterestId": "c2751c57-26e3-44b6-81e4-c3b30f83f411",
                "interventionIds": [
                  "b1910544-0787-404e-a24b-ce32eb468669"
                ],
                "intercurrentEvents": [
                  {
                    "id": "0456fd0a-5987-4118-9ae6-769fc24b0934",
                    "name": "Discontinuation of study drug",
                    "text": "Premature treatment discontinuation",
                    "strategy": "Hypothetical",
                    "instanceType": "IntercurrentEvent"
                  },
                  {
                    "id": "a12e8cd5-1abd-48af-80ff-aa1b4d27be06",
                    "name": "Rescue therapy",
                    "text": "Initiation of any rescue therapy",
                    "strategy": "Hypothetical",
                    "instanceType": "IntercurrentEvent"
                  }
                ],
                "instanceType": "Estimand",
                "treatment": "LY3298176 (5 mg, 10 mg, or 15 mg) once weekly vs Insulin Glargine",
                "analysisPopulation": "Modified intention-to-treat (mITT) population: all randomly assigned participants exposed to at least 1 dose of study drug",
                "variableOfInterest": "Mean change in HbA1c from baseline to 52 weeks",
                "summaryMeasure": "Difference in least squares means (MMRM)"
              },
              {
                "id": "5357d8f2-b5e0-43b6-924c-fa028e154dc6",
                "name": "Key Secondary Body Weight Estimand",
                "populationSummary": "Modified intention-to-treat (mITT) population Summary measure: Difference in least squares means.",
                "analysisPopulationId": "1f9a9360-77ff-4669-ac71-c1d2c77ccf7e",
                "variableOfInterestId": "2a91e2be-9449-4a30-8ee6-1ee722e06307",
                "interventionIds": [
                  "aa4982c9-6781-43ca-b88b-e28aa2567e46"
                ],
                "intercurrentEvents": [
                  {
                    "id": "fd18a3f6-e6b0-400e-8e10-dcb92fc3ec78",
                    "name": "Treatment discontinuation or rescue",
                    "text": "Events affecting the measurement of weight at 52 weeks",
                    "strategy": "Treatment Policy",
                    "instanceType": "IntercurrentEvent"
                  }
                ],
                "instanceType": "Estimand",
                "treatment": "LY3298176 (5 mg, 10 mg, or 15 mg) once weekly vs Insulin Glargine",
                "analysisPopulation": "Modified intention-to-treat (mITT) population",
                "variableOfInterest": "Mean change in body weight from baseline to 52 weeks",
                "summaryMeasure": "Difference in least squares means"
              }
            ],
            "scheduleTimelines": [
              {
                "id": "3083f0f2-ec5b-44d9-b34f-57ffa4b1ef5e",
                "name": "Main Schedule Timeline",
                "mainTimeline": true,
                "instanceType": "ScheduleTimeline",
                "entryCondition": "Subject enrolled in study",
                "entryId": "957eb24c-ae56-4272-872b-76439fa03520",
                "instances": [
                  {
                    "id": "957eb24c-ae56-4272-872b-76439fa03520",
                    "activityIds": [
                      "2addfc92-99d7-44f7-88ca-3e83090318bb"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_2@enc_3",
                    "encounterId": "bf212f93-eeb8-4f37-93fb-8d34d8a044d4",
                    "epochId": "7cd400af-071d-4c0d-ac31-146e94963378"
                  },
                  {
                    "id": "abeb20dd-4e7e-4f23-88b5-0a90bc43f79d",
                    "activityIds": [
                      "2addfc92-99d7-44f7-88ca-3e83090318bb"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_2@enc_5",
                    "encounterId": "cac63745-02d2-4d04-9961-3d511a951191",
                    "epochId": "7cd400af-071d-4c0d-ac31-146e94963378"
                  },
                  {
                    "id": "cb6e4685-2e24-4538-885f-84b3212b596a",
                    "activityIds": [
                      "2addfc92-99d7-44f7-88ca-3e83090318bb"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_2@enc_7",
                    "encounterId": "d38ce0c4-1f5d-4677-804f-fe1eb49559a4",
                    "epochId": "7cd400af-071d-4c0d-ac31-146e94963378"
                  },
                  {
                    "id": "0a12e345-ce29-46c8-b0b9-dd8291d2d37a",
                    "activityIds": [
                      "2addfc92-99d7-44f7-88ca-3e83090318bb"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_2@enc_11",
                    "encounterId": "008bc8ac-f8ac-4486-9a53-82b42e5971d5",
                    "epochId": "7cd400af-071d-4c0d-ac31-146e94963378"
                  },
                  {
                    "id": "d6ebcae1-cd2d-45ad-a058-957b8dc52de4",
                    "activityIds": [
                      "2addfc92-99d7-44f7-88ca-3e83090318bb"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_2@enc_13",
                    "encounterId": "c9f95502-a974-47dc-bfee-b7d51be116dd",
                    "epochId": "7cd400af-071d-4c0d-ac31-146e94963378"
                  },
                  {
                    "id": "b15d3e12-73fa-4dbd-826a-382d78eadd72",
                    "activityIds": [
                      "2addfc92-99d7-44f7-88ca-3e83090318bb"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_2@enc_15",
                    "encounterId": "1e93f4a1-6bf4-4411-99b7-186859665791",
                    "epochId": "7cd400af-071d-4c0d-ac31-146e94963378"
                  },
                  {
                    "id": "77bb94bb-e36a-45d6-bd8c-6d1065ca642c",
                    "activityIds": [
                      "2addfc92-99d7-44f7-88ca-3e83090318bb"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_2@enc_16",
                    "encounterId": "19202a29-d872-436b-99b1-1c94be69596e",
                    "epochId": "7cd400af-071d-4c0d-ac31-146e94963378"
                  },
                  {
                    "id": "6e6aa09e-5465-41d1-b777-f166e19b8f20",
                    "activityIds": [
                      "2addfc92-99d7-44f7-88ca-3e83090318bb"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_2@enc_18",
                    "encounterId": "2d09bd64-fa74-4268-ad3c-68f0694866d0",
                    "epochId": "7cd400af-071d-4c0d-ac31-146e94963378"
                  },
                  {
                    "id": "02ec7001-b41d-48c8-b607-8f51d7a12065",
                    "activityIds": [
                      "2addfc92-99d7-44f7-88ca-3e83090318bb"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_2@enc_23",
                    "encounterId": "fbf0cfbd-8d08-4b43-8d74-ed8a436c0992",
                    "epochId": "7cd400af-071d-4c0d-ac31-146e94963378"
                  },
                  {
                    "id": "3975b426-76cb-4a20-b07f-48e5eccacf80",
                    "activityIds": [
                      "2addfc92-99d7-44f7-88ca-3e83090318bb"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_2@enc_24",
                    "encounterId": "7f706578-7552-49e2-9f7b-865db718af41",
                    "epochId": "7cd400af-071d-4c0d-ac31-146e94963378"
                  },
                  {
                    "id": "3cb54f0a-1fc8-4616-8e46-5029edeced3d",
                    "activityIds": [
                      "2addfc92-99d7-44f7-88ca-3e83090318bb"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_2@enc_27",
                    "encounterId": "d3f18b50-5969-4dce-8865-22f7370cdfcd",
                    "epochId": "b3ce9d66-4927-47d5-b494-3333d89f8438"
                  },
                  {
                    "id": "c44df3f5-1e5d-4b70-bae4-09cd53c9f0c6",
                    "activityIds": [
                      "2addfc92-99d7-44f7-88ca-3e83090318bb"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_2@enc_29",
                    "encounterId": "a9f5177e-56a3-4747-b1b8-84be28c46941",
                    "epochId": "b3ce9d66-4927-47d5-b494-3333d89f8438"
                  },
                  {
                    "id": "a57e4b90-6d1c-459b-8be9-882db55057d2",
                    "activityIds": [
                      "2addfc92-99d7-44f7-88ca-3e83090318bb"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_2@enc_30",
                    "encounterId": "3dd9dfaf-55d2-40f0-a862-166f0c2ca596",
                    "epochId": "b3ce9d66-4927-47d5-b494-3333d89f8438"
                  },
                  {
                    "id": "ec7401a5-8b45-4d38-991e-89e4bc455875",
                    "activityIds": [
                      "2addfc92-99d7-44f7-88ca-3e83090318bb"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_2@enc_31",
                    "encounterId": "57dc0471-496f-4910-a73e-9761fada463a",
                    "epochId": "b3ce9d66-4927-47d5-b494-3333d89f8438"
                  },
                  {
                    "id": "a2d1d55a-5eac-41a8-b55c-d85747163eb0",
                    "activityIds": [
                      "2addfc92-99d7-44f7-88ca-3e83090318bb"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_2@enc_32",
                    "encounterId": "4c9a3fef-b5b4-4cd4-b7b1-055218ba6104",
                    "epochId": "f188cb50-86bc-4641-9f26-2d2c65b77eae"
                  },
                  {
                    "id": "a296ffec-3e6c-46c2-8788-eab961e89866",
                    "activityIds": [
                      "0a1162a6-2bf7-4df7-bd7e-64e9fbae97bd"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_3@enc_17",
                    "encounterId": "3ae278ae-b5d1-4c22-8776-4e01cc91f6bb",
                    "epochId": "7cd400af-071d-4c0d-ac31-146e94963378"
                  },
                  {
                    "id": "3568d1bf-3d0b-4b57-8359-4ab93e15a0ac",
                    "activityIds": [
                      "0a1162a6-2bf7-4df7-bd7e-64e9fbae97bd"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_3@enc_21",
                    "encounterId": "3e476009-0c1d-4a77-8285-6de377cf516f",
                    "epochId": "7cd400af-071d-4c0d-ac31-146e94963378"
                  },
                  {
                    "id": "ddbdc6ea-11c0-4bd2-a810-11a16db06bd3",
                    "activityIds": [
                      "8ca1ee1d-ba94-469e-b891-c15febfc96b1"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_4@enc_6",
                    "encounterId": "e0542240-4e70-4b81-87ee-0f95df20b186",
                    "epochId": "7cd400af-071d-4c0d-ac31-146e94963378"
                  },
                  {
                    "id": "e4999264-d401-4494-8470-67abae385069",
                    "activityIds": [
                      "8ca1ee1d-ba94-469e-b891-c15febfc96b1"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_4@enc_8",
                    "encounterId": "af5d22de-e56d-46d1-8bab-9cec87be3c17",
                    "epochId": "7cd400af-071d-4c0d-ac31-146e94963378"
                  },
                  {
                    "id": "6de3600b-347b-487d-af8c-922149b32e96",
                    "activityIds": [
                      "8ca1ee1d-ba94-469e-b891-c15febfc96b1"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_4@enc_9",
                    "encounterId": "fff7ffd8-4576-4870-8976-19d90622baa9",
                    "epochId": "7cd400af-071d-4c0d-ac31-146e94963378"
                  },
                  {
                    "id": "28412168-0d01-4005-a9ae-03c6c06cb936",
                    "activityIds": [
                      "8ca1ee1d-ba94-469e-b891-c15febfc96b1"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_4@enc_12",
                    "encounterId": "4c271306-0f25-4767-bd31-c9c003b42aef",
                    "epochId": "7cd400af-071d-4c0d-ac31-146e94963378"
                  },
                  {
                    "id": "deebf3cb-9637-4f77-abc9-5c169927138f",
                    "activityIds": [
                      "3b177c0a-e4f9-43f6-89b9-6b9b47b873a9"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_5@enc_3",
                    "encounterId": "bf212f93-eeb8-4f37-93fb-8d34d8a044d4",
                    "epochId": "7cd400af-071d-4c0d-ac31-146e94963378"
                  },
                  {
                    "id": "bc6fd9ce-36b1-4069-b5e9-47f861a41ae1",
                    "activityIds": [
                      "3b177c0a-e4f9-43f6-89b9-6b9b47b873a9"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_5@enc_24",
                    "encounterId": "7f706578-7552-49e2-9f7b-865db718af41",
                    "epochId": "7cd400af-071d-4c0d-ac31-146e94963378"
                  },
                  {
                    "id": "7fd60226-0c2e-4e8f-af64-bc1600ea7ca6",
                    "activityIds": [
                      "3b177c0a-e4f9-43f6-89b9-6b9b47b873a9"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_5@enc_31",
                    "encounterId": "57dc0471-496f-4910-a73e-9761fada463a",
                    "epochId": "b3ce9d66-4927-47d5-b494-3333d89f8438"
                  },
                  {
                    "id": "f58ef15f-a70c-475e-bc1d-234810d81d76",
                    "activityIds": [
                      "a9d00c14-b274-4075-9715-c4d36b1fa028"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_6@enc_3",
                    "encounterId": "bf212f93-eeb8-4f37-93fb-8d34d8a044d4",
                    "epochId": "7cd400af-071d-4c0d-ac31-146e94963378"
                  },
                  {
                    "id": "9d7dd1ea-f718-4288-9592-be51b500b03f",
                    "activityIds": [
                      "a9d00c14-b274-4075-9715-c4d36b1fa028"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_6@enc_24",
                    "encounterId": "7f706578-7552-49e2-9f7b-865db718af41",
                    "epochId": "7cd400af-071d-4c0d-ac31-146e94963378"
                  },
                  {
                    "id": "810ed923-cbd8-4f29-82f0-2d4a32e59f34",
                    "activityIds": [
                      "a9d00c14-b274-4075-9715-c4d36b1fa028"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_6@enc_31",
                    "encounterId": "57dc0471-496f-4910-a73e-9761fada463a",
                    "epochId": "b3ce9d66-4927-47d5-b494-3333d89f8438"
                  },
                  {
                    "id": "ca91aeb9-b94b-429a-9cd6-94fdab7f4a9e",
                    "activityIds": [
                      "04183b01-8004-4998-8090-13e85e435c40"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_7@enc_3",
                    "encounterId": "bf212f93-eeb8-4f37-93fb-8d34d8a044d4",
                    "epochId": "7cd400af-071d-4c0d-ac31-146e94963378"
                  },
                  {
                    "id": "0c433dc6-bbda-40c6-8f8f-46d3441be849",
                    "activityIds": [
                      "04183b01-8004-4998-8090-13e85e435c40"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_7@enc_24",
                    "encounterId": "7f706578-7552-49e2-9f7b-865db718af41",
                    "epochId": "7cd400af-071d-4c0d-ac31-146e94963378"
                  },
                  {
                    "id": "f0e2eabc-9831-4ce4-8155-69be796f4422",
                    "activityIds": [
                      "04183b01-8004-4998-8090-13e85e435c40"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_7@enc_31",
                    "encounterId": "57dc0471-496f-4910-a73e-9761fada463a",
                    "epochId": "b3ce9d66-4927-47d5-b494-3333d89f8438"
                  },
                  {
                    "id": "9aee359e-055a-44bb-a1af-29eedd6b65a1",
                    "activityIds": [
                      "6911f511-61cc-4c40-969c-9ce1ae33e869"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_8@enc_3",
                    "encounterId": "bf212f93-eeb8-4f37-93fb-8d34d8a044d4",
                    "epochId": "7cd400af-071d-4c0d-ac31-146e94963378"
                  },
                  {
                    "id": "5a140cd0-e735-4fb7-b9df-0da4db67d694",
                    "activityIds": [
                      "d97370a1-6f05-4900-9adf-be8f63372036"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_9@enc_24",
                    "encounterId": "7f706578-7552-49e2-9f7b-865db718af41",
                    "epochId": "7cd400af-071d-4c0d-ac31-146e94963378"
                  },
                  {
                    "id": "4e7b6863-8c35-47ed-9239-389caf3d244d",
                    "activityIds": [
                      "d97370a1-6f05-4900-9adf-be8f63372036"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_9@enc_31",
                    "encounterId": "57dc0471-496f-4910-a73e-9761fada463a",
                    "epochId": "b3ce9d66-4927-47d5-b494-3333d89f8438"
                  },
                  {
                    "id": "13716864-1ece-4a90-bcca-b4588a2c8356",
                    "name": "InformedConsent",
                    "description": "Event anchor: InformedConsent",
                    "activityIds": [],
                    "instanceType": "ScheduledActivityInstance",
                    "extensionAttributes": [
                      {
                        "id": "a8f39db5-7301-4653-9344-bf6e0c48ac3d",
                        "url": "http://example.org/usdm/anchorClassification",
                        "instanceType": "ExtensionAttribute",
                        "valueString": "Event"
                      },
                      {
                        "id": "0af59b29-9f22-48ec-8994-50e4d928ec3e",
                        "url": "http://example.org/usdm/intraDayOrder",
                        "instanceType": "ExtensionAttribute",
                        "valueInteger": 10
                      }
                    ],
                    "epochId": "7cd400af-071d-4c0d-ac31-146e94963378",
                    "scheduledDay": 1
                  },
                  {
                    "id": "0ed6564b-a71d-4834-be95-828f3fa0eb11",
                    "name": "Randomization",
                    "description": "Event anchor: Randomization",
                    "activityIds": [],
                    "instanceType": "ScheduledActivityInstance",
                    "extensionAttributes": [
                      {
                        "id": "a8f39db5-7301-4653-9344-bf6e0c48ac3d",
                        "url": "http://example.org/usdm/anchorClassification",
                        "instanceType": "ExtensionAttribute",
                        "valueString": "Event"
                      },
                      {
                        "id": "0af59b29-9f22-48ec-8994-50e4d928ec3e",
                        "url": "http://example.org/usdm/intraDayOrder",
                        "instanceType": "ExtensionAttribute",
                        "valueInteger": 40
                      }
                    ],
                    "epochId": "7cd400af-071d-4c0d-ac31-146e94963378",
                    "scheduledDay": 1
                  },
                  {
                    "id": "cd4b1d87-2600-47ad-943f-4920d83430d9",
                    "name": "Baseline",
                    "description": "Visit anchor: Baseline",
                    "encounterId": "30ee6efd-b4ef-408e-abde-79df85df20f4",
                    "epochId": "7cd400af-071d-4c0d-ac31-146e94963378",
                    "activityIds": [],
                    "instanceType": "ScheduledActivityInstance",
                    "extensionAttributes": [
                      {
                        "id": "a8f39db5-7301-4653-9344-bf6e0c48ac3d",
                        "url": "http://example.org/usdm/anchorClassification",
                        "instanceType": "ExtensionAttribute",
                        "valueString": "Visit"
                      },
                      {
                        "id": "0af59b29-9f22-48ec-8994-50e4d928ec3e",
                        "url": "http://example.org/usdm/intraDayOrder",
                        "instanceType": "ExtensionAttribute",
                        "valueInteger": 50
                      }
                    ],
                    "scheduledDay": 1
                  },
                  {
                    "id": "ce520f64-9387-4f4a-8236-f7adbd78117d",
                    "name": "FirstDose",
                    "description": "Event anchor: FirstDose",
                    "activityIds": [],
                    "instanceType": "ScheduledActivityInstance",
                    "extensionAttributes": [
                      {
                        "id": "a8f39db5-7301-4653-9344-bf6e0c48ac3d",
                        "url": "http://example.org/usdm/anchorClassification",
                        "instanceType": "ExtensionAttribute",
                        "valueString": "Event"
                      },
                      {
                        "id": "0af59b29-9f22-48ec-8994-50e4d928ec3e",
                        "url": "http://example.org/usdm/intraDayOrder",
                        "instanceType": "ExtensionAttribute",
                        "valueInteger": 60
                      }
                    ],
                    "epochId": "7cd400af-071d-4c0d-ac31-146e94963378",
                    "scheduledDay": 1
                  }
                ]
              }
            ],
            "encounters": [
              {
                "id": "bf212f93-eeb8-4f37-93fb-8d34d8a044d4",
                "name": "Visit 3a (Week 0)",
                "instanceType": "Encounter",
                "type": {
                  "id": "eeb21539-ce6b-4be8-9d45-36592ca01c35",
                  "code": "C98780",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Study Visit",
                  "instanceType": "Code"
                },
                "epochId": "7cd400af-071d-4c0d-ac31-146e94963378",
                "extensionAttributes": [
                  {
                    "id": "fccc5b75-59c2-40f9-8557-803492d5bad0",
                    "url": "https://protocol2usdm.io/extensions/x-encounterSources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "8d4b5cb4-ecb9-438c-afb0-ac8b8b662f7d",
                    "url": "https://protocol2usdm.io/extensions/x-encounterType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "visit"
                  },
                  {
                    "id": "ae476ca5-e430-4053-bdf8-e99f95920739",
                    "url": "https://protocol2usdm.io/extensions/x-encounterStudyWeek",
                    "instanceType": "ExtensionAttribute",
                    "valueInteger": 0
                  }
                ]
              },
              {
                "id": "bc964cf4-34fe-47ef-9afb-843e68ca5b49",
                "name": "Visit 4 (Week 1)",
                "instanceType": "Encounter",
                "type": {
                  "id": "770df6f4-eaed-4643-a73f-ab00f7f27463",
                  "code": "C98780",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Study Visit",
                  "instanceType": "Code"
                },
                "epochId": "7cd400af-071d-4c0d-ac31-146e94963378",
                "extensionAttributes": [
                  {
                    "id": "bfa01ffa-0897-4e65-99b5-a9018a6249f1",
                    "url": "https://protocol2usdm.io/extensions/x-encounterSources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "00d31d1f-b3bc-491d-8410-5db47f72a58e",
                    "url": "https://protocol2usdm.io/extensions/x-encounterType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "visit"
                  },
                  {
                    "id": "e1365806-b78f-44e6-801c-9dde47ac3b20",
                    "url": "https://protocol2usdm.io/extensions/x-encounterStudyWeek",
                    "instanceType": "ExtensionAttribute",
                    "valueInteger": 1
                  }
                ]
              },
              {
                "id": "cac63745-02d2-4d04-9961-3d511a951191",
                "name": "Visit 5 (Week 2)",
                "instanceType": "Encounter",
                "type": {
                  "id": "7a4e114c-0313-45e8-a355-7d90cdfe9f74",
                  "code": "C98780",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Study Visit",
                  "instanceType": "Code"
                },
                "epochId": "7cd400af-071d-4c0d-ac31-146e94963378",
                "extensionAttributes": [
                  {
                    "id": "8537cb01-7186-454a-9488-5abf1a5013f9",
                    "url": "https://protocol2usdm.io/extensions/x-encounterSources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "bcbdcfd8-7890-4d9b-b576-99fcdd647a44",
                    "url": "https://protocol2usdm.io/extensions/x-encounterType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "visit"
                  },
                  {
                    "id": "dd05c017-9665-4f2f-ae50-d3926d8ef1dd",
                    "url": "https://protocol2usdm.io/extensions/x-encounterStudyWeek",
                    "instanceType": "ExtensionAttribute",
                    "valueInteger": 2
                  }
                ]
              },
              {
                "id": "e0542240-4e70-4b81-87ee-0f95df20b186",
                "name": "Visit 6 (Week 3)",
                "instanceType": "Encounter",
                "type": {
                  "id": "9730b3ba-fb80-41b7-88a5-18be7c088766",
                  "code": "C98780",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Study Visit",
                  "instanceType": "Code"
                },
                "epochId": "7cd400af-071d-4c0d-ac31-146e94963378",
                "extensionAttributes": [
                  {
                    "id": "cff04399-d694-4971-99d9-be89e2a4a8c1",
                    "url": "https://protocol2usdm.io/extensions/x-encounterSources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "7e5a49cc-f77d-4d40-ab91-4fa5e0a5ef60",
                    "url": "https://protocol2usdm.io/extensions/x-encounterType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "visit"
                  },
                  {
                    "id": "0accdd03-86d6-4943-8e87-b9129d30cfcf",
                    "url": "https://protocol2usdm.io/extensions/x-encounterStudyWeek",
                    "instanceType": "ExtensionAttribute",
                    "valueInteger": 3
                  }
                ]
              },
              {
                "id": "d38ce0c4-1f5d-4677-804f-fe1eb49559a4",
                "name": "Visit 7 (Week 4)",
                "instanceType": "Encounter",
                "type": {
                  "id": "85748042-a000-4438-a380-88d788472030",
                  "code": "C98780",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Study Visit",
                  "instanceType": "Code"
                },
                "epochId": "7cd400af-071d-4c0d-ac31-146e94963378",
                "extensionAttributes": [
                  {
                    "id": "665fb4bc-31e1-4eec-9c52-7919b1e55642",
                    "url": "https://protocol2usdm.io/extensions/x-encounterSources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "4db7e14f-c53e-4279-8ca0-ccc2fa534d8f",
                    "url": "https://protocol2usdm.io/extensions/x-encounterType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "visit"
                  },
                  {
                    "id": "3921c8e7-7649-4698-a1ef-12c4b28bcdf4",
                    "url": "https://protocol2usdm.io/extensions/x-encounterStudyWeek",
                    "instanceType": "ExtensionAttribute",
                    "valueInteger": 4
                  }
                ]
              },
              {
                "id": "af5d22de-e56d-46d1-8bab-9cec87be3c17",
                "name": "Visit 8 (Week 5)",
                "instanceType": "Encounter",
                "type": {
                  "id": "9de57b56-239f-4759-ad53-5f757e651fa3",
                  "code": "C98780",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Study Visit",
                  "instanceType": "Code"
                },
                "epochId": "7cd400af-071d-4c0d-ac31-146e94963378",
                "extensionAttributes": [
                  {
                    "id": "ed75be1c-3d81-44e4-87fc-af53188c9e00",
                    "url": "https://protocol2usdm.io/extensions/x-encounterSources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "ab17f9e9-4bb8-4778-a196-503a5379a913",
                    "url": "https://protocol2usdm.io/extensions/x-encounterType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "visit"
                  },
                  {
                    "id": "e98ffe7d-5211-4c18-aee2-1b92e2f591b6",
                    "url": "https://protocol2usdm.io/extensions/x-encounterStudyWeek",
                    "instanceType": "ExtensionAttribute",
                    "valueInteger": 5
                  }
                ]
              },
              {
                "id": "fff7ffd8-4576-4870-8976-19d90622baa9",
                "name": "Visit 9 (Week 6)",
                "instanceType": "Encounter",
                "type": {
                  "id": "09631723-008f-4355-8c7e-2b34ee056157",
                  "code": "C98780",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Study Visit",
                  "instanceType": "Code"
                },
                "epochId": "7cd400af-071d-4c0d-ac31-146e94963378",
                "extensionAttributes": [
                  {
                    "id": "8f614f7f-a4ac-410f-a417-322b7900055a",
                    "url": "https://protocol2usdm.io/extensions/x-encounterSources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "faae6c05-388b-4d5f-bece-a27c86e95501",
                    "url": "https://protocol2usdm.io/extensions/x-encounterType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "visit"
                  },
                  {
                    "id": "0aad7553-8037-4e45-b74c-66d62955cb3b",
                    "url": "https://protocol2usdm.io/extensions/x-encounterStudyWeek",
                    "instanceType": "ExtensionAttribute",
                    "valueInteger": 6
                  }
                ]
              },
              {
                "id": "56991f60-5669-41fb-a97d-71890c3aa01c",
                "name": "Visit 10 (Week 7)",
                "instanceType": "Encounter",
                "type": {
                  "id": "7c007c6b-03b3-4b5a-bbf8-f6d389b4985f",
                  "code": "C98780",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Study Visit",
                  "instanceType": "Code"
                },
                "epochId": "7cd400af-071d-4c0d-ac31-146e94963378",
                "extensionAttributes": [
                  {
                    "id": "49ecbf1d-88b4-4272-836b-fe74bab10d12",
                    "url": "https://protocol2usdm.io/extensions/x-encounterSources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "8ff20e9d-0842-49ce-942a-599a6e64f33f",
                    "url": "https://protocol2usdm.io/extensions/x-encounterType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "visit"
                  },
                  {
                    "id": "9b0981d0-c4a6-4bae-93ba-13a7e82364cb",
                    "url": "https://protocol2usdm.io/extensions/x-encounterStudyWeek",
                    "instanceType": "ExtensionAttribute",
                    "valueInteger": 7
                  }
                ]
              },
              {
                "id": "008bc8ac-f8ac-4486-9a53-82b42e5971d5",
                "name": "Visit 11 (Week 8)",
                "instanceType": "Encounter",
                "type": {
                  "id": "d8bc6af2-305e-47b9-8c34-cd503c5ec52a",
                  "code": "C98780",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Study Visit",
                  "instanceType": "Code"
                },
                "epochId": "7cd400af-071d-4c0d-ac31-146e94963378",
                "extensionAttributes": [
                  {
                    "id": "071e016f-1bd5-4f1c-9c1b-78a59b1c6d00",
                    "url": "https://protocol2usdm.io/extensions/x-encounterSources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "efffec1a-1de8-4df5-ae9e-a384ac545b93",
                    "url": "https://protocol2usdm.io/extensions/x-encounterType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "visit"
                  },
                  {
                    "id": "0cee5440-606c-428d-a880-e30ed98ef3aa",
                    "url": "https://protocol2usdm.io/extensions/x-encounterStudyWeek",
                    "instanceType": "ExtensionAttribute",
                    "valueInteger": 8
                  }
                ]
              },
              {
                "id": "4c271306-0f25-4767-bd31-c9c003b42aef",
                "name": "Visit 12 (Week 10)",
                "instanceType": "Encounter",
                "type": {
                  "id": "42f4576f-e415-4127-a7e3-75e1cf97be4a",
                  "code": "C98780",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Study Visit",
                  "instanceType": "Code"
                },
                "epochId": "7cd400af-071d-4c0d-ac31-146e94963378",
                "extensionAttributes": [
                  {
                    "id": "82eb493f-80ac-41b1-ae18-dea57e5501e5",
                    "url": "https://protocol2usdm.io/extensions/x-encounterSources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "ea7db4f1-1a18-43a5-9870-93c9ab72de92",
                    "url": "https://protocol2usdm.io/extensions/x-encounterType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "visit"
                  },
                  {
                    "id": "8b09e34d-29be-450d-8f0e-fee3d90dec16",
                    "url": "https://protocol2usdm.io/extensions/x-encounterStudyWeek",
                    "instanceType": "ExtensionAttribute",
                    "valueInteger": 10
                  }
                ]
              },
              {
                "id": "c9f95502-a974-47dc-bfee-b7d51be116dd",
                "name": "Visit 13 (Week 12)",
                "instanceType": "Encounter",
                "type": {
                  "id": "5b97a48a-672d-4941-ad59-6d2b5e467026",
                  "code": "C98780",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Study Visit",
                  "instanceType": "Code"
                },
                "epochId": "7cd400af-071d-4c0d-ac31-146e94963378",
                "extensionAttributes": [
                  {
                    "id": "a9a90fdf-2799-4012-b73d-1f6a4c592359",
                    "url": "https://protocol2usdm.io/extensions/x-encounterSources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "c7f5255f-f3b3-4499-8354-4c337b503122",
                    "url": "https://protocol2usdm.io/extensions/x-encounterType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "visit"
                  },
                  {
                    "id": "f6079829-52c2-4b2f-93f6-6f8531521e00",
                    "url": "https://protocol2usdm.io/extensions/x-encounterStudyWeek",
                    "instanceType": "ExtensionAttribute",
                    "valueInteger": 12
                  }
                ]
              },
              {
                "id": "528e30fd-b519-4c41-bc3a-ca679dfd735d",
                "name": "Visit 14 (Week 15)",
                "instanceType": "Encounter",
                "type": {
                  "id": "6d871d9e-f673-452a-a9f9-179e108dc0b5",
                  "code": "C98780",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Study Visit",
                  "instanceType": "Code"
                },
                "epochId": "7cd400af-071d-4c0d-ac31-146e94963378",
                "extensionAttributes": [
                  {
                    "id": "5c4f2731-8499-4bb1-922b-d718ac33515e",
                    "url": "https://protocol2usdm.io/extensions/x-encounterSources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "4b801a0e-7df3-4651-b568-ded55a23cc69",
                    "url": "https://protocol2usdm.io/extensions/x-encounterType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "visit"
                  },
                  {
                    "id": "93f4662e-3ab4-4843-9421-92409672a725",
                    "url": "https://protocol2usdm.io/extensions/x-encounterStudyWeek",
                    "instanceType": "ExtensionAttribute",
                    "valueInteger": 15
                  }
                ]
              },
              {
                "id": "1e93f4a1-6bf4-4411-99b7-186859665791",
                "name": "Visit 15 (Week 16)",
                "instanceType": "Encounter",
                "type": {
                  "id": "a2bde0ba-9a13-4c76-addf-7f939aeb3609",
                  "code": "C98780",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Study Visit",
                  "instanceType": "Code"
                },
                "epochId": "7cd400af-071d-4c0d-ac31-146e94963378",
                "extensionAttributes": [
                  {
                    "id": "334d4a62-6457-40a6-be34-2fb3255e025b",
                    "url": "https://protocol2usdm.io/extensions/x-encounterSources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "a77611f7-bbf9-4fe4-9383-f3809fdeb13b",
                    "url": "https://protocol2usdm.io/extensions/x-encounterType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "visit"
                  },
                  {
                    "id": "acc13aca-bbf2-48e5-9564-0db1d410c1c3",
                    "url": "https://protocol2usdm.io/extensions/x-encounterStudyWeek",
                    "instanceType": "ExtensionAttribute",
                    "valueInteger": 16
                  }
                ]
              },
              {
                "id": "19202a29-d872-436b-99b1-1c94be69596e",
                "name": "Visit 16 (Week 20)",
                "instanceType": "Encounter",
                "type": {
                  "id": "4fe0921c-24e7-4ccf-bbcf-913c509eaef8",
                  "code": "C98780",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Study Visit",
                  "instanceType": "Code"
                },
                "epochId": "7cd400af-071d-4c0d-ac31-146e94963378",
                "extensionAttributes": [
                  {
                    "id": "fa93e09e-c204-4092-9963-6e95935d7f3f",
                    "url": "https://protocol2usdm.io/extensions/x-encounterSources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "67d9e393-9125-4714-b3a2-eae5eb2d3649",
                    "url": "https://protocol2usdm.io/extensions/x-encounterType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "visit"
                  },
                  {
                    "id": "05cfd5bb-c48d-408d-b282-79e73bc040e2",
                    "url": "https://protocol2usdm.io/extensions/x-encounterStudyWeek",
                    "instanceType": "ExtensionAttribute",
                    "valueInteger": 20
                  }
                ]
              },
              {
                "id": "3ae278ae-b5d1-4c22-8776-4e01cc91f6bb",
                "name": "Visit 17 (Week 23)",
                "instanceType": "Encounter",
                "type": {
                  "id": "c5d2cd88-b76d-4328-868c-580bef929b24",
                  "code": "C98780",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Study Visit",
                  "instanceType": "Code"
                },
                "epochId": "7cd400af-071d-4c0d-ac31-146e94963378",
                "extensionAttributes": [
                  {
                    "id": "e6e9cd2a-77cf-4cfd-9780-9a2b0c2d3711",
                    "url": "https://protocol2usdm.io/extensions/x-encounterSources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "536080a0-6315-4d99-9238-c755645089cf",
                    "url": "https://protocol2usdm.io/extensions/x-encounterType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "visit"
                  },
                  {
                    "id": "b3cc35d0-37d9-4e72-9829-d83161fdde59",
                    "url": "https://protocol2usdm.io/extensions/x-encounterStudyWeek",
                    "instanceType": "ExtensionAttribute",
                    "valueInteger": 23
                  }
                ]
              },
              {
                "id": "2d09bd64-fa74-4268-ad3c-68f0694866d0",
                "name": "Visit 18 (Week 24)",
                "instanceType": "Encounter",
                "type": {
                  "id": "3c86f7f1-4ddb-4438-a3fe-b676efe2a62d",
                  "code": "C98780",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Study Visit",
                  "instanceType": "Code"
                },
                "epochId": "7cd400af-071d-4c0d-ac31-146e94963378",
                "extensionAttributes": [
                  {
                    "id": "053a08ba-2994-4f80-aea9-2a3b2be1e9af",
                    "url": "https://protocol2usdm.io/extensions/x-encounterSources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "bdc8575d-a675-491f-8a34-0de98a388845",
                    "url": "https://protocol2usdm.io/extensions/x-encounterType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "visit"
                  },
                  {
                    "id": "9430fbf4-7b9a-4664-acd4-f1ad4ce17313",
                    "url": "https://protocol2usdm.io/extensions/x-encounterStudyWeek",
                    "instanceType": "ExtensionAttribute",
                    "valueInteger": 24
                  }
                ]
              },
              {
                "id": "a3335f0e-2aa5-4ce9-9725-b3ef560ae3db",
                "name": "Visit 19 (Week 28)",
                "instanceType": "Encounter",
                "type": {
                  "id": "0159a8f7-fa85-4694-9707-d2d7d39ccae6",
                  "code": "C98780",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Study Visit",
                  "instanceType": "Code"
                },
                "epochId": "7cd400af-071d-4c0d-ac31-146e94963378",
                "extensionAttributes": [
                  {
                    "id": "d1e9125a-5076-4453-9e5d-11e8478b5ba6",
                    "url": "https://protocol2usdm.io/extensions/x-encounterSources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "a54a4bab-8c5d-4e1c-87e7-2a39cac1dff2",
                    "url": "https://protocol2usdm.io/extensions/x-encounterType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "visit"
                  },
                  {
                    "id": "39e43622-6294-42b1-97f1-5b0271d11d9f",
                    "url": "https://protocol2usdm.io/extensions/x-encounterStudyWeek",
                    "instanceType": "ExtensionAttribute",
                    "valueInteger": 28
                  }
                ]
              },
              {
                "id": "133bf69f-aed6-4052-b42d-9ff03765ec60",
                "name": "Visit 20 (Week 32)",
                "instanceType": "Encounter",
                "type": {
                  "id": "b859f8a9-876b-43cf-95dc-972dacbb043c",
                  "code": "C98780",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Study Visit",
                  "instanceType": "Code"
                },
                "epochId": "7cd400af-071d-4c0d-ac31-146e94963378",
                "extensionAttributes": [
                  {
                    "id": "3545a630-0573-4167-b186-5fa804a131a9",
                    "url": "https://protocol2usdm.io/extensions/x-encounterSources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "d3c2c2d7-abdb-4e73-a9af-42db5b3bfa2b",
                    "url": "https://protocol2usdm.io/extensions/x-encounterType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "visit"
                  },
                  {
                    "id": "53628852-1e3c-4e72-868d-1138d89056bf",
                    "url": "https://protocol2usdm.io/extensions/x-encounterStudyWeek",
                    "instanceType": "ExtensionAttribute",
                    "valueInteger": 32
                  }
                ]
              },
              {
                "id": "3e476009-0c1d-4a77-8285-6de377cf516f",
                "name": "Visit 21 (Week 35)",
                "instanceType": "Encounter",
                "type": {
                  "id": "a17b8b8d-41fd-4b89-8e0b-6b1411b56469",
                  "code": "C98780",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Study Visit",
                  "instanceType": "Code"
                },
                "epochId": "7cd400af-071d-4c0d-ac31-146e94963378",
                "extensionAttributes": [
                  {
                    "id": "0d268c89-0b00-4cda-8769-251f2a5d8c83",
                    "url": "https://protocol2usdm.io/extensions/x-encounterSources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "bbb55774-3723-4f98-a5e0-8e30fe15cce1",
                    "url": "https://protocol2usdm.io/extensions/x-encounterType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "visit"
                  },
                  {
                    "id": "3af91a7b-190d-4523-935c-edb18fd9b0a6",
                    "url": "https://protocol2usdm.io/extensions/x-encounterStudyWeek",
                    "instanceType": "ExtensionAttribute",
                    "valueInteger": 35
                  }
                ]
              },
              {
                "id": "981efe9a-a862-4a69-9ece-d068d81e97c2",
                "name": "Visit 22 (Week 36)",
                "instanceType": "Encounter",
                "type": {
                  "id": "cfb25ad8-6e8c-4018-a165-5e8e1ec35bdb",
                  "code": "C98780",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Study Visit",
                  "instanceType": "Code"
                },
                "epochId": "7cd400af-071d-4c0d-ac31-146e94963378",
                "extensionAttributes": [
                  {
                    "id": "36b015e5-b706-47cd-aefd-6f85491e1afb",
                    "url": "https://protocol2usdm.io/extensions/x-encounterSources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "f3339d3a-eb9c-4174-ba3e-bd9b7dc339d4",
                    "url": "https://protocol2usdm.io/extensions/x-encounterType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "visit"
                  },
                  {
                    "id": "2e69d441-a7b0-4bb0-92a8-17daf4672296",
                    "url": "https://protocol2usdm.io/extensions/x-encounterStudyWeek",
                    "instanceType": "ExtensionAttribute",
                    "valueInteger": 36
                  }
                ]
              },
              {
                "id": "fbf0cfbd-8d08-4b43-8d74-ed8a436c0992",
                "name": "Visit 23 (Week 42)",
                "instanceType": "Encounter",
                "type": {
                  "id": "c9f26607-0b62-4327-8e79-a29015289af1",
                  "code": "C98780",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Study Visit",
                  "instanceType": "Code"
                },
                "epochId": "7cd400af-071d-4c0d-ac31-146e94963378",
                "extensionAttributes": [
                  {
                    "id": "1c914117-df93-4ebc-a62c-807bbeb09a3f",
                    "url": "https://protocol2usdm.io/extensions/x-encounterSources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "1345c07c-f59f-498a-8901-1e5d311fa0ff",
                    "url": "https://protocol2usdm.io/extensions/x-encounterType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "visit"
                  },
                  {
                    "id": "0e0cd9d7-998f-43d6-8c0e-f8281f83eeb3",
                    "url": "https://protocol2usdm.io/extensions/x-encounterStudyWeek",
                    "instanceType": "ExtensionAttribute",
                    "valueInteger": 42
                  }
                ]
              },
              {
                "id": "7f706578-7552-49e2-9f7b-865db718af41",
                "name": "Visit 24 (Week 52)",
                "instanceType": "Encounter",
                "type": {
                  "id": "24791300-0a46-448c-a468-f003443984c7",
                  "code": "C98780",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Study Visit",
                  "instanceType": "Code"
                },
                "epochId": "7cd400af-071d-4c0d-ac31-146e94963378",
                "extensionAttributes": [
                  {
                    "id": "ff4a22a3-603b-4816-af22-fa7674fa725d",
                    "url": "https://protocol2usdm.io/extensions/x-encounterSources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "a826ece1-72ff-4644-b3d4-1fab756a9057",
                    "url": "https://protocol2usdm.io/extensions/x-encounterType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "visit"
                  },
                  {
                    "id": "4d68bd25-83a6-4964-92ca-47fdcd275b1d",
                    "url": "https://protocol2usdm.io/extensions/x-encounterStudyWeek",
                    "instanceType": "ExtensionAttribute",
                    "valueInteger": 52
                  }
                ]
              },
              {
                "id": "f8d5c3a6-6d9f-4a2a-a46e-078985647f74",
                "name": "Visit 25 (Week 62)",
                "instanceType": "Encounter",
                "type": {
                  "id": "cdc5c63f-1c88-473f-9a49-910cdc5e3be6",
                  "code": "C98780",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Study Visit",
                  "instanceType": "Code"
                },
                "epochId": "b3ce9d66-4927-47d5-b494-3333d89f8438",
                "extensionAttributes": [
                  {
                    "id": "e1121a54-7c08-4502-85bd-930b04066d47",
                    "url": "https://protocol2usdm.io/extensions/x-encounterSources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "4fb6ebe0-71ba-4729-97cc-d0d32c0c93b6",
                    "url": "https://protocol2usdm.io/extensions/x-encounterType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "visit"
                  },
                  {
                    "id": "7707fa45-5a53-486d-a972-2bd6c2c43fe9",
                    "url": "https://protocol2usdm.io/extensions/x-encounterStudyWeek",
                    "instanceType": "ExtensionAttribute",
                    "valueInteger": 62
                  }
                ]
              },
              {
                "id": "0871f7db-2fc2-462e-9138-b128ee2ae49c",
                "name": "Visit 26 (Week 72)",
                "instanceType": "Encounter",
                "type": {
                  "id": "b0a280f6-625c-46c2-85ee-7a51e0ea0b8c",
                  "code": "C98780",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Study Visit",
                  "instanceType": "Code"
                },
                "epochId": "b3ce9d66-4927-47d5-b494-3333d89f8438",
                "extensionAttributes": [
                  {
                    "id": "01b0d285-304b-4f5e-a7b5-3b142debd5d8",
                    "url": "https://protocol2usdm.io/extensions/x-encounterSources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "744f2f5f-b8b9-49c8-98af-1ab5a86b0d5b",
                    "url": "https://protocol2usdm.io/extensions/x-encounterType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "visit"
                  },
                  {
                    "id": "5fba030a-8334-495c-8111-90c2abbb5c9a",
                    "url": "https://protocol2usdm.io/extensions/x-encounterStudyWeek",
                    "instanceType": "ExtensionAttribute",
                    "valueInteger": 72
                  }
                ]
              },
              {
                "id": "d3f18b50-5969-4dce-8865-22f7370cdfcd",
                "name": "Visit 27 (Week 78)",
                "instanceType": "Encounter",
                "type": {
                  "id": "04fe817c-7c9e-4b75-872f-55e9534c1f5c",
                  "code": "C98780",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Study Visit",
                  "instanceType": "Code"
                },
                "epochId": "b3ce9d66-4927-47d5-b494-3333d89f8438",
                "extensionAttributes": [
                  {
                    "id": "2e99cbcd-ee84-4d69-8b9e-18409d9ed78f",
                    "url": "https://protocol2usdm.io/extensions/x-encounterSources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "43327e8c-b170-4dd5-9dac-717d955965df",
                    "url": "https://protocol2usdm.io/extensions/x-encounterType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "visit"
                  },
                  {
                    "id": "384485ee-e4f6-46db-b15a-06f1a9750cd3",
                    "url": "https://protocol2usdm.io/extensions/x-encounterStudyWeek",
                    "instanceType": "ExtensionAttribute",
                    "valueInteger": 78
                  }
                ]
              },
              {
                "id": "11ad33b9-cc96-4aa6-8913-2c619b246197",
                "name": "Visit 28 (Week 88)",
                "instanceType": "Encounter",
                "type": {
                  "id": "c29f4955-1344-4ba2-9937-d6a96e171d02",
                  "code": "C98780",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Study Visit",
                  "instanceType": "Code"
                },
                "epochId": "b3ce9d66-4927-47d5-b494-3333d89f8438",
                "extensionAttributes": [
                  {
                    "id": "958ab51c-1030-4003-9baf-c1edb13d6845",
                    "url": "https://protocol2usdm.io/extensions/x-encounterSources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "34a6ab70-ea5a-4df6-87df-470894b25b54",
                    "url": "https://protocol2usdm.io/extensions/x-encounterType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "visit"
                  },
                  {
                    "id": "3402d93b-48c6-4cda-bc65-02b0a77b01a9",
                    "url": "https://protocol2usdm.io/extensions/x-encounterStudyWeek",
                    "instanceType": "ExtensionAttribute",
                    "valueInteger": 88
                  }
                ]
              },
              {
                "id": "a9f5177e-56a3-4747-b1b8-84be28c46941",
                "name": "Visit 29 (Week 104)",
                "instanceType": "Encounter",
                "type": {
                  "id": "38668b87-4cc1-47e9-8e75-71c8eaa31d0f",
                  "code": "C98780",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Study Visit",
                  "instanceType": "Code"
                },
                "epochId": "b3ce9d66-4927-47d5-b494-3333d89f8438",
                "extensionAttributes": [
                  {
                    "id": "1fe7a2d7-bd61-44c8-96c1-6b061ff20ea8",
                    "url": "https://protocol2usdm.io/extensions/x-encounterSources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "28fb3dd1-735e-4857-b292-cbe1ddb3468f",
                    "url": "https://protocol2usdm.io/extensions/x-encounterType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "visit"
                  },
                  {
                    "id": "05ef0bc0-8585-4bbf-bfe4-ed2c4a8c5ddb",
                    "url": "https://protocol2usdm.io/extensions/x-encounterStudyWeek",
                    "instanceType": "ExtensionAttribute",
                    "valueInteger": 104
                  }
                ]
              },
              {
                "id": "57dc0471-496f-4910-a73e-9761fada463a",
                "name": "ET (Early Termination)",
                "instanceType": "Encounter",
                "type": {
                  "id": "e689bdfe-354e-4496-83fc-b3e4e1b80caa",
                  "code": "C98780",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Early Termination Visit",
                  "instanceType": "Code"
                },
                "epochId": "b3ce9d66-4927-47d5-b494-3333d89f8438",
                "extensionAttributes": [
                  {
                    "id": "4fdae821-459e-4085-ac3d-924d7ced3e32",
                    "url": "https://protocol2usdm.io/extensions/x-encounterSources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "bc1f8f9a-ba11-46a9-bd3a-82e429088a22",
                    "url": "https://protocol2usdm.io/extensions/x-encounterType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "visit"
                  }
                ]
              },
              {
                "id": "3dd9dfaf-55d2-40f0-a862-166f0c2ca596",
                "name": "FTV (Final Treatment Visit)",
                "instanceType": "Encounter",
                "type": {
                  "id": "6d904877-08ec-4a04-8505-0f6e849f5720",
                  "code": "C98780",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Treatment Visit",
                  "instanceType": "Code"
                },
                "epochId": "b3ce9d66-4927-47d5-b494-3333d89f8438",
                "extensionAttributes": [
                  {
                    "id": "d1fc934d-4354-48dd-a204-eed2a0acf3a2",
                    "url": "https://protocol2usdm.io/extensions/x-encounterSources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "ab03da28-2b50-443e-a73f-2286e4de0756",
                    "url": "https://protocol2usdm.io/extensions/x-encounterType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "visit"
                  }
                ]
              },
              {
                "id": "30ee6efd-b4ef-408e-abde-79df85df20f4",
                "name": "Visit 1 (Week -3)",
                "instanceType": "Encounter",
                "type": {
                  "id": "681f59b2-9567-4c29-84f4-423218e8bdbf",
                  "code": "C98780",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Study Visit",
                  "instanceType": "Code"
                },
                "epochId": "38f89303-7b16-408d-b45a-60e38a3bf61c",
                "extensionAttributes": [
                  {
                    "id": "6566bd6b-eadd-4823-8852-01331bd2a99f",
                    "url": "https://protocol2usdm.io/extensions/x-encounterSources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "c7955633-3c78-4916-9d0a-13629cd5e61b",
                    "url": "https://protocol2usdm.io/extensions/x-encounterType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "visit"
                  }
                ]
              },
              {
                "id": "f16f775e-d359-4469-af01-31d2944bc579",
                "name": "Visit 2 (Week -2)",
                "instanceType": "Encounter",
                "type": {
                  "id": "4140ead8-5b37-4b73-80d0-fd974da99a97",
                  "code": "C98780",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Study Visit",
                  "instanceType": "Code"
                },
                "epochId": "38f89303-7b16-408d-b45a-60e38a3bf61c",
                "extensionAttributes": [
                  {
                    "id": "0d5fefdc-13ff-43e0-88f4-421b8d3c71b1",
                    "url": "https://protocol2usdm.io/extensions/x-encounterSources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "b55ca8e6-72c9-459f-b92f-dde9008de1d8",
                    "url": "https://protocol2usdm.io/extensions/x-encounterType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "visit"
                  }
                ]
              },
              {
                "id": "4c9a3fef-b5b4-4cd4-b7b1-055218ba6104",
                "name": "Visit 801 (Safety F/U)",
                "instanceType": "Encounter",
                "type": {
                  "id": "0fb99f26-98e5-423a-8c33-a48c38e36e49",
                  "code": "C98780",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Early Termination Visit",
                  "instanceType": "Code"
                },
                "epochId": "f188cb50-86bc-4641-9f26-2d2c65b77eae",
                "extensionAttributes": [
                  {
                    "id": "1635f706-f545-4b9a-9bd1-28029a65c6bf",
                    "url": "https://protocol2usdm.io/extensions/x-encounterSources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "e577e4c4-cc39-444a-9e9d-5baffc587dfb",
                    "url": "https://protocol2usdm.io/extensions/x-encounterType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "visit"
                  }
                ]
              }
            ],
            "activities": [
              {
                "id": "3b177c0a-e4f9-43f6-89b9-6b9b47b873a9",
                "name": "APPADL",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "d3c4cb21-bcf7-4f41-9610-32fef723dcf1",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "28ae77fb-69ca-400b-84b5-b4d789138c19",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "other"
                  },
                  {
                    "id": "1b4987ac-d843-43f8-a282-35b0eec84515",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "248c777e-4fb7-4ec2-8325-a20164e18b9f",
                "name": "Allowable Deviation (days)",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "1a55246b-7438-4525-a2a9-b5bf6aa601ab",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "fd6b029b-73aa-493f-9c1b-c029d054adf4",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "other"
                  },
                  {
                    "id": "b3b3b0e4-b61e-4845-9c67-573b6ee8ad8a",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "procedure_enrichment",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "d97370a1-6f05-4900-9adf-be8f63372036",
                "name": "DTSQc",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "ed69c062-b5ba-47d3-a847-84e77672c2a6",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "0da7bfef-9c08-4362-9797-94c4d83d9a49",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "other"
                  },
                  {
                    "id": "79fb4035-4c5e-43fa-b90d-3c992ca0774f",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "6911f511-61cc-4c40-969c-9ce1ae33e869",
                "name": "DTSQs",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "e178efc8-aa1f-4e16-ba05-d5c61873c860",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "d7de6d22-d7aa-4ef9-8265-dd4b1fee3bd1",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "other"
                  },
                  {
                    "id": "8b977771-240d-4a2a-bbb6-14350ecb30e5",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "09298cbd-d8bb-4a42-bf10-c64ef9406bba",
                "name": "Dilated Fundoscopic Exam",
                "instanceType": "Activity",
                "definedProcedures": [
                  {
                    "id": "09298cbd-d8bb-4a42-bf10-c64ef9406bba",
                    "name": "Dilated Fundoscopic Exam",
                    "procedureType": "Imaging Technique",
                    "code": {
                      "id": "7df7ea71-731b-4989-bb50-a597844e8f5c",
                      "code": "92225",
                      "codeSystem": "CPT",
                      "codeSystemVersion": "",
                      "decode": "Ophthalmoscopy, extended, with retinal drawing",
                      "instanceType": "Code"
                    },
                    "instanceType": "Procedure",
                    "label": "Eye Exam",
                    "description": "Examination of the retina by an ophthalmologist or optometrist to exclude proliferative retinopathy"
                  }
                ],
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "bc138a68-a24d-44ea-9169-680d3b3ab50a",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedures"
                  },
                  {
                    "id": "66741eaf-2ee0-402f-a019-34bb5065e2d3",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedure"
                  },
                  {
                    "id": "a8575eba-58d9-4185-9900-33346e5cf174",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "procedure_enrichment",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "a9d00c14-b274-4075-9715-c4d36b1fa028",
                "name": "EQ-5D-5L",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "4b684d62-1a80-4185-9fd1-c09af910d657",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "fde5295a-77fb-4baf-a249-e87283679c9f",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "other"
                  },
                  {
                    "id": "cbef9b92-8400-49a1-8ecb-959bef46126b",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "35b767fa-a190-4135-920a-1552c321929a",
                "name": "Electrocardiogram",
                "instanceType": "Activity",
                "definedProcedures": [
                  {
                    "id": "35b767fa-a190-4135-920a-1552c321929a",
                    "name": "Electrocardiogram",
                    "procedureType": "Diagnostic Procedure",
                    "code": {
                      "id": "9047ef65-df3f-4d59-b21b-eb0dce4fbece",
                      "code": "93000",
                      "codeSystem": "CPT",
                      "codeSystemVersion": "",
                      "decode": "Electrocardiogram, routine ECG with at least 12 leads",
                      "instanceType": "Code"
                    },
                    "instanceType": "Procedure",
                    "label": "ECG",
                    "description": "Recording of the electrical activity of the heart"
                  }
                ],
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "97fa1c9e-2e02-4257-b17d-688b118abc27",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedures"
                  },
                  {
                    "id": "93e6e384-7004-47fb-842f-0befa2db91f7",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedure"
                  },
                  {
                    "id": "021dd4a5-95ee-480c-a4c2-204e4f3dc6dd",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "procedure_enrichment",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "2addfc92-99d7-44f7-88ca-3e83090318bb",
                "name": "Fasting Visit",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "40970bff-2632-40b5-b304-b5b0608b9cf1",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "3e809478-2cc0-424e-affb-744efaa3b1f3",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "other"
                  },
                  {
                    "id": "cae484a7-fed0-4622-bb59-2ae93762ce45",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "04183b01-8004-4998-8090-13e85e435c40",
                "name": "IW-SP",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "3262218a-ae8f-4dff-a6b3-823c2ba37d45",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "9fee6c58-23a3-4b8e-be24-4472ab9a1914",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "other"
                  },
                  {
                    "id": "949afd9a-354e-4e67-98fa-73fea6d5199a",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "0a1162a6-2bf7-4df7-bd7e-64e9fbae97bd",
                "name": "PK only Visit",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "5481e554-aa65-416c-864c-c693b706fb2a",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "ff04f7a5-77f2-41b4-a7b2-e9f6b368579d",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "other"
                  },
                  {
                    "id": "997ed9cc-68b4-4363-8998-e33a615cdd22",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "c2968f1b-656c-4aef-b65c-45ccf8adcca8",
                "name": "Physical Examination",
                "instanceType": "Activity",
                "definedProcedures": [
                  {
                    "id": "c2968f1b-656c-4aef-b65c-45ccf8adcca8",
                    "name": "Physical Examination",
                    "procedureType": "Assessment",
                    "code": {
                      "id": "6956ecf9-2177-42ec-85fa-0e5601a9a233",
                      "code": "C25218",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "Assessment",
                      "instanceType": "Code"
                    },
                    "instanceType": "Procedure",
                    "label": "Physical",
                    "description": "General physical assessment of the patient"
                  }
                ],
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "2ddefd0a-d0bd-41d6-8095-f81cbfb2cf28",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedures"
                  },
                  {
                    "id": "bf5159f9-3715-4f67-9895-b1d702ab8e6d",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedure"
                  },
                  {
                    "id": "e3b50995-0ea7-4d11-ba50-d5a24236010e",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "procedure_enrichment",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "0fc16637-6bb8-4dbf-8cdc-8e8615e1ed2b",
                "name": "Self-Monitored Blood Glucose",
                "instanceType": "Activity",
                "definedProcedures": [
                  {
                    "id": "0fc16637-6bb8-4dbf-8cdc-8e8615e1ed2b",
                    "name": "Self-Monitored Blood Glucose",
                    "procedureType": "Monitoring",
                    "code": {
                      "id": "ceb9072d-da9f-429d-9cc4-234fb57b4785",
                      "code": "C25548",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "Monitoring",
                      "instanceType": "Code"
                    },
                    "instanceType": "Procedure",
                    "label": "SMBG",
                    "description": "Patient-performed blood glucose monitoring (4-point or 7-point profiles)"
                  }
                ],
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "343b7ea6-308b-4f12-857c-9799586b82ae",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedures"
                  },
                  {
                    "id": "6fd63703-d33c-44aa-8cbd-3ed143dff1ae",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedure"
                  },
                  {
                    "id": "1c1e9c7b-0d0f-40b2-a97c-da8ebc932755",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "procedure_enrichment",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "4465961f-544f-4527-a764-e59f0f935bd8",
                "name": "Subcutaneous Injection",
                "instanceType": "Activity",
                "definedProcedures": [
                  {
                    "id": "4465961f-544f-4527-a764-e59f0f935bd8",
                    "name": "Subcutaneous Injection",
                    "procedureType": "Therapeutic Procedure",
                    "code": {
                      "id": "f03df2e2-e01b-4b72-bd53-fb55c4dd0929",
                      "code": "96372",
                      "codeSystem": "CPT",
                      "codeSystemVersion": "",
                      "decode": "Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular",
                      "instanceType": "Code"
                    },
                    "instanceType": "Procedure",
                    "label": "SC Injection",
                    "description": "Administration of LY3298176 or insulin glargine"
                  }
                ],
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "eec6ed0f-346e-401c-99ef-1e30d93c3519",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedures"
                  },
                  {
                    "id": "e8b06db1-5a0f-4c68-a92e-48abbff1fb55",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedure"
                  },
                  {
                    "id": "08ae21f8-559b-4213-9bfb-e9099fc33305",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "procedure_enrichment",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "8ca1ee1d-ba94-469e-b891-c15febfc96b1",
                "name": "Telephone Visit",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "1d1c4a3c-5d18-4c5d-8931-366b00dde75f",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "fef9d05d-b1d1-4eef-a36c-33dcaec9a770",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "other"
                  },
                  {
                    "id": "5d7da06f-c554-466d-81f7-144ef3c57963",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "d2f43e76-bf50-40c5-a7d3-fce25dadd69b",
                "name": "Urine Pregnancy Test",
                "instanceType": "Activity",
                "definedProcedures": [
                  {
                    "id": "d2f43e76-bf50-40c5-a7d3-fce25dadd69b",
                    "name": "Urine Pregnancy Test",
                    "procedureType": "Biospecimen Collection",
                    "code": {
                      "id": "fc34ac68-0cca-4a24-af89-ea5e492a7750",
                      "code": "81025",
                      "codeSystem": "CPT",
                      "codeSystemVersion": "",
                      "decode": "Urine pregnancy test, by visual color comparison methods",
                      "instanceType": "Code"
                    },
                    "instanceType": "Procedure",
                    "label": "UPT",
                    "description": "Urine collection for pregnancy testing"
                  }
                ],
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "d3d68769-444f-4b8a-88ca-85b64a442e92",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedures"
                  },
                  {
                    "id": "aaae2a00-4bf4-4b6d-af40-926278946e8b",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedure"
                  },
                  {
                    "id": "1186001d-1602-4d25-be40-52147abad0ea",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "procedure_enrichment",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "7a9f1f12-b1d0-4447-9334-a96fe89ed4cd",
                "name": "Venipuncture",
                "instanceType": "Activity",
                "definedProcedures": [
                  {
                    "id": "7a9f1f12-b1d0-4447-9334-a96fe89ed4cd",
                    "name": "Venipuncture",
                    "procedureType": "Biospecimen Collection",
                    "code": {
                      "id": "d86d4592-5b4c-464c-b118-c4d4592e079b",
                      "code": "36415",
                      "codeSystem": "CPT",
                      "codeSystemVersion": "",
                      "decode": "Collection of venous blood by venipuncture",
                      "instanceType": "Code"
                    },
                    "instanceType": "Procedure",
                    "label": "Blood Draw",
                    "description": "Collection of blood samples for laboratory assessments, PK, and ADA"
                  }
                ],
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "0ee33460-ceda-4df7-861a-19484524e616",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedures"
                  },
                  {
                    "id": "4e5e1103-9697-4aa3-b8d3-ee6f1ec9d058",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedure"
                  },
                  {
                    "id": "60de9ea6-be36-4c1a-9389-2d59be129e1a",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "procedure_enrichment",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "d672b3f6-473d-467b-8790-ed5475b64d63",
                "name": "Vital Signs",
                "instanceType": "Activity",
                "definedProcedures": [
                  {
                    "id": "d672b3f6-473d-467b-8790-ed5475b64d63",
                    "name": "Vital Signs",
                    "procedureType": "Monitoring",
                    "code": {
                      "id": "21a0f9e3-dcc5-4c92-b684-0d288aa73c39",
                      "code": "C25548",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "Monitoring",
                      "instanceType": "Code"
                    },
                    "instanceType": "Procedure",
                    "label": "Vital Signs",
                    "description": "Measurement of sitting blood pressure and heart rate"
                  }
                ],
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "3df73392-34ca-4ced-9de0-53397447e2ec",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedures"
                  },
                  {
                    "id": "100ab0d8-2b06-43bd-9245-e1fec2adbfe6",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedure"
                  },
                  {
                    "id": "5d422631-a6f6-469b-9a5c-dc342a1e0ed2",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "procedure_enrichment",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "e713e6cb-ba86-4da8-8354-3f66b1d847fe",
                "name": "Waist Circumference Measurement",
                "instanceType": "Activity",
                "definedProcedures": [
                  {
                    "id": "e713e6cb-ba86-4da8-8354-3f66b1d847fe",
                    "name": "Waist Circumference Measurement",
                    "procedureType": "Assessment",
                    "code": {
                      "id": "ea6e1a52-ad55-4b75-b141-f3175e95c301",
                      "code": "C25218",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "Assessment",
                      "instanceType": "Code"
                    },
                    "instanceType": "Procedure",
                    "label": "Waist Circumference",
                    "description": "Measurement of the patient's waist"
                  }
                ],
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "08f2f905-305a-4b49-a7ac-5cba9e8574a5",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedures"
                  },
                  {
                    "id": "ba4ae8b2-b3c8-4b91-8f8a-db3e4c6cf385",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedure"
                  },
                  {
                    "id": "89c5a731-249c-4dc5-bf63-722561b9ca5b",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "procedure_enrichment",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              }
            ],
            "epochs": [
              {
                "id": "38f89303-7b16-408d-b45a-60e38a3bf61c",
                "name": "Study Period I (Screening Lead in) | Screening/Lead-in",
                "instanceType": "StudyEpoch",
                "type": {
                  "id": "008ac0fd-7707-4799-b527-13d75fcbc758",
                  "code": "C98779",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Screening Epoch",
                  "instanceType": "Code"
                },
                "extensionAttributes": [
                  {
                    "id": "6ad9f60f-bf2a-49df-ab1c-c1f2fb7193ac",
                    "url": "https://protocol2usdm.io/extensions/x-studyepochSources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "traversal,soa"
                  },
                  {
                    "id": "0e8c961e-eb43-48b9-b531-cca61f9302c5",
                    "url": "https://protocol2usdm.io/extensions/x-epochCategory",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "main"
                  },
                  {
                    "id": "f3ca6bef-19a1-44a4-afc7-073fc6287228",
                    "url": "https://protocol2usdm.io/extensions/x-epochSequenceOrder",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "1"
                  }
                ]
              },
              {
                "id": "7cd400af-071d-4c0d-ac31-146e94963378",
                "name": "Study Period II (52 Weeks Treatment Period) | Treatment Period",
                "instanceType": "StudyEpoch",
                "type": {
                  "id": "0f2d6204-caad-439d-9a7c-ea69cf349c27",
                  "code": "C98780",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Treatment Epoch",
                  "instanceType": "Code"
                },
                "extensionAttributes": [
                  {
                    "id": "35657504-a9f1-4afa-be3d-6fee0a81d271",
                    "url": "https://protocol2usdm.io/extensions/x-studyepochSources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "traversal,soa"
                  },
                  {
                    "id": "ce39c43d-f775-491c-8a4e-84f349e636f1",
                    "url": "https://protocol2usdm.io/extensions/x-epochCategory",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "main"
                  },
                  {
                    "id": "cf30d362-7e10-4dd1-95d9-52dc3242992d",
                    "url": "https://protocol2usdm.io/extensions/x-epochSequenceOrder",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "3"
                  }
                ]
              },
              {
                "id": "f188cb50-86bc-4641-9f26-2d2c65b77eae",
                "name": "Study Period IV (Safety F/U) | Safety Follow-up",
                "instanceType": "StudyEpoch",
                "type": {
                  "id": "9c76ca47-56b7-43a6-bf21-445abaaae9ac",
                  "code": "C98780",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Treatment Epoch",
                  "instanceType": "Code"
                },
                "extensionAttributes": [
                  {
                    "id": "ae703733-f299-4207-b996-8e89526ceb0c",
                    "url": "https://protocol2usdm.io/extensions/x-studyepochSources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "traversal,soa"
                  },
                  {
                    "id": "424b73be-389f-4cfe-b8f8-88478160e706",
                    "url": "https://protocol2usdm.io/extensions/x-epochCategory",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "main"
                  },
                  {
                    "id": "c6ace7bf-a454-46ad-8125-1357fbfce3d1",
                    "url": "https://protocol2usdm.io/extensions/x-epochSequenceOrder",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "4"
                  }
                ]
              },
              {
                "id": "b3ce9d66-4927-47d5-b494-3333d89f8438",
                "name": "Study Period III (Variable) | Safety Follow-up",
                "instanceType": "StudyEpoch",
                "type": {
                  "id": "a4cd793d-928e-4bbf-b4cc-2b689a9b7dff",
                  "code": "C98780",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Treatment Epoch",
                  "instanceType": "Code"
                },
                "extensionAttributes": [
                  {
                    "id": "71c71f47-8249-4672-9f1b-2124604960b8",
                    "url": "https://protocol2usdm.io/extensions/x-studyepochSources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "76fd6e10-be7f-4b37-a048-44235c599bb5",
                    "url": "https://protocol2usdm.io/extensions/x-epochCategory",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "sub"
                  }
                ]
              }
            ],
            "activityGroups": [
              {
                "id": "106251f7-8cf6-4e6b-a519-f1116bcd4279",
                "name": "General Assessments",
                "description": null,
                "childIds": [
                  "2addfc92-99d7-44f7-88ca-3e83090318bb",
                  "0a1162a6-2bf7-4df7-bd7e-64e9fbae97bd",
                  "8ca1ee1d-ba94-469e-b891-c15febfc96b1"
                ],
                "instanceType": "Activity",
                "activityNames": [
                  "Allowable Deviation (days)",
                  "Fasting Visit",
                  "PK only Visit",
                  "Telephone Visit"
                ]
              },
              {
                "id": "0ae5121f-3bd2-4510-93af-576b87963983",
                "name": "Patient-Reported Outcomes (PROs)",
                "description": null,
                "childIds": [
                  "3b177c0a-e4f9-43f6-89b9-6b9b47b873a9",
                  "a9d00c14-b274-4075-9715-c4d36b1fa028",
                  "04183b01-8004-4998-8090-13e85e435c40",
                  "6911f511-61cc-4c40-969c-9ce1ae33e869",
                  "d97370a1-6f05-4900-9adf-be8f63372036"
                ],
                "instanceType": "Activity",
                "activityNames": [
                  "APPADL",
                  "EQ-5D-5L",
                  "IW-SP",
                  "DTSQs",
                  "DTSQc"
                ]
              }
            ],
            "notes": [
              {
                "id": "7b11a220-9adc-475a-8867-de188855a8fa",
                "text": "a Baseline assessments must be completed before processing in the interactive web-response system (IWRS).",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "6af78ef9-32d1-4c23-8cad-1a0893e39cbe",
                "text": "b Patients who are unable or unwilling to continue in the study for any reason will perform an ET visit. If the patient is discontinuing during an unscheduled visit, that visit should be performed as the ET visit. If the patient is discontinuing during a scheduled visit, that visit should be performed as an ET visit. Visit 801 (safety follow-up visit) should be performed 4 weeks after the ET visit as the final study visit.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "d869cc37-750a-4416-a0b2-902693d47d0a",
                "text": "c The visit date is determined in relation to the date of the randomization visit ( the allowed visit window).",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "2b506784-90c3-4a62-83a5-ada88cd2a278",
                "text": "d On visits 3, 5, 7, 11, 13, 15, 16, 18, 23, 24, 27, 29, ET, and at follow-up (801), patients should be reminded to report to the site in a fasting condition, after a period of approximately 8 hours without eating, drinking (except water), or any significant physical activity and before taking study drug(s), metformin (if used), SGLT-2i (if used), SU (if used).",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "34f290b8-4fd8-496d-93b9-8c3464a323af",
                "text": "e Medical history includes assessment of preexisting conditions (including history of gall bladder disease, cardiovascular disease, and medullary thyroid carcinoma) and substance usage (such as, alcohol and tobacco).",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "14bebe3e-4e64-4910-ab7c-2496ad101f26",
                "text": "f Weight measurements should be obtained per the detailed guidance in the Manual of Operations.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "654ca341-bf8c-43d6-ac4f-05b1ab4196cf",
                "text": "g Vital sign measurements should be taken before obtaining an ECG tracing and before collection of blood samples for laboratory testing, at visits where required. The participant should sit quietly for 5 minutes before vital sign measurements are taken. For each parameter, 2 measurements will be taken using the same arm; the recordings should be taken at least 1 minute apart. BP must be taken with an automated blood pressure machine.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "1ee22f3f-53c2-4376-9a43-6fa72ae79dfd",
                "text": "h Dilated fundoscopic exam will be performed by an eye care professional (ophthalmologist or optometrist) for all patients between Visit 2 and Visit 3 to exclude patients with proliferative retinopathy and/or maculopathy. The results from this exam will be recorded on a specific retinopathy eCRF as a baseline measure of retinopathy. A follow-up dilated fundoscopic exam should be performed when clinically indicated by any adverse event suspected of worsening retinopathy, and the findings should be recorded on the retinopathy eCRF.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "855c7e61-66bf-4186-a34e-91539bee1d42",
                "text": "i Includes counseling on diet and exercise, management of hypoglycemia and hyperglycemia, etc.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "2eb5b652-adce-4ef3-9957-cf30e2835da4",
                "text": "j All training should be repeated as needed to ensure patient compliance.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "6dcea3e0-7d6c-4790-87df-81ffcb07ca6c",
                "text": "k Patient is required to collect two 7-point SMBGs on nonconsecutive days prior to the next visit. A 7-point SMBG consists of measurements before and 2 hours after each of 3 main meals within the same day and at bedtime. These SMBG profiles will be collected by the patient within 2 weeks prior to the assigned visits. If 7-point SMBG is not performed, then data from the most recent nonconsecutive 4-point SMBG profiles can be used. If more than 2 SMBG profiles are available, the 2 most recent nonconsecutive profiles should be used.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "2e432f6e-a441-4146-8b37-d86a3b871b4e",
                "text": "l Patients should administer their first dose of LY3298176 at the end of this visit, after other study procedures and randomization.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "f9869742-2769-4e5e-9615-02db6db44158",
                "text": "m LY3298176 patients only.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "01ac0030-089b-4667-b84e-75861f443f78",
                "text": "n During the first 8 weeks, the dose adjustment will be determined by the investigator in discussion with the patient by following a TTT algorithm. After Week 8, the dose adjustment will be determined by the patient in a weekly manner and will be reviewed by the investigator at each office visit. Patient will have weekly visits (clinic or phone) in the first 8 weeks and then visits every 2-3 weeks (clinic or phone) until Week 16 in order to improve compliance with the TTT algorithm.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "9084ceee-381d-4746-836f-96184e6bc416",
                "text": "o Insulin glargine patients only. A review of the patients compliance to the TTT algorithm will still be conducted during the telephone Visits 6, 8, 9, and 12, but the patients compliance for these visits will be collected in the eCRF at Visits 7, 10 and 13 for the period since the previous visit.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "d11dd2ed-9bd7-4ea2-93df-bf99ab8a0a57",
                "text": "p A serum pregnancy test will be performed at Visit 1 for women of childbearing potential only.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "2789bf1c-bbd2-402e-9f3b-3ae0c01270d7",
                "text": "q A urine pregnancy test must be performed at Visit 3 with the result available prior to randomization and first injection of study drug(s) for women of childbearing potential only. Additional pregnancy tests may be performed at the investigators discretion during the study. If required per local regulations and/or institutional guidelines, pregnancy testing can also occur at other times during the study treatment period.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "a8bc04d4-8658-4467-84ae-e819f2d618ab",
                "text": "r Follicle-stimulating hormone test performed at Visit 1 for postmenopausal women at least 50 years of age with an intact uterus, without a history of oophorectomy or bilateral tubal ligation, not on hormone therapy, and who have had spontaneous amenorrhea for more than 6 months and less than 12 months.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "e51fbda7-e1cb-45b7-9eb9-fb6b7e3849a0",
                "text": "s Screening visit assessment will serve as baseline.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "493250cc-0f60-4900-852e-7b41031f8464",
                "text": "t The CKD-EPI equation will be used by the central lab to estimate and report eGFR. For patients who meet inclusion criterion [4] based solely on history of chronic kidney disease and eGFR <60 mL/min/1.73m, the eGFR value must be confirmed to be <60 mL/min/1.73m at Visit 2.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "8a9bbf3d-3926-47fe-b866-9807cab14379",
                "text": "u This sample is required only for patients who meet inclusion criterion [4] based solely on history of chronic kidney disease and eGFR <60 mL/min/1.73m.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "32dae166-a310-4b17-b5a2-c17918dd2e35",
                "text": "v In the event of systemic drug hypersensitivity reactions (immediate or nonimmediate), additional blood samples will be collected including ADA, PK, and, exploratory biomarker sample.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "4c4ee741-cc8b-4367-bcf1-2afdad1b67d1",
                "text": "w PK sample for immunogenicity must be collected prior to drug administration.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "3a9af126-46da-4cb0-a86c-ca9c1c39bdc8",
                "text": "x PK samples will not be collected from patients who were randomized to insulin glargine since it is an open-label study. PK samples will be collected at these visits at time windows of 1 to 24 hours, 24 to 96 hours, OR 120 to 168 hours post dose, as assigned by IWRS. Dependent on the time-windows to which a patient gets assigned, they may be required to come to site for PK-specific visits. Draw PK at ET visit only if patient discontinues study prior to Week 35. Visits 10 and 14 are for all patients, but only those patients assigned to PK will get a PK blood draw. Visits 17 and 21 are for patients assigned to a PK blood draw only.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "bd20a559-cdcb-4a72-9607-ea93abc2eff8",
                "text": "y PROs should be completed before any other study procedures if the patient is not adversely affected by the fasting condition or completed after the patient has sufficiently recovered from the preceding visit procedures.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "27e118b8-2630-4ccd-a867-fe5153637872",
                "text": "z When the sponsor determines that the study has met the completion criteria, all patients remaining in the study will return to the site for a FTV within approximately 30 days. The safety follow-up visit will be approximately 30 days after the FTV.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "a4e37807-4c62-411c-aa06-34681638d83c",
                "text": "e Medical history includes assessment of preexisting conditions (including history of gall bladder disease, cardiovascular disease, and medullary thyroid carcinoma) and substance usage (such as, alcohol and tobacco).",
                "instanceType": "Note"
              },
              {
                "id": "1f9a0455-6605-44c7-9895-1a3702501a78",
                "text": "f Weight measurements should be obtained per the detailed guidance in the Manual of Operations.",
                "instanceType": "Note"
              },
              {
                "id": "81325dc4-3a27-4bfd-8aa1-4a0ef3c8a89e",
                "text": "i Includes counseling on diet and exercise, management of hypoglycemia and hyperglycemia, etc.",
                "instanceType": "Note"
              },
              {
                "id": "0c6aa4db-42fa-4903-b566-3fcf905f7ddf",
                "text": "j All training should be repeated as needed to ensure patient compliance.",
                "instanceType": "Note"
              },
              {
                "id": "b35d111c-733e-4376-8a8a-3b0e3fd85f01",
                "text": "v In the event of systemic drug hypersensitivity reactions (immediate or nonimmediate), additional blood samples will be collected including ADA, PK, and, exploratory biomarker sample.",
                "instanceType": "Note"
              },
              {
                "id": "ba9eccb8-f375-4e92-ae91-21de8c34c4d3",
                "text": "w PK sample for immunogenicity must be collected prior to drug administration.",
                "instanceType": "Note"
              },
              {
                "id": "5ed7c7ad-501f-4d0e-afc0-4b853366e6f4",
                "text": "a. Coronary heart disease documented as having any of the following: 1) History of acute myocardial infarction (ST elevation or non-ST elevation) 2) Stenosis of 50% in at least 1 major (left main, left anterior descending, ramus intermedius, left circumflex, right) coronary artery as determined by cardiac imaging 3) Coronary calcium score 300 4) Stable angina pectoris treated with anti-anginal medication 5) Asymptomatic cardiac ischemia documented by cardiac imaging on exercise or pharmacologi",
                "instanceType": "Note"
              },
              {
                "id": "bef4c44c-e11a-4dcc-8f57-cf195cdf6527",
                "text": "b. Peripheral arterial disease presumed to be of atherosclerotic origin documented as a history of any of the following: 1) Current or intermittent claudication 2) Resting limb ischemia 3) Stenosis of >50% in an iliac, femoral, popliteal, or subclavian artery 4) An ankle-brachial index 0.90 5) Peripheral arterial revascularization or amputation due to atherosclerotic vascular disease 6) Asymptomatic carotid artery stenosis 70% 7) Carotid artery revascularization",
                "instanceType": "Note"
              },
              {
                "id": "ed9bede7-e2ec-4f9b-ab83-0310dee46e61",
                "text": "1. Have been diagnosed with T2DM based on the World Health Organization classification or other locally applicable diagnostic standards Patient Characteristics",
                "instanceType": "Note"
              }
            ],
            "model": {
              "id": "f334c9de-871e-4f4e-8014-7bf020abc722",
              "code": "C82639",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-09-27",
              "decode": "Parallel Study",
              "instanceType": "Code"
            },
            "indications": [
              {
                "id": "e8129225-12b4-42bf-9b41-8e9039ef4f14",
                "name": "Type 2 Diabetes",
                "isRareDisease": false,
                "instanceType": "Indication",
                "description": "Patients with Type 2 Diabetes and Increased Cardiovascular Risk"
              }
            ],
            "procedures": [
              {
                "id": "7a9f1f12-b1d0-4447-9334-a96fe89ed4cd",
                "name": "Venipuncture",
                "procedureType": "Biospecimen Collection",
                "code": {
                  "id": "d86d4592-5b4c-464c-b118-c4d4592e079b",
                  "code": "36415",
                  "codeSystem": "CPT",
                  "codeSystemVersion": "",
                  "decode": "Collection of venous blood by venipuncture",
                  "instanceType": "Code"
                },
                "instanceType": "Procedure",
                "label": "Blood Draw",
                "description": "Collection of blood samples for laboratory assessments, PK, and ADA"
              },
              {
                "id": "35b767fa-a190-4135-920a-1552c321929a",
                "name": "Electrocardiogram",
                "procedureType": "Diagnostic Procedure",
                "code": {
                  "id": "9047ef65-df3f-4d59-b21b-eb0dce4fbece",
                  "code": "93000",
                  "codeSystem": "CPT",
                  "codeSystemVersion": "",
                  "decode": "Electrocardiogram, routine ECG with at least 12 leads",
                  "instanceType": "Code"
                },
                "instanceType": "Procedure",
                "label": "ECG",
                "description": "Recording of the electrical activity of the heart"
              },
              {
                "id": "d672b3f6-473d-467b-8790-ed5475b64d63",
                "name": "Vital Signs",
                "procedureType": "Monitoring",
                "code": {
                  "id": "21a0f9e3-dcc5-4c92-b684-0d288aa73c39",
                  "code": "C25548",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.01d",
                  "decode": "Monitoring",
                  "instanceType": "Code"
                },
                "instanceType": "Procedure",
                "label": "Vital Signs",
                "description": "Measurement of sitting blood pressure and heart rate"
              },
              {
                "id": "c2968f1b-656c-4aef-b65c-45ccf8adcca8",
                "name": "Physical Examination",
                "procedureType": "Assessment",
                "code": {
                  "id": "6956ecf9-2177-42ec-85fa-0e5601a9a233",
                  "code": "C25218",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.01d",
                  "decode": "Assessment",
                  "instanceType": "Code"
                },
                "instanceType": "Procedure",
                "label": "Physical",
                "description": "General physical assessment of the patient"
              },
              {
                "id": "09298cbd-d8bb-4a42-bf10-c64ef9406bba",
                "name": "Dilated Fundoscopic Exam",
                "procedureType": "Imaging Technique",
                "code": {
                  "id": "7df7ea71-731b-4989-bb50-a597844e8f5c",
                  "code": "92225",
                  "codeSystem": "CPT",
                  "codeSystemVersion": "",
                  "decode": "Ophthalmoscopy, extended, with retinal drawing",
                  "instanceType": "Code"
                },
                "instanceType": "Procedure",
                "label": "Eye Exam",
                "description": "Examination of the retina by an ophthalmologist or optometrist to exclude proliferative retinopathy"
              },
              {
                "id": "4465961f-544f-4527-a764-e59f0f935bd8",
                "name": "Subcutaneous Injection",
                "procedureType": "Therapeutic Procedure",
                "code": {
                  "id": "f03df2e2-e01b-4b72-bd53-fb55c4dd0929",
                  "code": "96372",
                  "codeSystem": "CPT",
                  "codeSystemVersion": "",
                  "decode": "Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular",
                  "instanceType": "Code"
                },
                "instanceType": "Procedure",
                "label": "SC Injection",
                "description": "Administration of LY3298176 or insulin glargine"
              },
              {
                "id": "0fc16637-6bb8-4dbf-8cdc-8e8615e1ed2b",
                "name": "Self-Monitored Blood Glucose",
                "procedureType": "Monitoring",
                "code": {
                  "id": "ceb9072d-da9f-429d-9cc4-234fb57b4785",
                  "code": "C25548",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.01d",
                  "decode": "Monitoring",
                  "instanceType": "Code"
                },
                "instanceType": "Procedure",
                "label": "SMBG",
                "description": "Patient-performed blood glucose monitoring (4-point or 7-point profiles)"
              },
              {
                "id": "d2f43e76-bf50-40c5-a7d3-fce25dadd69b",
                "name": "Urine Pregnancy Test",
                "procedureType": "Biospecimen Collection",
                "code": {
                  "id": "fc34ac68-0cca-4a24-af89-ea5e492a7750",
                  "code": "81025",
                  "codeSystem": "CPT",
                  "codeSystemVersion": "",
                  "decode": "Urine pregnancy test, by visual color comparison methods",
                  "instanceType": "Code"
                },
                "instanceType": "Procedure",
                "label": "UPT",
                "description": "Urine collection for pregnancy testing"
              },
              {
                "id": "e713e6cb-ba86-4da8-8354-3f66b1d847fe",
                "name": "Waist Circumference Measurement",
                "procedureType": "Assessment",
                "code": {
                  "id": "ea6e1a52-ad55-4b75-b141-f3175e95c301",
                  "code": "C25218",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.01d",
                  "decode": "Assessment",
                  "instanceType": "Code"
                },
                "instanceType": "Procedure",
                "label": "Waist Circumference",
                "description": "Measurement of the patient's waist"
              }
            ],
            "analysisPopulations": [
              {
                "id": "2a45f8a7-64ca-49d3-afd3-6929cbd24249",
                "name": "Screened population",
                "text": "All participants who sign informed consent",
                "populationType": "Other",
                "instanceType": "AnalysisPopulation",
                "label": "Screened",
                "populationDescription": "All participants who sign informed consent",
                "criteria": "Signed informed consent"
              },
              {
                "id": "9ba2e538-0448-4358-a193-06c8e5422820",
                "name": "Randomized population",
                "text": "All patients who are randomly assigned a treatment arm",
                "populationType": "Other",
                "instanceType": "AnalysisPopulation",
                "label": "Randomized",
                "populationDescription": "All patients who are randomly assigned a treatment arm",
                "criteria": "Randomly assigned to a treatment arm"
              },
              {
                "id": "abd28e14-4f6c-452e-8931-5dbc5c559a81",
                "name": "Modified intent-to-treat population",
                "text": "All randomly assigned participants who are exposed to at least 1 dose of study drug.",
                "populationType": "Efficacy/Safety",
                "instanceType": "AnalysisPopulation",
                "label": "mITT",
                "populationDescription": "All randomly assigned participants who are exposed to at least 1 dose of study drug.",
                "criteria": "Randomized AND received >=1 dose of study drug"
              },
              {
                "id": "a7183921-d5a1-4ae5-97b9-35eaf000520d",
                "name": "Efficacy analysis set",
                "text": "Data obtained during Study Period II and III from mITT, excluding patients discontinuing study drug due to inadvertent enrollment and data after initiating rescue antihyperglycemic medication or discontinuation of study drug (last dose date + 7 days).",
                "populationType": "Efficacy",
                "instanceType": "AnalysisPopulation",
                "label": "EAS",
                "populationDescription": "Data obtained during Study Period II and III from mITT, excluding patients discontinuing study drug due to inadvertent enrollment and data after initiating rescue antihyperglycemic medication or discontinuation of study drug (last dose date + 7 days).",
                "criteria": "mITT AND not discontinued due to inadvertent enrollment AND data prior to rescue medication/drug discontinuation (+7 days)"
              },
              {
                "id": "945e7b75-02fb-4012-a1a7-7d498c6dc427",
                "name": "Full analysis set",
                "text": "Data obtained during Study Period II and III from mITT, excluding patients discontinuing study drug due to inadvertent enrollment, regardless of adherence to study drug or initiation of rescue antihyperglycemic medication.",
                "populationType": "Efficacy",
                "instanceType": "AnalysisPopulation",
                "label": "FAS",
                "populationDescription": "Data obtained during Study Period II and III from mITT, excluding patients discontinuing study drug due to inadvertent enrollment, regardless of adherence to study drug or initiation of rescue antihyperglycemic medication.",
                "criteria": "mITT AND not discontinued due to inadvertent enrollment"
              },
              {
                "id": "ea2d5967-1f7a-453c-8344-c34c6a7cedf0",
                "name": "Safety analysis set",
                "text": "Data obtained during Study Period II, III, and IV from mITT, regardless of adherence to study drug or initiation of new antihyperglycemic medication.",
                "populationType": "Safety",
                "instanceType": "AnalysisPopulation",
                "label": "SS",
                "populationDescription": "Data obtained during Study Period II, III, and IV from mITT, regardless of adherence to study drug or initiation of new antihyperglycemic medication.",
                "criteria": "mITT population"
              }
            ],
            "characteristics": [
              {
                "id": "d76e243c-521d-41c9-843b-c130a50bfc0e",
                "code": "HBA1C",
                "codeSystem": "http://www.cdisc.org/baseline-characteristics",
                "codeSystemVersion": "2024-03-29",
                "decode": "HbA1c",
                "instanceType": "Code"
              },
              {
                "id": "1947ef06-f5b2-4cbe-8f1b-df4405e18137",
                "code": "SGLT-2I_USE",
                "codeSystem": "http://www.cdisc.org/baseline-characteristics",
                "codeSystemVersion": "2024-03-29",
                "decode": "SGLT-2i use",
                "instanceType": "Code"
              },
              {
                "id": "d8ac1414-0e14-4042-8ca0-77ab9d9d63eb",
                "code": "BODY_WEIGHT",
                "codeSystem": "http://www.cdisc.org/baseline-characteristics",
                "codeSystemVersion": "2024-03-29",
                "decode": "Body weight",
                "instanceType": "Code"
              }
            ],
            "extensionAttributes": [
              {
                "id": "d18de797-e86c-4c66-a193-5ad9cb158f8d",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-entityMaps",
                "instanceType": "ExtensionAttribute",
                "valueString": "{\"epochAliases\": {\"STUDY PERIOD I (SCREENING LEAD IN)\": \"epoch_1\", \"STUDY_PERIOD_I_(SCREENING_LEAD_IN)\": \"epoch_1\", \"SCREENING\": \"epoch_1\", \"STUDY PERIOD II (52 WEEKS TREATMENT PERIOD)\": \"epoch_2\", \"STUDY_PERIOD_II_(52_WEEKS_TREATMENT_PERIOD)\": \"epoch_2\", \"TREATMENT\": \"epoch_2\", \"STUDY PERIOD III (VARIABLE)\": \"epoch_3\", \"STUDY_PERIOD_III_(VARIABLE)\": \"epoch_3\", \"STUDY PERIOD IV (SAFETY F/U)\": \"epoch_4\", \"STUDY_PERIOD_IV_(SAFETY_F/U)\": \"epoch_4\", \"SAFETY_FOLLOW_UP\": \"epoch_4\", \"LEAD_IN\": \"epoch_1\", \"END_OF_STUDY\": \"epoch_4\"}, \"visitAliases\": {\"VISIT 1 (WEEK -3)\": \"enc_1\", \"VISIT_1_(WEEK_-3)\": \"enc_1\", \"VISIT 2 (WEEK -2)\": \"enc_2\", \"VISIT_2_(WEEK_-2)\": \"enc_2\", \"VISIT 3A (WEEK 0)\": \"enc_3\", \"VISIT_3A_(WEEK_0)\": \"enc_3\", \"VISIT 4 (WEEK 1)\": \"enc_4\", \"VISIT_4_(WEEK_1)\": \"enc_4\", \"VISIT 5 (WEEK 2)\": \"enc_5\", \"VISIT_5_(WEEK_2)\": \"enc_5\", \"VISIT 6 (WEEK 3)\": \"enc_6\", \"VISIT_6_(WEEK_3)\": \"enc_6\", \"VISIT 7 (WEEK 4)\": \"enc_7\", \"VISIT_7_(WEEK_4)\": \"enc_7\", \"VISIT 8 (WEEK 5)\": \"enc_8\", \"VISIT_8_(WEEK_5)\": \"enc_8\", \"VISIT 9 (WEEK 6)\": \"enc_9\", \"VISIT_9_(WEEK_6)\": \"enc_9\", \"VISIT 10 (WEEK 7)\": \"enc_10\", \"VISIT_10_(WEEK_7)\": \"enc_10\", \"VISIT 11 (WEEK 8)\": \"enc_11\", \"VISIT_11_(WEEK_8)\": \"enc_11\", \"VISIT 12 (WEEK 10)\": \"enc_12\", \"VISIT_12_(WEEK_10)\": \"enc_12\", \"VISIT 13 (WEEK 12)\": \"enc_13\", \"VISIT_13_(WEEK_12)\": \"enc_13\", \"VISIT 14 (WEEK 15)\": \"enc_14\", \"VISIT_14_(WEEK_15)\": \"enc_14\", \"VISIT 15 (WEEK 16)\": \"enc_15\", \"VISIT_15_(WEEK_16)\": \"enc_15\", \"VISIT 16 (WEEK 20)\": \"enc_16\", \"VISIT_16_(WEEK_20)\": \"enc_16\", \"VISIT 17 (WEEK 23)\": \"enc_17\", \"VISIT_17_(WEEK_23)\": \"enc_17\", \"VISIT 18 (WEEK 24)\": \"enc_18\", \"VISIT_18_(WEEK_24)\": \"enc_18\", \"VISIT 19 (WEEK 28)\": \"enc_19\", \"VISIT_19_(WEEK_28)\": \"enc_19\", \"VISIT 20 (WEEK 32)\": \"enc_20\", \"VISIT_20_(WEEK_32)\": \"enc_20\", \"VISIT 21 (WEEK 35)\": \"enc_21\", \"VISIT_21_(WEEK_35)\": \"enc_21\", \"VISIT 22 (WEEK 36)\": \"enc_22\", \"VISIT_22_(WEEK_36)\": \"enc_22\", \"VISIT 23 (WEEK 42)\": \"enc_23\", \"VISIT_23_(WEEK_42)\": \"enc_23\", \"VISIT 24 (WEEK 52)\": \"enc_24\", \"VISIT_24_(WEEK_52)\": \"enc_24\", \"VISIT 25 (WEEK 62)\": \"enc_25\", \"VISIT_25_(WEEK_62)\": \"enc_25\", \"VISIT 26 (WEEK 72)\": \"enc_26\", \"VISIT_26_(WEEK_72)\": \"enc_26\", \"VISIT 27 (WEEK 78)\": \"enc_27\", \"VISIT_27_(WEEK_78)\": \"enc_27\", \"VISIT 28 (WEEK 88)\": \"enc_28\", \"VISIT_28_(WEEK_88)\": \"enc_28\", \"VISIT 29 (WEEK 104)\": \"enc_29\", \"VISIT_29_(WEEK_104)\": \"enc_29\", \"FTV (FINAL TREATMENT VISIT)\": \"enc_30\", \"FTV_(FINAL_TREATMENT_VISIT)\": \"enc_30\", \"ET (EARLY TERMINATION)\": \"enc_31\", \"ET_(EARLY_TERMINATION)\": \"enc_31\", \"VISIT 801 (SAFETY F/U)\": \"enc_32\", \"VISIT_801_(SAFETY_F/U)\": \"enc_32\", \"Early Termination\": \"enc_31\", \"Visit 801\": \"enc_32\", \"Visit 2\": \"enc_2\", \"Visit 1\": \"enc_1\", \"Visit 3\": \"enc_3\", \"Visit 25\": \"enc_25\", \"Visit 29\": \"enc_29\", \"Visit 13\": \"enc_13\", \"Week 1\": \"enc_4\", \"Week 2\": \"enc_5\", \"Week 3\": \"enc_6\", \"Week 4\": \"enc_7\", \"Week 5\": \"enc_8\", \"Week 6\": \"enc_9\", \"Week 8\": \"enc_11\", \"Week 10\": \"enc_12\", \"Week 12\": \"enc_13\", \"Week 16\": \"enc_15\", \"Week 20\": \"enc_16\", \"Week 24\": \"enc_18\", \"Week 28\": \"enc_19\", \"Week 32\": \"enc_20\", \"Week 35\": \"enc_21\", \"Week 36\": \"enc_22\", \"Week 42\": \"enc_23\", \"Week 52\": \"enc_24\", \"Week 62\": \"enc_25\", \"Week 72\": \"enc_26\", \"Week 78\": \"enc_27\", \"Week 88\": \"enc_28\", \"Week 104\": \"enc_29\"}}"
              },
              {
                "id": "9dc184ef-b5aa-4fd2-b224-cffb0183cf3e",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-classifiedIssues",
                "instanceType": "ExtensionAttribute",
                "valueString": "[{\"severity\": \"warning\", \"category\": \"dosing_fragmentation\", \"message\": \"Dosing regimen has prose fragment as treatment name: 'with LY3298176...'\", \"affectedPath\": \"$.dosingRegimens[]\", \"affectedIds\": [\"31c01fc3-7672-418d-9c8c-3bf8999c7dfa\"], \"suggestion\": \"Consolidate with parent intervention regimen\"}]"
              },
              {
                "id": "261e393f-8ee3-4a38-a446-3a6d3eae7809",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-timeAnchors",
                "instanceType": "ExtensionAttribute",
                "valueString": "[{\"id\": \"d97f56f0-21d4-43cc-bfb4-f62b28719b45\", \"definition\": \"First administration of investigational product\", \"anchorType\": \"FirstDose\", \"classification\": \"Event\", \"timelineId\": null, \"dayValue\": 1, \"intraDayOrder\": 60, \"sourceText\": \"first dose of \\nstudy drug\", \"encounterId\": null, \"activityId\": null}, {\"id\": \"739ff35f-0418-4d45-90aa-150c6fd123ae\", \"definition\": \"Date of subject randomization\", \"anchorType\": \"Randomization\", \"classification\": \"Event\", \"timelineId\": null, \"dayValue\": 1, \"intraDayOrder\": 40, \"sourceText\": \"randomization visit\", \"encounterId\": null, \"activityId\": null}, {\"id\": \"d4c89535-777f-4b21-876c-907335907ae3\", \"definition\": \"Baseline visit/assessment\", \"anchorType\": \"Baseline\", \"classification\": \"Visit\", \"timelineId\": null, \"dayValue\": 1, \"intraDayOrder\": 50, \"sourceText\": \"Baseline assessment\", \"encounterId\": null, \"activityId\": null}, {\"id\": \"60997f85-db35-4add-a7d1-e8491c0adc6d\", \"definition\": \"Informed consent obtained\", \"anchorType\": \"InformedConsent\", \"classification\": \"Event\", \"timelineId\": null, \"dayValue\": 1, \"intraDayOrder\": 10, \"sourceText\": \"Informed \\nconsent\", \"encounterId\": null, \"activityId\": null}, {\"id\": \"9d2dfa91-7899-4f5e-afc0-894e83ae505d\", \"definition\": \"procedure\", \"anchorType\": \"Custom\", \"classification\": \"Conceptual\", \"timelineId\": null, \"dayValue\": 1, \"intraDayOrder\": 100, \"sourceText\": \"procedure\", \"encounterId\": null, \"activityId\": null}]"
              },
              {
                "id": "e866293f-759e-4a7f-a35b-92e16720710d",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-repetitions",
                "instanceType": "ExtensionAttribute",
                "valueString": "[{\"id\": \"c55be0c5-9594-4cda-a5e6-7539aed5802d\", \"type\": \"Daily\", \"interval\": \"P1D\", \"sourceText\": \"once daily\"}, {\"id\": \"e982d09a-4195-474e-9d28-83300cfff954\", \"type\": \"Daily\", \"interval\": \"P1D\", \"sourceText\": \"od\"}, {\"id\": \"11ad9a84-9216-4384-8541-219388ed5870\", \"type\": \"Interval\", \"sourceText\": \"bid\"}, {\"id\": \"5321395f-d59b-4681-b4a9-8860a9adcb4d\", \"type\": \"Interval\", \"sourceText\": \"tid\"}, {\"id\": \"66631257-3318-40fe-a2fa-52e794e78551\", \"type\": \"Continuous\", \"startOffset\": \"P8D\", \"endOffset\": \"P16D\", \"sourceText\": \"Week 8 to Week 16\"}, {\"id\": \"231366d2-cee2-4fe4-87f9-8519a308843f\", \"type\": \"Continuous\", \"endOffset\": \"P3D\", \"sourceText\": \"Weeks\\n0 to 3\"}, {\"id\": \"b73b2b06-6d50-452a-b9e3-66cfd2165c17\", \"type\": \"Continuous\", \"startOffset\": \"P4D\", \"endOffset\": \"P7D\", \"sourceText\": \"Weeks\\n4 to 7\"}, {\"id\": \"81dd3ded-2f37-4aab-846d-2a9b000536d6\", \"type\": \"Continuous\", \"startOffset\": \"P8D\", \"endOffset\": \"P11D\", \"sourceText\": \"Weeks\\n8 to 11\"}, {\"id\": \"6b6bd27f-9ef9-4866-add8-68c7a420ea52\", \"type\": \"Continuous\", \"startOffset\": \"P12D\", \"endOffset\": \"P15D\", \"sourceText\": \"Weeks\\n12 to 15\"}, {\"id\": \"b02cf6d3-6e4d-462a-970b-06b0a1755a5f\", \"type\": \"Continuous\", \"startOffset\": \"P16D\", \"endOffset\": \"P19D\", \"sourceText\": \"Weeks\\n16 to 19\"}, {\"id\": \"1366a270-a5e2-4ef5-9d67-cb6346f6663b\", \"type\": \"Continuous\", \"startOffset\": \"P20D\", \"endOffset\": \"P104D\", \"sourceText\": \"Weeks\\n20 to 104\"}, {\"id\": \"12afa8f2-859a-4d3e-94e1-689aba4bd2ea\", \"type\": \"Continuous\", \"startOffset\": \"P8D\", \"endOffset\": \"P16D\", \"sourceText\": \"from Week 8 to Week 16\"}, {\"id\": \"6069f58b-9272-4eff-9bd7-81e730cc9d8f\", \"type\": \"Continuous\", \"sourceText\": \"treatment period\"}, {\"id\": \"8eae5986-38df-4fb2-b1fb-38e957588ee4\", \"type\": \"Continuous\", \"sourceText\": \"Treatment Period\"}, {\"id\": \"f1121bfc-4586-45f2-bf89-6d7414647f30\", \"type\": \"Continuous\", \"sourceText\": \"follow-up period\"}, {\"id\": \"e45e6e82-d462-46b9-830e-dbee5ff9e4c2\", \"type\": \"Continuous\", \"sourceText\": \"2 \\nhours after\"}, {\"id\": \"e83289a0-2cb4-4e04-82ca-edaff9861919\", \"type\": \"Daily\", \"startOffset\": \"null\", \"endOffset\": \"null\", \"interval\": \"P1D\", \"exitCondition\": \"null\", \"sourceText\": \"Ability to Perform Physical Activities of Daily Living (APPADL)\"}]"
              },
              {
                "id": "398dbc9e-a5f1-47ef-b40b-06698729b3c6",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-traversalConstraints",
                "instanceType": "ExtensionAttribute",
                "valueString": "[{\"id\": \"fe5e543e-ecb2-4e34-9349-c46aed12aa17\", \"requiredSequence\": [\"epoch_1\", \"epoch_1\", \"epoch_2\", \"epoch_4\", \"epoch_4\"], \"allowEarlyExit\": true, \"exitEpochIds\": [], \"mandatoryVisits\": [\"enc_32\", \"enc_30\", \"enc_1\"], \"sourceText\": \"[{'condition': 'Permanent Discontinuation from Study Treatment', 'path': ['EARLY_TREATMENT_DISCONTINUATION_VISIT', 'CONTINUED_STUDY_OBSERVATION', 'SAFETY_FOLLOW_UP']}, {'condition': 'Temporary Interruption of Study Treatment', 'path': ['TREATMENT_PAUSE', 'TREATMENT_RE_INITIATION']}, {'condition': 'Inadvertently Enrolled Patients', 'path': ['IMMEDIATE_DISCONTINUATION']}]\"}]"
              },
              {
                "id": "df241c4b-628f-4f23-9acc-92945f80fd12",
                "url": "https://protocol2usdm.io/extensions/x-footnoteConditions",
                "instanceType": "ExtensionAttribute",
                "valueString": "[{\"id\": \"189ed620-3d73-4231-bf0f-6b602361336e\", \"conditionType\": \"timing_before\", \"text\": \"a Baseline assessments must be completed before processing in the interactive web-response system (IWRS).\", \"footnoteId\": \"548b8495-96ff-4b51-90d7-a66f21ff6b1a\", \"structuredCondition\": \"timing.before(IWRS_Processing)\", \"appliesToActivityIds\": [\"106251f7-8cf6-4e6b-a519-f1116bcd4279\"], \"sourceText\": \"a Baseline assessments must be completed before processing in the interactive web-response system (I\"}, {\"id\": \"4cec5201-b2a3-4113-b6bc-f46340d49c7e\", \"conditionType\": \"timing_after\", \"text\": \"b Patients who are unable or unwilling to continue in the study for any reason will perform an ET visit. If the patient is discontinuing during an unscheduled visit, that visit should be performed as the ET visit. If the patient is discontinuing during a scheduled visit, that visit should be performed as an ET visit. Visit 801 (safety follow-up visit) should be performed 4 weeks after the ET visit as the final study visit.\", \"footnoteId\": \"9c312ce3-7adf-45b3-ae10-098df2cc4cbb\", \"structuredCondition\": \"timing.after(ET_Visit, P4W)\", \"appliesToActivityIds\": [\"2addfc92-99d7-44f7-88ca-3e83090318bb\"], \"sourceText\": \"b Patients who are unable or unwilling to continue in the study for any reason will perform an ET vi\"}, {\"id\": \"7beb3bae-6fb2-4467-9225-03af2db1109d\", \"conditionType\": \"general\", \"text\": \"c The visit date is determined in relation to the date of the randomization visit (\\u00b1 the allowed visit window).\", \"footnoteId\": \"bc2a96e9-664f-4e8c-9f2a-18973f4c3a2b\", \"sourceText\": \"c The visit date is determined in relation to the date of the randomization visit (\\u00b1 the allowed vis\", \"appliesToActivityIds\": [\"2addfc92-99d7-44f7-88ca-3e83090318bb\"]}, {\"id\": \"07532fe6-d530-47e4-83ee-1fdfc50dd3d5\", \"conditionType\": \"timing_before\", \"text\": \"d On visits 3, 5, 7, 11, 13, 15, 16, 18, 23, 24, 27, 29, ET, and at follow-up (801), patients should be reminded to report to the site in a fasting condition, after a period of approximately 8 hours without eating, drinking (except water), or any significant physical activity and before taking study drug(s), metformin (if used), SGLT-2i (if used), SU (if used).\", \"footnoteId\": \"887f069e-dd6c-4563-b9a2-2266c92ba7ee\", \"structuredCondition\": \"state.fasting(duration=PT8H) AND timing.before(study_drug, metformin, SGLT-2i, SU)\", \"appliesToActivityIds\": [\"2addfc92-99d7-44f7-88ca-3e83090318bb\"], \"timingConstraint\": \"PT8H\", \"sourceText\": \"d On visits 3, 5, 7, 11, 13, 15, 16, 18, 23, 24, 27, 29, ET, and at follow-up (801), patients should\"}, {\"id\": \"6fbda380-f6cb-425c-b7fe-fb2aaf8fb3c2\", \"conditionType\": \"general\", \"text\": \"e Medical history includes assessment of preexisting conditions (including history of gall bladder disease, cardiovascular disease, and medullary thyroid carcinoma) and substance usage (such as, alcohol and tobacco).\", \"footnoteId\": \"3223bee3-9d59-43d2-873c-5fec30d8e642\", \"sourceText\": \"e Medical history includes assessment of preexisting conditions (including history of gall bladder d\"}, {\"id\": \"03dfe860-b3cb-4ffd-9acf-03a5b7d8c260\", \"conditionType\": \"general\", \"text\": \"f Weight measurements should be obtained per the detailed guidance in the Manual of Operations.\", \"footnoteId\": \"1a34d6dd-9c0f-4da4-8fec-256ba5cde7ce\", \"sourceText\": \"f Weight measurements should be obtained per the detailed guidance in the Manual of Operations.\"}, {\"id\": \"048d118a-7e8e-4dff-814d-bae479f3a8eb\", \"conditionType\": \"timing_before\", \"text\": \"g Vital sign measurements should be taken before obtaining an ECG tracing and before collection of blood samples for laboratory testing, at visits where required. The participant should sit quietly for 5 minutes before vital sign measurements are taken. For each parameter, 2 measurements will be taken using the same arm; the recordings should be taken at least 1 minute apart. BP must be taken with an automated blood pressure machine.\", \"footnoteId\": \"8014efcc-90a2-4b3a-aff3-ad2126afc706\", \"structuredCondition\": \"timing.before(vital sign measurements are taken. for each parameter, 2 measurements will be taken using the same arm; the recordings should be taken at least 1 minute apart. bp must be taken with an automated blood pressure machine., PT5M)\", \"appliesToActivityIds\": [\"2addfc92-99d7-44f7-88ca-3e83090318bb\"], \"timingConstraint\": \"PT5M\", \"sourceText\": \"g Vital sign measurements should be taken before obtaining an ECG tracing and before collection of b\"}, {\"id\": \"00a217b9-0b54-4d12-b897-d31b9d80d6b0\", \"conditionType\": \"procedure_conditional\", \"text\": \"h Dilated fundoscopic exam will be performed by an eye care professional (ophthalmologist or optometrist) for all patients between Visit 2 and Visit 3 to exclude patients with proliferative retinopathy and/or maculopathy. The results from this exam will be recorded on a specific retinopathy eCRF as a baseline measure of retinopathy. A follow-up dilated fundoscopic exam should be performed when clinically indicated by any adverse event suspected of worsening retinopathy, and the findings should be recorded on the retinopathy eCRF.\", \"footnoteId\": \"985ed096-e288-45dd-a394-5584ffac6dfa\", \"structuredCondition\": \"timing.between(Visit_2, Visit_3)\", \"appliesToActivityIds\": [\"2addfc92-99d7-44f7-88ca-3e83090318bb\"], \"sourceText\": \"h Dilated fundoscopic exam will be performed by an eye care professional (ophthalmologist or optomet\"}, {\"id\": \"d14c2e2d-38cd-4cca-a664-9b81f845dbc3\", \"conditionType\": \"general\", \"text\": \"i Includes counseling on diet and exercise, management of hypoglycemia and hyperglycemia, etc.\", \"footnoteId\": \"b93de2c8-0292-4cd9-ba2e-8d6e832db712\", \"sourceText\": \"i Includes counseling on diet and exercise, management of hypoglycemia and hyperglycemia, etc.\"}, {\"id\": \"1f5322ec-52ca-4d1b-b642-c1c11aee9096\", \"conditionType\": \"general\", \"text\": \"j All training should be repeated as needed to ensure patient compliance.\", \"footnoteId\": \"3cd3b044-52ab-43b1-ad0f-b8c95e654f7a\", \"sourceText\": \"j All training should be repeated as needed to ensure patient compliance.\"}, {\"id\": \"1cc8aacd-5fd2-488e-b3ec-ffc860cd2eb5\", \"conditionType\": \"timing_before\", \"text\": \"k Patient is required to collect two 7-point SMBGs on nonconsecutive days prior to the next visit. A 7-point SMBG consists of measurements before and 2 hours after each of 3 main meals within the same day and at bedtime. These SMBG profiles will be collected by the patient within 2 weeks prior to the assigned visits. If 7-point SMBG is not performed, then data from the most recent nonconsecutive 4-point SMBG profiles can be used. If more than 2 SMBG profiles are available, the 2 most recent nonconsecutive profiles should be used.\", \"footnoteId\": \"ce5d21df-7cb4-4635-8ee1-cb5d699c92e1\", \"structuredCondition\": \"timing.after(each of 3 main meals within the same day and at bedtime. these smbg profiles will be collected by the patient within 2 weeks prior to the assigned visits. if 7-point smbg is not performed, then data from the most recent nonconsecutive 4-point smbg profiles can be used. if more than 2 smbg profiles are available, the 2 most recent nonconsecutive profiles should be used., PT2M)\", \"appliesToActivityIds\": [\"2addfc92-99d7-44f7-88ca-3e83090318bb\"], \"timingConstraint\": \"PT2H\", \"sourceText\": \"k Patient is required to collect two 7-point SMBGs on nonconsecutive days prior to the next visit. A\"}, {\"id\": \"462ecf60-1f61-4060-a5a5-766eb893aa31\", \"conditionType\": \"timing_after\", \"text\": \"l Patients should administer their first dose of LY3298176 at the end of this visit, after other study procedures and randomization.\", \"footnoteId\": \"3c4a86ec-ed3f-4daa-bd20-b27cac5a44bc\", \"structuredCondition\": \"timing.after(Randomization) AND timing.after(Study_Procedures)\", \"appliesToActivityIds\": [\"2addfc92-99d7-44f7-88ca-3e83090318bb\"], \"sourceText\": \"l Patients should administer their first dose of LY3298176 at the end of this visit, after other stu\"}, {\"id\": \"dfde1752-69e7-477d-b565-68eeffbbda77\", \"conditionType\": \"general\", \"text\": \"m LY3298176 patients only.\", \"footnoteId\": \"312f11c2-88cd-4954-9dbc-a2f404af2b28\", \"structuredCondition\": \"patient.cohort == 'LY3298176'\", \"appliesToActivityIds\": [\"0a1162a6-2bf7-4df7-bd7e-64e9fbae97bd\"], \"sourceText\": \"m LY3298176 patients only.\"}, {\"id\": \"7e2a0f6a-94d0-472f-a633-6962c0bff1e7\", \"conditionType\": \"timing_after\", \"text\": \"n During the first 8 weeks, the dose adjustment will be determined by the investigator in discussion with the patient by following a TTT algorithm. After Week 8, the dose adjustment will be determined by the patient in a weekly manner and will be reviewed by the investigator at each office visit. Patient will have weekly visits (clinic or phone) in the first 8 weeks and then visits every 2-3 weeks (clinic or phone) until Week 16 in order to improve compliance with the TTT algorithm.\", \"footnoteId\": \"12cd244d-a15b-468f-87cb-6309233d0a6e\", \"sourceText\": \"n During the first 8 weeks, the dose adjustment will be determined by the investigator in discussion\", \"appliesToActivityIds\": [\"2addfc92-99d7-44f7-88ca-3e83090318bb\"]}, {\"id\": \"528aa55d-da3e-4a99-8f20-5a20e3999261\", \"conditionType\": \"procedure_timepoints\", \"text\": \"o Insulin glargine patients only. A review of the patient\\u2019s compliance to the TTT algorithm will still be conducted during the telephone Visits 6, 8, 9, and 12, but the patient\\u2019s compliance for these visits will be collected in the eCRF at Visits 7, 10 and 13 for the period since the previous visit.\", \"footnoteId\": \"0dc13c61-162f-47de-81c2-c6b5656611eb\", \"sourceText\": \"o Insulin glargine patients only. A review of the patient\\u2019s compliance to the TTT algorithm will sti\", \"appliesToActivityIds\": [\"0a1162a6-2bf7-4df7-bd7e-64e9fbae97bd\", \"8ca1ee1d-ba94-469e-b891-c15febfc96b1\", \"2addfc92-99d7-44f7-88ca-3e83090318bb\"]}, {\"id\": \"59dc1461-33e2-4d2d-8389-76c59d1d8692\", \"conditionType\": \"eligibility_wocbp\", \"text\": \"p A serum pregnancy test will be performed at Visit 1 for women of childbearing potential only.\", \"footnoteId\": \"ff35b2a7-60cb-4494-b4bf-ba5b60d1ea72\", \"structuredCondition\": \"subject.sex == 'Female' AND subject.isOfChildbearingPotential == true\", \"appliesToActivityIds\": [\"0a1162a6-2bf7-4df7-bd7e-64e9fbae97bd\", \"2addfc92-99d7-44f7-88ca-3e83090318bb\"], \"sourceText\": \"p A serum pregnancy test will be performed at Visit 1 for women of childbearing potential only.\"}, {\"id\": \"469ca952-6ebd-4f45-900e-2066c5b417f5\", \"conditionType\": \"timing_before\", \"text\": \"q A urine pregnancy test must be performed at Visit 3 with the result available prior to randomization and first injection of study drug(s) for women of childbearing potential only. Additional pregnancy tests may be performed at the investigator\\u2019s discretion during the study. If required per local regulations and/or institutional guidelines, pregnancy testing can also occur at other times during the study treatment period.\", \"footnoteId\": \"3044ccfc-4571-4ddb-b5d2-9929bd15fa2b\", \"structuredCondition\": \"timing.before(Randomization) AND timing.before(First_Injection)\", \"appliesToActivityIds\": [\"0a1162a6-2bf7-4df7-bd7e-64e9fbae97bd\", \"2addfc92-99d7-44f7-88ca-3e83090318bb\"], \"sourceText\": \"q A urine pregnancy test must be performed at Visit 3 with the result available prior to randomizati\"}, {\"id\": \"7ab95df8-f804-4f5d-9c44-a56f4f7c37a1\", \"conditionType\": \"procedure_timepoints\", \"text\": \"r Follicle-stimulating hormone test performed at Visit 1 for postmenopausal women at least 50 years of age with an intact uterus, without a history of oophorectomy or bilateral tubal ligation, not on hormone therapy, and who have had spontaneous amenorrhea for more than 6 months and less than 12 months.\", \"footnoteId\": \"04be48a1-8db9-4258-ab7d-44e8a812928d\", \"sourceText\": \"r Follicle-stimulating hormone test performed at Visit 1 for postmenopausal women at least 50 years \", \"appliesToActivityIds\": [\"2addfc92-99d7-44f7-88ca-3e83090318bb\"]}, {\"id\": \"5b1158d3-ffa4-42ef-9200-bf0ca3147e34\", \"conditionType\": \"general\", \"text\": \"s Screening visit assessment will serve as baseline.\", \"footnoteId\": \"bfcbb23e-b7d0-449e-b707-d8045f76ebd4\", \"sourceText\": \"s Screening visit assessment will serve as baseline.\", \"appliesToActivityIds\": [\"2addfc92-99d7-44f7-88ca-3e83090318bb\"]}, {\"id\": \"9193997d-8add-4846-81cc-78c5d3e4c37b\", \"conditionType\": \"procedure_timepoints\", \"text\": \"t The CKD-EPI equation will be used by the central lab to estimate and report eGFR. For patients who meet inclusion criterion [4] based solely on history of chronic kidney disease and eGFR <60 mL/min/1.73m\\u00b2, the eGFR value must be confirmed to be <60 mL/min/1.73m\\u00b2 at Visit 2.\", \"footnoteId\": \"189518f8-e15d-421a-999b-3a1c89bc10f1\", \"sourceText\": \"t The CKD-EPI equation will be used by the central lab to estimate and report eGFR. For patients who\", \"appliesToActivityIds\": [\"2addfc92-99d7-44f7-88ca-3e83090318bb\"]}, {\"id\": \"794fd0bc-6840-4412-8285-f3ff05b4e2fb\", \"conditionType\": \"general\", \"text\": \"u This sample is required only for patients who meet inclusion criterion [4] based solely on history of chronic kidney disease and eGFR <60 mL/min/1.73m\\u00b2.\", \"footnoteId\": \"f8cd90c6-8c3d-4865-869f-adb65ff82bda\", \"sourceText\": \"u This sample is required only for patients who meet inclusion criterion [4] based solely on history\", \"appliesToActivityIds\": [\"0a1162a6-2bf7-4df7-bd7e-64e9fbae97bd\"]}, {\"id\": \"e75d71f4-f258-462c-8939-ebec789d3e7f\", \"conditionType\": \"general\", \"text\": \"v In the event of systemic drug hypersensitivity reactions (immediate or nonimmediate), additional blood samples will be collected including ADA, PK, and, exploratory biomarker sample.\", \"footnoteId\": \"f5ac956c-8f06-4341-8b8f-90a49ef14f2e\", \"sourceText\": \"v In the event of systemic drug hypersensitivity reactions (immediate or nonimmediate), additional b\"}, {\"id\": \"49f6f72e-78c1-4ab0-bda5-96f6924bf92f\", \"conditionType\": \"timing_before\", \"text\": \"w PK sample for immunogenicity must be collected prior to drug administration.\", \"footnoteId\": \"d2cf220c-67bd-46fa-b8ff-724af6fb2dbe\", \"structuredCondition\": \"timing.before(Drug_Administration)\", \"appliesToActivityIds\": [\"PK sample for immunogenicity\"], \"sourceText\": \"w PK sample for immunogenicity must be collected prior to drug administration.\"}, {\"id\": \"fdc009fc-20a8-472d-9324-ec6d6619f86a\", \"conditionType\": \"timing_before\", \"text\": \"x PK samples will not be collected from patients who were randomized to insulin glargine since it is an open-label study. PK samples will be collected at these visits at time windows of 1 to 24 hours, 24 to 96 hours, OR 120 to 168 hours post dose, as assigned by IWRS. Dependent on the time-windows to which a patient gets assigned, they may be required to come to site for PK-specific visits. Draw PK at ET visit only if patient discontinues study prior to Week 35. Visits 10 and 14 are for all patients, but only those patients assigned to PK will get a PK blood draw. Visits 17 and 21 are for patients assigned to a PK blood draw only.\", \"footnoteId\": \"207ca9ae-0873-4255-a164-680a544c0606\", \"timingConstraint\": \"PT24H\", \"sourceText\": \"x PK samples will not be collected from patients who were randomized to insulin glargine since it is\", \"appliesToActivityIds\": [\"0a1162a6-2bf7-4df7-bd7e-64e9fbae97bd\", \"2addfc92-99d7-44f7-88ca-3e83090318bb\"]}, {\"id\": \"aecbcbba-3fd1-4674-8649-c44ad9b3cfa5\", \"conditionType\": \"timing_before\", \"text\": \"y PROs should be completed before any other study procedures if the patient is not adversely affected by the fasting condition or completed after the patient has sufficiently recovered from the preceding visit procedures.\", \"footnoteId\": \"ba443ffd-77f4-471c-9f84-43b4b805a691\", \"structuredCondition\": \"timing.before(Other_Procedures) IF patient.fasting_status == 'tolerated'\", \"appliesToActivityIds\": [\"0ae5121f-3bd2-4510-93af-576b87963983\"], \"sourceText\": \"y PROs should be completed before any other study procedures if the patient is not adversely affecte\"}, {\"id\": \"268b3837-b00e-4484-a02c-a7404cd6c5ae\", \"conditionType\": \"timing_after\", \"text\": \"z When the sponsor determines that the study has met the completion criteria, all patients remaining in the study will return to the site for a FTV within approximately 30 days. The safety follow-up visit will be approximately 30 days after the FTV.\", \"footnoteId\": \"70407f7f-55d6-4de0-a558-318d3613a9f3\", \"sourceText\": \"z When the sponsor determines that the study has met the completion criteria, all patients remaining\", \"appliesToActivityIds\": [\"2addfc92-99d7-44f7-88ca-3e83090318bb\"]}, {\"id\": \"321de1f9-bb8b-4d6c-8d73-73aa9f82b23b\", \"conditionType\": \"general\", \"text\": \"a. Coronary heart disease documented as having any of the following: 1) History of acute myocardial infarction (ST elevation or non-ST elevation) 2) Stenosis of \\u226550% in at least 1 major (left main, left anterior descending, ramus intermedius, left circumflex, right) coronary artery as determined by cardiac imaging 3) Coronary calcium score \\u2265300 4) Stable angina pectoris treated with anti-anginal medication 5) Asymptomatic cardiac ischemia documented by cardiac imaging on exercise or pharmacological stress test 6) History of coronary revascularization (percutaneous coronary intervention or coronary artery bypass surgery) OR\", \"footnoteId\": \"83a5cb55-ebc5-428c-921b-3d868d1eff40\", \"sourceText\": \"a. Coronary heart disease documented as having any of the following: 1) History of acute myocardial \"}, {\"id\": \"d826f506-e28d-4ba8-8eea-6ecb5d134c6e\", \"conditionType\": \"general\", \"text\": \"b. Peripheral arterial disease presumed to be of atherosclerotic origin documented as a history of any of the following: 1) Current or intermittent claudication 2) Resting limb ischemia 3) Stenosis of >50% in an iliac, femoral, popliteal, or subclavian artery 4) An ankle-brachial index \\u22640.90 5) Peripheral arterial revascularization or amputation due to atherosclerotic vascular disease 6) Asymptomatic carotid artery stenosis \\u226570% 7) Carotid artery revascularization\", \"footnoteId\": \"46d619dd-ae51-4764-980a-97f205687866\", \"sourceText\": \"b. Peripheral arterial disease presumed to be of atherosclerotic origin documented as a history of a\"}, {\"id\": \"e8fbaa36-403f-45bb-bf27-68e4809b02a9\", \"conditionType\": \"procedure_timepoints\", \"text\": \"4. based solely on history of chronic kidney disease and eGFR <60 mL/min/1.73m2, the eGFR value must be confirmed to be <60 mL/min/1.73m2 at Visit 2. u This sample is required only for patients who meet inclusion criterion\", \"footnoteId\": \"e26e3395-a366-4a8f-8642-43a6c003c4b6\", \"sourceText\": \"4. based solely on history of chronic kidney disease and eGFR <60 mL/min/1.73m2, the eGFR value must\", \"appliesToActivityIds\": [\"0a1162a6-2bf7-4df7-bd7e-64e9fbae97bd\", \"2addfc92-99d7-44f7-88ca-3e83090318bb\"]}, {\"id\": \"8831876e-6ece-4cc4-ad6d-e4d7f1fb0f2c\", \"conditionType\": \"general\", \"text\": \"1. Have been diagnosed with T2DM based on the World Health Organization classification or other locally applicable diagnostic standards Patient Characteristics\", \"footnoteId\": \"eee0d99b-76f9-4895-bdf2-d449d65759eb\", \"sourceText\": \"1. Have been diagnosed with T2DM based on the World Health Organization classification or other loca\"}, {\"id\": \"0813dd21-c5ef-42f9-ac90-7a47625ffd47\", \"conditionType\": \"procedure_timepoints\", \"text\": \"2. Have HbA1c between \\u22657.5% (58 mmol/mol) and \\u226410.5% (91 mmol/mol) at screening as determined by the central laboratory at Visit 1\", \"footnoteId\": \"45931c68-6838-4861-90cf-83f1042bc5c6\", \"sourceText\": \"2. Have HbA1c between \\u22657.5% (58 mmol/mol) and \\u226410.5% (91 mmol/mol) at screening as determined by the\", \"appliesToActivityIds\": [\"2addfc92-99d7-44f7-88ca-3e83090318bb\"]}, {\"id\": \"75cf12d5-7ea4-46d7-a78c-8df7edf4a881\", \"conditionType\": \"timing_before\", \"text\": \"3. On stable treatment with unchanged dose of at least 1 and no more than 3 oral antihyperglycemic drugs, which may only include metformin, SGLT-2i, and/or sulfonylurea for at least 3 months before Visit 1\", \"footnoteId\": \"6220c92c-1490-45d7-a457-38fee11fc4e9\", \"sourceText\": \"3. On stable treatment with unchanged dose of at least 1 and no more than 3 oral antihyperglycemic d\", \"appliesToActivityIds\": [\"0a1162a6-2bf7-4df7-bd7e-64e9fbae97bd\", \"2addfc92-99d7-44f7-88ca-3e83090318bb\"]}, {\"id\": \"5e4e36bf-dec8-46ac-9db6-eb1acb3e17fc\", \"conditionType\": \"general\", \"text\": \"6. Study Population Prospective approval of protocol deviations to recruitment and enrollment criteria, also known as protocol waivers or exemptions, are not permitted.\", \"footnoteId\": \"721c9fe8-a09f-41c1-bfc0-9195228c95f9\", \"sourceText\": \"6. Study Population Prospective approval of protocol deviations to recruitment and enrollment criter\", \"appliesToActivityIds\": [\"248c777e-4fb7-4ec2-8325-a20164e18b9f\"]}]"
              },
              {
                "id": "b4a0b1c4-6cc8-451e-bedb-9641c0944669",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-endpointAlgorithms",
                "instanceType": "ExtensionAttribute",
                "valueString": "[{\"id\": \"c2751c57-26e3-44b6-81e4-c3b30f83f411\", \"name\": \"Primary: Mean change in HbA1c\", \"endpointType\": \"Primary\", \"inputs\": [\"HbA1c_baseline\", \"HbA1c_week52\"], \"timeWindow\": {\"reference\": \"baseline\", \"duration\": \"P52W\"}, \"algorithm\": \"HbA1c_week52 - HbA1c_baseline\", \"successCriteria\": \"Noninferiority of LY3298176 10 mg and/or 15 mg to insulin glargine (2-sided 0.05 level)\", \"sourceText\": \"The primary endpoint will be the mean change in hemoglobin A1c (HbA1c) levels from baseline to 52 weeks.\"}, {\"id\": \"dd354d38-6065-4f10-951c-c3e42b57949d\", \"name\": \"Key Secondary: Mean change in HbA1c (5 mg)\", \"endpointType\": \"Secondary\", \"inputs\": [\"HbA1c_baseline\", \"HbA1c_week52\"], \"timeWindow\": {\"reference\": \"baseline\", \"duration\": \"P52W\"}, \"algorithm\": \"HbA1c_week52 - HbA1c_baseline\", \"successCriteria\": \"Noninferiority of LY3298176 5 mg to insulin glargine\", \"sourceText\": \"To demonstrate that QW LY3298176 5 mg is noninferior to insulin glargine for change from baseline in HbA1c at 52 weeks\"}, {\"id\": \"2a91e2be-9449-4a30-8ee6-1ee722e06307\", \"name\": \"Key Secondary: Superiority in HbA1c\", \"endpointType\": \"Secondary\", \"inputs\": [\"HbA1c_baseline\", \"HbA1c_week52\"], \"timeWindow\": {\"reference\": \"baseline\", \"duration\": \"P52W\"}, \"algorithm\": \"HbA1c_week52 - HbA1c_baseline\", \"successCriteria\": \"Superiority of LY3298176 5 mg, 10 mg, and/or 15 mg to insulin glargine\", \"sourceText\": \"To demonstrate that QW LY3298176 5 mg, 10 mg, and/or 15 mg is superior to insulin glargine for change from baseline in HbA1c at 52 weeks\"}, {\"id\": \"b19a9dc5-c807-4cbc-a87e-cd9adff9f7b2\", \"name\": \"Key Secondary: Mean change in body weight\", \"endpointType\": \"Secondary\", \"inputs\": [\"weight_baseline\", \"weight_week52\"], \"timeWindow\": {\"reference\": \"baseline\", \"duration\": \"P52W\"}, \"algorithm\": \"weight_week52 - weight_baseline\", \"successCriteria\": \"Superiority of LY3298176 5 mg, 10 mg, and/or 15 mg to insulin glargine\", \"sourceText\": \"To demonstrate that QW LY3298176 5 mg, 10 mg, and/or 15 mg is superior to insulin glargine for change from baseline in weight at 52 weeks\"}]"
              },
              {
                "id": "1fc14882-ae48-46fe-a953-a3a6dd3919f4",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-derivedVariables",
                "instanceType": "ExtensionAttribute",
                "valueString": "[{\"id\": \"222df0f1-51b6-4568-b6c6-fa29af822087\", \"name\": \"Change from baseline in HbA1c\", \"variableType\": \"ChangeFromBaseline\", \"sourceVariables\": [\"HbA1c\"], \"derivationRule\": \"Value at 52 weeks - Baseline value\", \"baselineDefinition\": \"Value at randomization/Day 1\", \"baselineVisit\": \"Baseline\", \"analysisWindow\": \"52 weeks\", \"imputationRule\": \"Modified Intention-to-Treat (mITT) / MMRM (implied by Phase 3 standard)\", \"unit\": \"%\"}, {\"id\": \"df73bdf9-7ce6-4462-8492-95d977bb5d48\", \"name\": \"Change from baseline in body weight\", \"variableType\": \"ChangeFromBaseline\", \"sourceVariables\": [\"Body weight\"], \"derivationRule\": \"Value at 52 weeks - Baseline value\", \"baselineDefinition\": \"Value at randomization/Day 1\", \"baselineVisit\": \"Baseline\", \"analysisWindow\": \"52 weeks\", \"imputationRule\": \"mITT\", \"unit\": \"kg\"}, {\"id\": \"1c64e53f-854f-426d-a7ba-f2f4134e4cf6\", \"name\": \"Proportion of patients with HbA1c <7.0%\", \"variableType\": \"Categorical\", \"sourceVariables\": [\"HbA1c\"], \"derivationRule\": \"1 if HbA1c < 7.0% (53 mmol/mol) at 52 weeks, else 0\", \"baselineDefinition\": \"Not applicable for status at 52 weeks\", \"baselineVisit\": \"Baseline\", \"analysisWindow\": \"52 weeks\", \"imputationRule\": \"mITT\", \"unit\": \"proportion\"}, {\"id\": \"0b3274e9-b94f-4f84-a15d-07157b4da086\", \"name\": \"Change from baseline in fasting serum glucose\", \"variableType\": \"ChangeFromBaseline\", \"sourceVariables\": [\"Fasting serum glucose\"], \"derivationRule\": \"Value at 52 weeks - Baseline value\", \"baselineDefinition\": \"Value at randomization/Day 1\", \"baselineVisit\": \"Baseline\", \"analysisWindow\": \"52 weeks\", \"imputationRule\": \"mITT\", \"unit\": \"mg/dL or mmol/L\"}, {\"id\": \"2395f390-90b0-4b14-a816-6e7d2928f351\", \"name\": \"Proportion of patients with HbA1c <=6.5%\", \"variableType\": \"Categorical\", \"sourceVariables\": [\"HbA1c\"], \"derivationRule\": \"1 if HbA1c <= 6.5% (48 mmol/mol) at 52 weeks, else 0\", \"baselineDefinition\": \"Not applicable\", \"baselineVisit\": \"Baseline\", \"analysisWindow\": \"52 weeks\", \"imputationRule\": \"mITT\", \"unit\": \"proportion\"}, {\"id\": \"c82c64f8-6438-459c-bfe1-20a364b9477f\", \"name\": \"Proportion of patients with HbA1c <5.7%\", \"variableType\": \"Categorical\", \"sourceVariables\": [\"HbA1c\"], \"derivationRule\": \"1 if HbA1c < 5.7% (39 mmol/mol) at 52 weeks, else 0\", \"baselineDefinition\": \"Not applicable\", \"baselineVisit\": \"Baseline\", \"analysisWindow\": \"52 weeks\", \"imputationRule\": \"mITT\", \"unit\": \"proportion\"}, {\"id\": \"0a8017ab-d88c-4184-a182-ccbbb0159d5b\", \"name\": \"Weight loss categories (>=5%, >10%, >15%)\", \"variableType\": \"PercentChange\", \"sourceVariables\": [\"Body weight\"], \"derivationRule\": \"((Value at 52 weeks - Baseline value) / Baseline value) * 100\", \"baselineDefinition\": \"Value at randomization/Day 1\", \"baselineVisit\": \"Baseline\", \"analysisWindow\": \"52 weeks\", \"imputationRule\": \"mITT\", \"unit\": \"%\"}, {\"id\": \"9376008c-c599-4264-bf48-3f959414b6f3\", \"name\": \"Time to initiation of rescue therapy\", \"variableType\": \"TimeToEvent\", \"sourceVariables\": [\"Rescue therapy start date\", \"Randomization date\"], \"derivationRule\": \"Rescue therapy start date - Randomization date\", \"baselineDefinition\": \"Date of randomization\", \"baselineVisit\": \"Day 1\", \"analysisWindow\": \"From randomization to end of study\", \"imputationRule\": \"Censoring at last contact if no rescue therapy\", \"unit\": \"days\"}, {\"id\": \"e4283ba6-f5a9-4750-b83b-4d535406c6c5\", \"name\": \"Composite CV endpoint\", \"variableType\": \"Composite\", \"sourceVariables\": [\"Cardiovascular death\", \"Myocardial infarction\", \"Stroke\", \"Hospitalization for unstable angina\"], \"derivationRule\": \"Occurrence of any of the four component events\", \"baselineDefinition\": \"Post-randomization occurrence\", \"baselineVisit\": \"Baseline\", \"analysisWindow\": \"Duration of study\", \"imputationRule\": \"Adjudicated events\", \"unit\": \"count/incidence\"}]"
              },
              {
                "id": "3088a531-7dd3-4b7e-838f-bc64dfb91877",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-stateMachine",
                "instanceType": "ExtensionAttribute",
                "valueString": "{\"id\": \"cb1dd7e0-07c1-4981-9474-f55947cf7a40\", \"initialState\": \"Screening\", \"terminalStates\": [\"Early Termination\", \"Completed\"], \"states\": [\"Screening\", \"Lead In\", \"Treatment\", \"Safety Follow Up\", \"End Of Study\", \"Early Termination\"], \"transitions\": [{\"fromState\": \"Screening\", \"toState\": \"Lead In\", \"trigger\": \"Progress to Lead In\"}, {\"fromState\": \"Lead In\", \"toState\": \"Treatment\", \"trigger\": \"Progress to Treatment\"}, {\"fromState\": \"Treatment\", \"toState\": \"Safety Follow Up\", \"trigger\": \"Progress to Safety Follow Up\"}, {\"fromState\": \"Safety Follow Up\", \"toState\": \"End Of Study\", \"trigger\": \"Progress to End Of Study\"}, {\"fromState\": \"Treatment\", \"toState\": \"Early Termination\", \"trigger\": \"Subject exits to Early Termination\"}], \"epochIds\": {\"Screening\": \"SCREENING\", \"Lead In\": \"LEAD_IN\", \"Treatment\": \"TREATMENT\", \"Safety Follow Up\": \"SAFETY_FOLLOW_UP\", \"End Of Study\": \"END_OF_STUDY\", \"Early Termination\": \"EARLY_TERMINATION\"}}"
              },
              {
                "id": "71eeff40-0814-4713-a212-0ed4f6432ab2",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-dosingRegimens",
                "instanceType": "ExtensionAttribute",
                "valueString": "[{\"id\": \"e441ab77-003e-4336-8f7e-aab28b1d17ff\", \"treatmentName\": \"QW LY3298176\", \"frequency\": \"QW\", \"route\": \"Oral\", \"startDay\": 1, \"doseLevels\": [{\"amount\": 10.0, \"unit\": \"mg\"}, {\"amount\": 15.0, \"unit\": \"mg\"}], \"durationDescription\": \"52 weeks\", \"sourceText\": \"ascular (CV) risk. The primary endpoint will be the mean change in hemoglobin A1c (HbA1c) levels from baseline to 52 weeks. Objective(s)/Endpoints: Objectives Endpoints Primary \\uf0b7 To demonstrate that Q\"}, {\"id\": \"0b7ed4ce-23b8-4913-bfec-35fbd2abaeb4\", \"treatmentName\": \"compare LY3298176\", \"frequency\": \"QD\", \"route\": \"Oral\", \"startDay\": 1, \"doseLevels\": [{\"amount\": 5.0, \"unit\": \"mg\"}, {\"amount\": 10.0, \"unit\": \"mg\"}, {\"amount\": 15.0, \"unit\": \"mg\"}], \"sourceText\": \"posure and safety, tolerability, and efficacy measures \\uf0b7 Population PK and PD parameters Tertiary/Exploratory \\uf0b7 To characterize long-term glycemic control with LY3298176 5 mg, 10 mg, and 15 mg \\uf0b7 To co\"}, {\"id\": \"a4b559af-8298-4990-9423-8393eed1b6d3\", \"treatmentName\": \"LY3298176\", \"frequency\": \"QW\", \"route\": \"SC\", \"startDay\": 1, \"durationDescription\": \"Not specified in provided text\", \"titrationSchedule\": \"Mentioned in Section 7.4.1 'Study Drugs' and 7.2.1.1, though specific increments are not in this excerpt.\", \"doseModifications\": [\"Dosage modification details located in Section 7.4\"]}, {\"id\": \"6a23d129-f248-4bec-9c42-d84d0dfb04c8\", \"treatmentName\": \"Insulin Glargine\", \"frequency\": \"QD\", \"route\": \"SC\", \"startDay\": 1, \"durationDescription\": \"Not specified in provided text\", \"titrationSchedule\": \"Mentioned in Section 7.2.1.2 and 7.4.1.\", \"doseModifications\": [\"Reduction and/or Discontinuation of Concomitant Antihyperglycemic Medications (Section 7.4.2)\"]}]"
              },
              {
                "id": "0a05881f-eb13-465a-95e0-7df3fccf2e8d",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-visitWindows",
                "instanceType": "ExtensionAttribute",
                "valueString": "[{\"id\": \"ed1490c3-b955-4fa6-8d00-764f2f6de4ad\", \"visitName\": \"Screening\", \"targetDay\": -14, \"windowBefore\": 7, \"windowAfter\": 3, \"isRequired\": true, \"visitNumber\": 1, \"epoch\": \"Study Period I: Screening\", \"sourceText\": \"Screening Lead in Treatment Period\"}, {\"id\": \"2a0e92f1-4e7c-453c-9a1e-fd3520086060\", \"visitName\": \"Safety Follow-Up\", \"targetDay\": 757, \"windowBefore\": 3, \"windowAfter\": 3, \"isRequired\": true, \"visitNumber\": 801, \"targetWeek\": 108, \"epoch\": \"Study Period IV: Safety F/U\"}, {\"id\": \"5b308f19-e154-4ac8-a114-50c36a026472\", \"visitName\": \"baseline\", \"targetDay\": 0, \"windowBefore\": 1, \"windowAfter\": 1, \"isRequired\": true, \"visitNumber\": 3, \"sourceText\": \"(central laboratory) from baseline \\uf0b7 The proportion of patients achieving an HbA1c\"}, {\"id\": \"8be8a907-4ca8-4174-a45a-d105ce938fe8\", \"visitName\": \"Visit 801\", \"targetDay\": null, \"windowBefore\": 3, \"windowAfter\": 3, \"isRequired\": true, \"visitNumber\": 4, \"sourceText\": \"Visit 801 (safety follow-up visit) should be performed 4 weeks after the ET visit as the final study visit. c The visit date is determined in relation to the date of the randomization visit (\\u00b1 the all\"}, {\"id\": \"e04ad0ee-a656-4573-b154-aca81119cf2c\", \"visitName\": \"Visit 2\", \"targetDay\": null, \"windowBefore\": 3, \"windowAfter\": 3, \"isRequired\": true, \"visitNumber\": 5, \"sourceText\": \"Dilated fundoscopic exam will be performed by an eye care professional (ophthalmologist or optometrist) for all patients between Visit 2 and Visit 3 to exclude patients with proliferative retinopathy \"}, {\"id\": \"c02c671e-73c3-4a94-b32e-01767c853e0f\", \"visitName\": \"Visit 1\", \"targetDay\": null, \"windowBefore\": 3, \"windowAfter\": 3, \"isRequired\": true, \"visitNumber\": 6, \"sourceText\": \"A serum pregnancy test will be performed at Visit 1 for women of childbearing potential only. q A urine pregnancy test must be performed at Visit 3 with the result available prior to randomization and\"}, {\"id\": \"23695061-8e73-4bb1-b8be-4b089c283e12\", \"visitName\": \"Visit 3\", \"targetDay\": null, \"windowBefore\": 3, \"windowAfter\": 3, \"isRequired\": true, \"visitNumber\": 7, \"sourceText\": \"A urine pregnancy test must be performed at Visit 3 with the result available prior to randomization and first injection of study drug(s) for women of childbearing potential only. Additional pregnancy\"}, {\"id\": \"9417e5e1-e000-4564-b8a6-69889cc64fe7\", \"visitName\": \"Visit 25\", \"targetDay\": null, \"windowBefore\": 3, \"windowAfter\": 3, \"isRequired\": true, \"visitNumber\": 8, \"sourceText\": \"Long-term safety period (Visit 25 to Visit 29): Some patients will continue to receive LY3298176 or insulin glargine for up to, but not longer than, 24 months, as determined by the sponsor.\"}, {\"id\": \"c339e2cb-a125-4d9c-aa0d-d26fccb90c9c\", \"visitName\": \"Visit 29\", \"targetDay\": null, \"windowBefore\": 3, \"windowAfter\": 3, \"isRequired\": true, \"visitNumber\": 9, \"sourceText\": \"attend Visit 29 (24 months) or the FTV are considered to have completed the treatment period. Study Period IV (safety follow-up period) Safety follow-up (Visit 801) visits:\"}, {\"id\": \"100330a4-29fe-4ede-85a8-b1e66072fbcb\", \"visitName\": \"End of Study\", \"targetDay\": null, \"windowBefore\": 3, \"windowAfter\": 7, \"isRequired\": true, \"visitNumber\": 10, \"sourceText\": \"End of Study Definition End of the study is the date of the last visit or last scheduled procedure shown in the Schedule of Activities (Section 2) for the last patient.\"}, {\"id\": \"91d69a1f-ded6-4e2a-802f-81e172afcc5b\", \"visitName\": \"Visit 13\", \"targetDay\": null, \"windowBefore\": 3, \"windowAfter\": 3, \"isRequired\": false, \"visitNumber\": 11, \"sourceText\": \"scheduled visits, the IWRS will have unscheduled visits (for example, Visit 13a) dedicated to provide dispensing information for patients whose dose has been de-escalated. Those patients who have thei\"}, {\"id\": \"d25a4fbb-43eb-4d03-a588-e4d3fc9a39c5\", \"visitName\": \"randomization\", \"targetDay\": 1, \"windowBefore\": 7, \"windowAfter\": 7, \"isRequired\": true, \"visitNumber\": 12, \"epoch\": \"Study Period II: Treatment Period\", \"sourceText\": \"or insulin glargine. The randomization will be stratified by country, baseline HbA1c concentration (\\u22648.5%, \\u02c38.5% [\\u226469, \\u02c369 mmol/mol]), and sodium-glucose co-transporter-2 inhibitors (SGLT-2i) use (Yes\"}, {\"id\": \"1f3bc91a-8fde-4814-be6d-ba64d70d6a52\", \"visitName\": \"Week 1\", \"targetDay\": 8, \"windowBefore\": 3, \"windowAfter\": 3, \"isRequired\": true, \"visitNumber\": 4, \"targetWeek\": 1, \"epoch\": \"Study Period II: Treatment Period\"}, {\"id\": \"592976ea-bff4-404c-805e-08aac31845c8\", \"visitName\": \"Week 2\", \"targetDay\": 15, \"windowBefore\": 3, \"windowAfter\": 3, \"isRequired\": true, \"visitNumber\": 5, \"targetWeek\": 2, \"epoch\": \"Study Period II: Treatment Period\"}, {\"id\": \"7d0ebdab-ca9f-4697-b68f-7b22eae5377c\", \"visitName\": \"Week 3\", \"targetDay\": 22, \"windowBefore\": 3, \"windowAfter\": 3, \"isRequired\": true, \"visitNumber\": 6, \"targetWeek\": 3, \"epoch\": \"Study Period II: Treatment Period\"}, {\"id\": \"2f317ffa-ed84-469f-a15c-65f9640c2bae\", \"visitName\": \"Week 4\", \"targetDay\": 29, \"windowBefore\": 3, \"windowAfter\": 3, \"isRequired\": true, \"visitNumber\": 7, \"targetWeek\": 4, \"epoch\": \"Study Period II: Treatment Period\"}, {\"id\": \"55698f8d-cf26-4213-9359-5b8064558b31\", \"visitName\": \"Week 5\", \"targetDay\": 36, \"windowBefore\": 3, \"windowAfter\": 3, \"isRequired\": true, \"visitNumber\": 8, \"targetWeek\": 5, \"epoch\": \"Study Period II: Treatment Period\"}, {\"id\": \"e0861992-9215-4467-9f13-15e351be2222\", \"visitName\": \"Week 6\", \"targetDay\": 43, \"windowBefore\": 3, \"windowAfter\": 3, \"isRequired\": true, \"visitNumber\": 9, \"targetWeek\": 6, \"epoch\": \"Study Period II: Treatment Period\"}, {\"id\": \"5b760fea-56e9-4eb4-98fd-62937a1a1d2d\", \"visitName\": \"Week 8\", \"targetDay\": 50, \"windowBefore\": 3, \"windowAfter\": 3, \"isRequired\": true, \"visitNumber\": 19, \"targetWeek\": 8, \"epoch\": \"Study Period II: Treatment Period\", \"sourceText\": \"Week 8, the dose adjustment will be determined by the patient in a weekly manner and will be reviewed by the investigator at each office visit. Patient will have weekly visits (clinic or phone) in the\"}, {\"id\": \"905e2fcd-c9c5-4cb2-b249-75c8e62be12c\", \"visitName\": \"Week 10\", \"targetDay\": 71, \"windowBefore\": 3, \"windowAfter\": 3, \"isRequired\": true, \"visitNumber\": 12, \"targetWeek\": 10, \"epoch\": \"Study Period II: Treatment Period\"}, {\"id\": \"8d8967b5-d0f0-4ea8-aeee-f998bd16c276\", \"visitName\": \"Week 12\", \"targetDay\": 85, \"windowBefore\": 3, \"windowAfter\": 3, \"isRequired\": true, \"visitNumber\": 13, \"targetWeek\": 12, \"epoch\": \"Study Period II: Treatment Period\"}, {\"id\": \"1e28e39b-ff4b-44a4-bf2e-b3313f1137fb\", \"visitName\": \"Week 16\", \"targetDay\": 106, \"windowBefore\": 3, \"windowAfter\": 3, \"isRequired\": true, \"visitNumber\": 22, \"targetWeek\": 16, \"epoch\": \"Study Period II: Treatment Period\", \"sourceText\": \"have weekly visits (clinic or phone) in the first 8 weeks and then visits every 2-3 weeks (clinic or phone) until Week 16 in order to improve compliance with the TTT algorithm. o\"}, {\"id\": \"e3d9f690-591e-425a-81c3-06fd6265d9c1\", \"visitName\": \"Week 20\", \"targetDay\": 141, \"windowBefore\": 3, \"windowAfter\": 3, \"isRequired\": true, \"visitNumber\": 16, \"targetWeek\": 20, \"epoch\": \"Study Period II: Treatment Period\"}, {\"id\": \"c27e366e-5b94-42a6-897e-78be1ec17c72\", \"visitName\": \"Week 24\", \"targetDay\": 162, \"windowBefore\": 3, \"windowAfter\": 3, \"isRequired\": true, \"visitNumber\": 24, \"targetWeek\": 24, \"epoch\": \"Study Period II: Treatment Period\", \"sourceText\": \"(Week 24), dose decreases will not be permitted. 7.8. Treatment after the End of the Study\"}, {\"id\": \"b40123a7-82a8-4b7b-b3d1-c3047c544500\", \"visitName\": \"Week 28\", \"targetDay\": 197, \"windowBefore\": 3, \"windowAfter\": 3, \"isRequired\": true, \"visitNumber\": 19, \"targetWeek\": 28, \"epoch\": \"Study Period II: Treatment Period\"}, {\"id\": \"4d19b5a1-0eab-4646-a8a6-84af0b2746a4\", \"visitName\": \"Week 32\", \"targetDay\": 225, \"windowBefore\": 3, \"windowAfter\": 3, \"isRequired\": true, \"visitNumber\": 20, \"targetWeek\": 32, \"epoch\": \"Study Period II: Treatment Period\"}, {\"id\": \"3de90fcc-32fc-4ea6-a4a9-8370b96a8b08\", \"visitName\": \"Week 35\", \"targetDay\": 239, \"windowBefore\": 3, \"windowAfter\": 3, \"isRequired\": true, \"visitNumber\": 27, \"targetWeek\": 35, \"epoch\": \"Study Period II: Treatment Period\", \"sourceText\": \"patient gets assigned, they may be required to come to site for PK-specific visits. Draw PK at ET visit only if patient discontinues study prior to Week 35. Visits 10 and 14 are for all patients, but \"}, {\"id\": \"4eb93fd3-1fd2-4a9c-80df-dd91e4148b54\", \"visitName\": \"Week 36\", \"targetDay\": 253, \"windowBefore\": 3, \"windowAfter\": 3, \"isRequired\": true, \"visitNumber\": 22, \"targetWeek\": 36, \"epoch\": \"Study Period II: Treatment Period\"}, {\"id\": \"d0ddda02-4dc2-43e6-934b-eba00c6f7f21\", \"visitName\": \"Week 42\", \"targetDay\": 295, \"windowBefore\": 7, \"windowAfter\": 7, \"isRequired\": true, \"visitNumber\": 23, \"targetWeek\": 42, \"epoch\": \"Study Period II: Treatment Period\"}, {\"id\": \"18e6bd58-cfbd-46fb-8720-0d0fe72244c3\", \"visitName\": \"Week 52\", \"targetDay\": 358, \"windowBefore\": 3, \"windowAfter\": 3, \"isRequired\": true, \"visitNumber\": 30, \"targetWeek\": 52, \"epoch\": \"Study Period II: Treatment Period\", \"sourceText\": \"same treatment arm who had their efficacy measure at the Week 52 visit assessed after early discontinuation of study drug and/or initiation of rescue medication (retrieved dropouts). Analysis will be \"}, {\"id\": \"e6d208bf-95b2-407b-9f33-af4de44cf414\", \"visitName\": \"Follow-up\", \"targetDay\": 365, \"windowBefore\": 7, \"windowAfter\": 7, \"isRequired\": true, \"visitNumber\": 31, \"sourceText\": \"safety follow-up period, with respect to the following outcomes \\uf0b7\"}, {\"id\": \"ee00941b-0ca8-4f03-b4b1-98f0b4a4f96c\", \"visitName\": \"Week 62\", \"targetDay\": 435, \"windowBefore\": 7, \"windowAfter\": 7, \"isRequired\": true, \"visitNumber\": 25, \"targetWeek\": 62, \"epoch\": \"Study Period III: Treatment Period\"}, {\"id\": \"0addec05-b578-47c5-8a59-d57dd9576b54\", \"visitName\": \"Week 72\", \"targetDay\": 505, \"windowBefore\": 7, \"windowAfter\": 7, \"isRequired\": true, \"visitNumber\": 26, \"targetWeek\": 72, \"epoch\": \"Study Period III: Treatment Period\"}, {\"id\": \"0f089e19-9d86-4af8-ab71-0476f7945b69\", \"visitName\": \"Week 78\", \"targetDay\": 547, \"windowBefore\": 7, \"windowAfter\": 7, \"isRequired\": true, \"visitNumber\": 27, \"targetWeek\": 78, \"epoch\": \"Study Period III: Treatment Period\"}, {\"id\": \"95b5cc74-0b69-4241-9af6-062bc3ea2ec6\", \"visitName\": \"Week 88\", \"targetDay\": 617, \"windowBefore\": 7, \"windowAfter\": 7, \"isRequired\": true, \"visitNumber\": 28, \"targetWeek\": 88, \"epoch\": \"Study Period III: Treatment Period\"}, {\"id\": \"c92f42c7-9e9a-4ada-a4ec-2bf41448a43d\", \"visitName\": \"Week 104\", \"targetDay\": 729, \"windowBefore\": 7, \"windowAfter\": 7, \"isRequired\": true, \"visitNumber\": 29, \"targetWeek\": 104, \"epoch\": \"Study Period III: Treatment Period\"}]"
              },
              {
                "id": "66f36d8d-8486-4c50-8003-51e464c6b33e",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-randomizationScheme",
                "instanceType": "ExtensionAttribute",
                "valueString": "{\"id\": \"b06e7130-58f7-4e85-9a81-21401629dfae\", \"ratio\": \"1:1:1:3\", \"method\": \"Stratified randomization\", \"centralRandomization\": true, \"stratificationFactors\": [{\"id\": \"5d10c26f-a80f-40b4-b014-a5c724683322\", \"name\": \"Country\", \"categories\": [\"Category 1\", \"Category 2\"], \"isBlocking\": false, \"sourceText\": \"country, baseline hba1c concentration (\\u22648\"}, {\"id\": \"e5dfcf33-ef6c-40ab-bfb2-9724dd01576b\", \"name\": \"Baseline\", \"categories\": [\"Category 1\", \"Category 2\"], \"isBlocking\": false, \"sourceText\": \"country, baseline hba1c concentration (\\u22648\"}, {\"id\": \"5be24278-7bf7-44f4-b58b-62d824dd6704\", \"name\": \"Baseline HbA1c concentration\", \"categories\": [\"\\u22648.5% (\\u226469 mmol/mol)\", \"\\u02c38.5% (\\u02c369 mmol/mol)\"], \"isBlocking\": false}, {\"id\": \"566f1f21-fceb-4f3e-835f-f492be30c18d\", \"name\": \"Sodium-glucose co-transporter-2 inhibitors (SGLT-2i) use\", \"categories\": [\"Yes\", \"No\"], \"isBlocking\": false}], \"sourceText\": \"I8F-MC-GPGM(b) Clinical Protocol\\nPage 11\\nLY3298176\\nSummary of Study Design:  \\nStudy GPGM is a Phase 3, open-label comparator, multicenter, parallel-arm, randomized study to compare the \\nsafety and eff\"}"
              },
              {
                "id": "20f3da41-8458-4362-90bc-16d1232398c9",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-analysisWindows",
                "instanceType": "ExtensionAttribute",
                "valueString": "[{\"id\": \"d453421e-2133-46db-80a0-9d094a185d11\", \"windowType\": \"treatment\", \"name\": \"Treatment Period\", \"startDay\": 3, \"endDay\": 2, \"description\": \"Active treatment from Day 3 to Day 2\", \"sourceText\": \"Treatment\\n-3\\n-2\"}]"
              },
              {
                "id": "ext_execution_model_bc4ace4b-b8ec-402f-a48d-f1095959f3d3",
                "url": "https://protocol2usdm.io/extensions/x-executionModel",
                "instanceType": "ExtensionAttribute",
                "valueObject": {
                  "schemaVersion": "1.0.0",
                  "extractionTimestamp": "2026-01-23T04:23:20.024263",
                  "executionModel": {
                    "timeAnchors": [
                      {
                        "id": "d97f56f0-21d4-43cc-bfb4-f62b28719b45",
                        "definition": "First administration of investigational product",
                        "anchorType": "FirstDose",
                        "classification": "Event",
                        "timelineId": null,
                        "dayValue": 1,
                        "intraDayOrder": 60,
                        "sourceText": "first dose of \nstudy drug",
                        "encounterId": null,
                        "activityId": null
                      },
                      {
                        "id": "739ff35f-0418-4d45-90aa-150c6fd123ae",
                        "definition": "Date of subject randomization",
                        "anchorType": "Randomization",
                        "classification": "Event",
                        "timelineId": null,
                        "dayValue": 1,
                        "intraDayOrder": 40,
                        "sourceText": "randomization visit",
                        "encounterId": null,
                        "activityId": null
                      },
                      {
                        "id": "d4c89535-777f-4b21-876c-907335907ae3",
                        "definition": "Baseline visit/assessment",
                        "anchorType": "Baseline",
                        "classification": "Visit",
                        "timelineId": null,
                        "dayValue": 1,
                        "intraDayOrder": 50,
                        "sourceText": "Baseline assessment",
                        "encounterId": null,
                        "activityId": null
                      },
                      {
                        "id": "60997f85-db35-4add-a7d1-e8491c0adc6d",
                        "definition": "Informed consent obtained",
                        "anchorType": "InformedConsent",
                        "classification": "Event",
                        "timelineId": null,
                        "dayValue": 1,
                        "intraDayOrder": 10,
                        "sourceText": "Informed \nconsent",
                        "encounterId": null,
                        "activityId": null
                      },
                      {
                        "id": "9d2dfa91-7899-4f5e-afc0-894e83ae505d",
                        "definition": "procedure",
                        "anchorType": "Custom",
                        "classification": "Conceptual",
                        "timelineId": null,
                        "dayValue": 1,
                        "intraDayOrder": 100,
                        "sourceText": "procedure",
                        "encounterId": null,
                        "activityId": null
                      }
                    ],
                    "repetitions": [
                      {
                        "id": "c55be0c5-9594-4cda-a5e6-7539aed5802d",
                        "type": "Daily",
                        "interval": "P1D",
                        "sourceText": "once daily"
                      },
                      {
                        "id": "e982d09a-4195-474e-9d28-83300cfff954",
                        "type": "Daily",
                        "interval": "P1D",
                        "sourceText": "od"
                      },
                      {
                        "id": "11ad9a84-9216-4384-8541-219388ed5870",
                        "type": "Interval",
                        "sourceText": "bid"
                      },
                      {
                        "id": "5321395f-d59b-4681-b4a9-8860a9adcb4d",
                        "type": "Interval",
                        "sourceText": "tid"
                      },
                      {
                        "id": "66631257-3318-40fe-a2fa-52e794e78551",
                        "type": "Continuous",
                        "startOffset": "P8D",
                        "endOffset": "P16D",
                        "sourceText": "Week 8 to Week 16"
                      },
                      {
                        "id": "231366d2-cee2-4fe4-87f9-8519a308843f",
                        "type": "Continuous",
                        "endOffset": "P3D",
                        "sourceText": "Weeks\n0 to 3"
                      },
                      {
                        "id": "b73b2b06-6d50-452a-b9e3-66cfd2165c17",
                        "type": "Continuous",
                        "startOffset": "P4D",
                        "endOffset": "P7D",
                        "sourceText": "Weeks\n4 to 7"
                      },
                      {
                        "id": "81dd3ded-2f37-4aab-846d-2a9b000536d6",
                        "type": "Continuous",
                        "startOffset": "P8D",
                        "endOffset": "P11D",
                        "sourceText": "Weeks\n8 to 11"
                      },
                      {
                        "id": "6b6bd27f-9ef9-4866-add8-68c7a420ea52",
                        "type": "Continuous",
                        "startOffset": "P12D",
                        "endOffset": "P15D",
                        "sourceText": "Weeks\n12 to 15"
                      },
                      {
                        "id": "b02cf6d3-6e4d-462a-970b-06b0a1755a5f",
                        "type": "Continuous",
                        "startOffset": "P16D",
                        "endOffset": "P19D",
                        "sourceText": "Weeks\n16 to 19"
                      },
                      {
                        "id": "1366a270-a5e2-4ef5-9d67-cb6346f6663b",
                        "type": "Continuous",
                        "startOffset": "P20D",
                        "endOffset": "P104D",
                        "sourceText": "Weeks\n20 to 104"
                      },
                      {
                        "id": "12afa8f2-859a-4d3e-94e1-689aba4bd2ea",
                        "type": "Continuous",
                        "startOffset": "P8D",
                        "endOffset": "P16D",
                        "sourceText": "from Week 8 to Week 16"
                      },
                      {
                        "id": "6069f58b-9272-4eff-9bd7-81e730cc9d8f",
                        "type": "Continuous",
                        "sourceText": "treatment period"
                      },
                      {
                        "id": "8eae5986-38df-4fb2-b1fb-38e957588ee4",
                        "type": "Continuous",
                        "sourceText": "Treatment Period"
                      },
                      {
                        "id": "f1121bfc-4586-45f2-bf89-6d7414647f30",
                        "type": "Continuous",
                        "sourceText": "follow-up period"
                      },
                      {
                        "id": "e45e6e82-d462-46b9-830e-dbee5ff9e4c2",
                        "type": "Continuous",
                        "sourceText": "2 \nhours after"
                      },
                      {
                        "id": "e83289a0-2cb4-4e04-82ca-edaff9861919",
                        "type": "Daily",
                        "startOffset": "null",
                        "endOffset": "null",
                        "interval": "P1D",
                        "exitCondition": "null",
                        "sourceText": "Ability to Perform Physical Activities of Daily Living (APPADL)"
                      }
                    ],
                    "samplingConstraints": [],
                    "traversalConstraints": [
                      {
                        "id": "fe5e543e-ecb2-4e34-9349-c46aed12aa17",
                        "requiredSequence": [
                          "epoch_1",
                          "epoch_1",
                          "epoch_2",
                          "epoch_4",
                          "epoch_4"
                        ],
                        "allowEarlyExit": true,
                        "exitEpochIds": [
                          "086c7f99-7504-483e-a31c-34ab32951743"
                        ],
                        "mandatoryVisits": [
                          "Safety Follow-up Visit",
                          "End of Study",
                          "Primary Endpoint Visit",
                          "Randomization",
                          "Screening"
                        ],
                        "sourceText": "[{'condition': 'Permanent Discontinuation from Study Treatment', 'path': ['EARLY_TREATMENT_DISCONTINUATION_VISIT', 'CONTINUED_STUDY_OBSERVATION', 'SAFETY_FOLLOW_UP']}, {'condition': 'Temporary Interruption of Study Treatment', 'path': ['TREATMENT_PAUSE', 'TREATMENT_RE_INITIATION']}, {'condition': 'Inadvertently Enrolled Patients', 'path': ['IMMEDIATE_DISCONTINUATION']}]"
                      }
                    ],
                    "executionTypes": [
                      {
                        "activityId": "Blood Sample",
                        "executionType": "Episode",
                        "rationale": "EPISODE signals: 1"
                      },
                      {
                        "activityId": "Vital Signs",
                        "executionType": "Single",
                        "rationale": "EPISODE signals: 1; SINGLE signals: 2"
                      },
                      {
                        "activityId": "Electrocardiogram",
                        "executionType": "Episode",
                        "rationale": "EPISODE signals: 1"
                      },
                      {
                        "activityId": "Pe",
                        "executionType": "Single",
                        "rationale": "No strong signals detected"
                      },
                      {
                        "activityId": "Adverse Events",
                        "executionType": "Single",
                        "rationale": "SINGLE signals: 5"
                      },
                      {
                        "activityId": "Concomitant \nMedications",
                        "executionType": "Single",
                        "rationale": "SINGLE signals: 2"
                      },
                      {
                        "activityId": "Laboratory Tests",
                        "executionType": "Single",
                        "rationale": "No strong signals detected"
                      },
                      {
                        "activityId": "Pharmacokinetic",
                        "executionType": "Episode",
                        "rationale": "EPISODE signals: 2"
                      },
                      {
                        "activityId": "Pharmacodynamic",
                        "executionType": "Single",
                        "rationale": "No strong signals detected"
                      },
                      {
                        "activityId": "Drug Administration",
                        "executionType": "Episode",
                        "rationale": "EPISODE signals: 2"
                      },
                      {
                        "activityId": "Imaging",
                        "executionType": "Single",
                        "rationale": "SINGLE signals: 2"
                      },
                      {
                        "activityId": "Epro",
                        "executionType": "Single",
                        "rationale": "No strong signals detected"
                      },
                      {
                        "activityId": "Informed Consent",
                        "executionType": "Single",
                        "rationale": "Obtained once at the start of the screening process."
                      },
                      {
                        "activityId": "LY3298176 Once Weekly Administration",
                        "executionType": "Single",
                        "rationale": "The drug is administered on a scheduled weekly basis throughout the treatment period."
                      },
                      {
                        "activityId": "Insulin Glargine Titration",
                        "executionType": "Single",
                        "rationale": "Dosing is adjusted based on specific glucose targets and decision points (treat-to-target)."
                      },
                      {
                        "activityId": "Safety and Efficacy Assessments",
                        "executionType": "Single",
                        "rationale": "Assessments are performed at multiple scheduled study visits as per the Schedule of Activities."
                      },
                      {
                        "activityId": "Screening Procedures",
                        "executionType": "Single",
                        "rationale": "Assessments performed only during the screening period to determine eligibility."
                      }
                    ],
                    "footnoteConditions": [
                      {
                        "id": "189ed620-3d73-4231-bf0f-6b602361336e",
                        "conditionType": "timing_before",
                        "text": "a Baseline assessments must be completed before processing in the interactive web-response system (IWRS).",
                        "footnoteId": "548b8495-96ff-4b51-90d7-a66f21ff6b1a",
                        "structuredCondition": "timing.before(IWRS_Processing)",
                        "appliesToActivityIds": [
                          "Baseline assessments"
                        ],
                        "sourceText": "a Baseline assessments must be completed before processing in the interactive web-response system (I"
                      },
                      {
                        "id": "4cec5201-b2a3-4113-b6bc-f46340d49c7e",
                        "conditionType": "timing_after",
                        "text": "b Patients who are unable or unwilling to continue in the study for any reason will perform an ET visit. If the patient is discontinuing during an unscheduled visit, that visit should be performed as the ET visit. If the patient is discontinuing during a scheduled visit, that visit should be performed as an ET visit. Visit 801 (safety follow-up visit) should be performed 4 weeks after the ET visit as the final study visit.",
                        "footnoteId": "9c312ce3-7adf-45b3-ae10-098df2cc4cbb",
                        "structuredCondition": "timing.after(ET_Visit, P4W)",
                        "appliesToActivityIds": [
                          "Visit 801",
                          "7324b55e-563b-4040-a428-d5bc40839de6"
                        ],
                        "sourceText": "b Patients who are unable or unwilling to continue in the study for any reason will perform an ET vi"
                      },
                      {
                        "id": "7beb3bae-6fb2-4467-9225-03af2db1109d",
                        "conditionType": "general",
                        "text": "c The visit date is determined in relation to the date of the randomization visit ( the allowed visit window).",
                        "footnoteId": "bc2a96e9-664f-4e8c-9f2a-18973f4c3a2b",
                        "sourceText": "c The visit date is determined in relation to the date of the randomization visit ( the allowed vis"
                      },
                      {
                        "id": "07532fe6-d530-47e4-83ee-1fdfc50dd3d5",
                        "conditionType": "timing_before",
                        "text": "d On visits 3, 5, 7, 11, 13, 15, 16, 18, 23, 24, 27, 29, ET, and at follow-up (801), patients should be reminded to report to the site in a fasting condition, after a period of approximately 8 hours without eating, drinking (except water), or any significant physical activity and before taking study drug(s), metformin (if used), SGLT-2i (if used), SU (if used).",
                        "footnoteId": "887f069e-dd6c-4563-b9a2-2266c92ba7ee",
                        "structuredCondition": "state.fasting(duration=PT8H) AND timing.before(study_drug, metformin, SGLT-2i, SU)",
                        "appliesToActivityIds": [
                          "Visit 3",
                          "Visit 5",
                          "Visit 7",
                          "Visit 11",
                          "Visit 13",
                          "Visit 15",
                          "Visit 16",
                          "Visit 18",
                          "Visit 23",
                          "Visit 24",
                          "Visit 27",
                          "Visit 29",
                          "ET",
                          "fb3f35bc-29bf-46b3-b1c6-be16aadc7023"
                        ],
                        "timingConstraint": "PT8H",
                        "sourceText": "d On visits 3, 5, 7, 11, 13, 15, 16, 18, 23, 24, 27, 29, ET, and at follow-up (801), patients should"
                      },
                      {
                        "id": "6fbda380-f6cb-425c-b7fe-fb2aaf8fb3c2",
                        "conditionType": "general",
                        "text": "e Medical history includes assessment of preexisting conditions (including history of gall bladder disease, cardiovascular disease, and medullary thyroid carcinoma) and substance usage (such as, alcohol and tobacco).",
                        "footnoteId": "3223bee3-9d59-43d2-873c-5fec30d8e642",
                        "sourceText": "e Medical history includes assessment of preexisting conditions (including history of gall bladder d"
                      },
                      {
                        "id": "03dfe860-b3cb-4ffd-9acf-03a5b7d8c260",
                        "conditionType": "general",
                        "text": "f Weight measurements should be obtained per the detailed guidance in the Manual of Operations.",
                        "footnoteId": "1a34d6dd-9c0f-4da4-8fec-256ba5cde7ce",
                        "sourceText": "f Weight measurements should be obtained per the detailed guidance in the Manual of Operations."
                      },
                      {
                        "id": "048d118a-7e8e-4dff-814d-bae479f3a8eb",
                        "conditionType": "timing_before",
                        "text": "g Vital sign measurements should be taken before obtaining an ECG tracing and before collection of blood samples for laboratory testing, at visits where required. The participant should sit quietly for 5 minutes before vital sign measurements are taken. For each parameter, 2 measurements will be taken using the same arm; the recordings should be taken at least 1 minute apart. BP must be taken with an automated blood pressure machine.",
                        "footnoteId": "8014efcc-90a2-4b3a-aff3-ad2126afc706",
                        "structuredCondition": "timing.before(vital sign measurements are taken. for each parameter, 2 measurements will be taken using the same arm; the recordings should be taken at least 1 minute apart. bp must be taken with an automated blood pressure machine., PT5M)",
                        "appliesToActivityIds": [
                          "Vital sign measurements"
                        ],
                        "timingConstraint": "PT5M",
                        "sourceText": "g Vital sign measurements should be taken before obtaining an ECG tracing and before collection of b"
                      },
                      {
                        "id": "00a217b9-0b54-4d12-b897-d31b9d80d6b0",
                        "conditionType": "procedure_conditional",
                        "text": "h Dilated fundoscopic exam will be performed by an eye care professional (ophthalmologist or optometrist) for all patients between Visit 2 and Visit 3 to exclude patients with proliferative retinopathy and/or maculopathy. The results from this exam will be recorded on a specific retinopathy eCRF as a baseline measure of retinopathy. A follow-up dilated fundoscopic exam should be performed when clinically indicated by any adverse event suspected of worsening retinopathy, and the findings should be recorded on the retinopathy eCRF.",
                        "footnoteId": "985ed096-e288-45dd-a394-5584ffac6dfa",
                        "structuredCondition": "timing.between(Visit_2, Visit_3)",
                        "appliesToActivityIds": [
                          "Dilated fundoscopic exam"
                        ],
                        "sourceText": "h Dilated fundoscopic exam will be performed by an eye care professional (ophthalmologist or optomet"
                      },
                      {
                        "id": "d14c2e2d-38cd-4cca-a664-9b81f845dbc3",
                        "conditionType": "general",
                        "text": "i Includes counseling on diet and exercise, management of hypoglycemia and hyperglycemia, etc.",
                        "footnoteId": "b93de2c8-0292-4cd9-ba2e-8d6e832db712",
                        "sourceText": "i Includes counseling on diet and exercise, management of hypoglycemia and hyperglycemia, etc."
                      },
                      {
                        "id": "1f5322ec-52ca-4d1b-b642-c1c11aee9096",
                        "conditionType": "general",
                        "text": "j All training should be repeated as needed to ensure patient compliance.",
                        "footnoteId": "3cd3b044-52ab-43b1-ad0f-b8c95e654f7a",
                        "sourceText": "j All training should be repeated as needed to ensure patient compliance."
                      },
                      {
                        "id": "1cc8aacd-5fd2-488e-b3ec-ffc860cd2eb5",
                        "conditionType": "timing_before",
                        "text": "k Patient is required to collect two 7-point SMBGs on nonconsecutive days prior to the next visit. A 7-point SMBG consists of measurements before and 2 hours after each of 3 main meals within the same day and at bedtime. These SMBG profiles will be collected by the patient within 2 weeks prior to the assigned visits. If 7-point SMBG is not performed, then data from the most recent nonconsecutive 4-point SMBG profiles can be used. If more than 2 SMBG profiles are available, the 2 most recent nonconsecutive profiles should be used.",
                        "footnoteId": "ce5d21df-7cb4-4635-8ee1-cb5d699c92e1",
                        "structuredCondition": "timing.after(each of 3 main meals within the same day and at bedtime. these smbg profiles will be collected by the patient within 2 weeks prior to the assigned visits. if 7-point smbg is not performed, then data from the most recent nonconsecutive 4-point smbg profiles can be used. if more than 2 smbg profiles are available, the 2 most recent nonconsecutive profiles should be used., PT2M)",
                        "appliesToActivityIds": [
                          "SMBG collection"
                        ],
                        "timingConstraint": "PT2H",
                        "sourceText": "k Patient is required to collect two 7-point SMBGs on nonconsecutive days prior to the next visit. A"
                      },
                      {
                        "id": "462ecf60-1f61-4060-a5a5-766eb893aa31",
                        "conditionType": "timing_after",
                        "text": "l Patients should administer their first dose of LY3298176 at the end of this visit, after other study procedures and randomization.",
                        "footnoteId": "3c4a86ec-ed3f-4daa-bd20-b27cac5a44bc",
                        "structuredCondition": "timing.after(Randomization) AND timing.after(Study_Procedures)",
                        "appliesToActivityIds": [
                          "First dose of LY3298176"
                        ],
                        "sourceText": "l Patients should administer their first dose of LY3298176 at the end of this visit, after other stu"
                      },
                      {
                        "id": "dfde1752-69e7-477d-b565-68eeffbbda77",
                        "conditionType": "general",
                        "text": "m LY3298176 patients only.",
                        "footnoteId": "312f11c2-88cd-4954-9dbc-a2f404af2b28",
                        "structuredCondition": "patient.cohort == 'LY3298176'",
                        "appliesToActivityIds": [
                          "All activities marked m"
                        ],
                        "sourceText": "m LY3298176 patients only."
                      },
                      {
                        "id": "7e2a0f6a-94d0-472f-a633-6962c0bff1e7",
                        "conditionType": "timing_after",
                        "text": "n During the first 8 weeks, the dose adjustment will be determined by the investigator in discussion with the patient by following a TTT algorithm. After Week 8, the dose adjustment will be determined by the patient in a weekly manner and will be reviewed by the investigator at each office visit. Patient will have weekly visits (clinic or phone) in the first 8 weeks and then visits every 2-3 weeks (clinic or phone) until Week 16 in order to improve compliance with the TTT algorithm.",
                        "footnoteId": "12cd244d-a15b-468f-87cb-6309233d0a6e",
                        "sourceText": "n During the first 8 weeks, the dose adjustment will be determined by the investigator in discussion"
                      },
                      {
                        "id": "528aa55d-da3e-4a99-8f20-5a20e3999261",
                        "conditionType": "procedure_timepoints",
                        "text": "o Insulin glargine patients only. A review of the patients compliance to the TTT algorithm will still be conducted during the telephone Visits 6, 8, 9, and 12, but the patients compliance for these visits will be collected in the eCRF at Visits 7, 10 and 13 for the period since the previous visit.",
                        "footnoteId": "0dc13c61-162f-47de-81c2-c6b5656611eb",
                        "sourceText": "o Insulin glargine patients only. A review of the patients compliance to the TTT algorithm will sti"
                      },
                      {
                        "id": "59dc1461-33e2-4d2d-8389-76c59d1d8692",
                        "conditionType": "eligibility_wocbp",
                        "text": "p A serum pregnancy test will be performed at Visit 1 for women of childbearing potential only.",
                        "footnoteId": "ff35b2a7-60cb-4494-b4bf-ba5b60d1ea72",
                        "structuredCondition": "subject.sex == 'Female' AND subject.isOfChildbearingPotential == true",
                        "appliesToActivityIds": [
                          "Serum pregnancy test"
                        ],
                        "sourceText": "p A serum pregnancy test will be performed at Visit 1 for women of childbearing potential only."
                      },
                      {
                        "id": "469ca952-6ebd-4f45-900e-2066c5b417f5",
                        "conditionType": "timing_before",
                        "text": "q A urine pregnancy test must be performed at Visit 3 with the result available prior to randomization and first injection of study drug(s) for women of childbearing potential only. Additional pregnancy tests may be performed at the investigators discretion during the study. If required per local regulations and/or institutional guidelines, pregnancy testing can also occur at other times during the study treatment period.",
                        "footnoteId": "3044ccfc-4571-4ddb-b5d2-9929bd15fa2b",
                        "structuredCondition": "timing.before(Randomization) AND timing.before(First_Injection)",
                        "appliesToActivityIds": [
                          "Urine pregnancy test"
                        ],
                        "sourceText": "q A urine pregnancy test must be performed at Visit 3 with the result available prior to randomizati"
                      },
                      {
                        "id": "7ab95df8-f804-4f5d-9c44-a56f4f7c37a1",
                        "conditionType": "procedure_timepoints",
                        "text": "r Follicle-stimulating hormone test performed at Visit 1 for postmenopausal women at least 50 years of age with an intact uterus, without a history of oophorectomy or bilateral tubal ligation, not on hormone therapy, and who have had spontaneous amenorrhea for more than 6 months and less than 12 months.",
                        "footnoteId": "04be48a1-8db9-4258-ab7d-44e8a812928d",
                        "sourceText": "r Follicle-stimulating hormone test performed at Visit 1 for postmenopausal women at least 50 years "
                      },
                      {
                        "id": "5b1158d3-ffa4-42ef-9200-bf0ca3147e34",
                        "conditionType": "general",
                        "text": "s Screening visit assessment will serve as baseline.",
                        "footnoteId": "bfcbb23e-b7d0-449e-b707-d8045f76ebd4",
                        "sourceText": "s Screening visit assessment will serve as baseline."
                      },
                      {
                        "id": "9193997d-8add-4846-81cc-78c5d3e4c37b",
                        "conditionType": "procedure_timepoints",
                        "text": "t The CKD-EPI equation will be used by the central lab to estimate and report eGFR. For patients who meet inclusion criterion [4] based solely on history of chronic kidney disease and eGFR <60 mL/min/1.73m, the eGFR value must be confirmed to be <60 mL/min/1.73m at Visit 2.",
                        "footnoteId": "189518f8-e15d-421a-999b-3a1c89bc10f1",
                        "sourceText": "t The CKD-EPI equation will be used by the central lab to estimate and report eGFR. For patients who"
                      },
                      {
                        "id": "794fd0bc-6840-4412-8285-f3ff05b4e2fb",
                        "conditionType": "general",
                        "text": "u This sample is required only for patients who meet inclusion criterion [4] based solely on history of chronic kidney disease and eGFR <60 mL/min/1.73m.",
                        "footnoteId": "f8cd90c6-8c3d-4865-869f-adb65ff82bda",
                        "sourceText": "u This sample is required only for patients who meet inclusion criterion [4] based solely on history"
                      },
                      {
                        "id": "e75d71f4-f258-462c-8939-ebec789d3e7f",
                        "conditionType": "general",
                        "text": "v In the event of systemic drug hypersensitivity reactions (immediate or nonimmediate), additional blood samples will be collected including ADA, PK, and, exploratory biomarker sample.",
                        "footnoteId": "f5ac956c-8f06-4341-8b8f-90a49ef14f2e",
                        "sourceText": "v In the event of systemic drug hypersensitivity reactions (immediate or nonimmediate), additional b"
                      },
                      {
                        "id": "49f6f72e-78c1-4ab0-bda5-96f6924bf92f",
                        "conditionType": "timing_before",
                        "text": "w PK sample for immunogenicity must be collected prior to drug administration.",
                        "footnoteId": "d2cf220c-67bd-46fa-b8ff-724af6fb2dbe",
                        "structuredCondition": "timing.before(Drug_Administration)",
                        "appliesToActivityIds": [
                          "PK sample for immunogenicity"
                        ],
                        "sourceText": "w PK sample for immunogenicity must be collected prior to drug administration."
                      },
                      {
                        "id": "fdc009fc-20a8-472d-9324-ec6d6619f86a",
                        "conditionType": "timing_before",
                        "text": "x PK samples will not be collected from patients who were randomized to insulin glargine since it is an open-label study. PK samples will be collected at these visits at time windows of 1 to 24 hours, 24 to 96 hours, OR 120 to 168 hours post dose, as assigned by IWRS. Dependent on the time-windows to which a patient gets assigned, they may be required to come to site for PK-specific visits. Draw PK at ET visit only if patient discontinues study prior to Week 35. Visits 10 and 14 are for all patients, but only those patients assigned to PK will get a PK blood draw. Visits 17 and 21 are for patients assigned to a PK blood draw only.",
                        "footnoteId": "207ca9ae-0873-4255-a164-680a544c0606",
                        "timingConstraint": "PT24H",
                        "sourceText": "x PK samples will not be collected from patients who were randomized to insulin glargine since it is"
                      },
                      {
                        "id": "aecbcbba-3fd1-4674-8649-c44ad9b3cfa5",
                        "conditionType": "timing_before",
                        "text": "y PROs should be completed before any other study procedures if the patient is not adversely affected by the fasting condition or completed after the patient has sufficiently recovered from the preceding visit procedures.",
                        "footnoteId": "ba443ffd-77f4-471c-9f84-43b4b805a691",
                        "structuredCondition": "timing.before(Other_Procedures) IF patient.fasting_status == 'tolerated'",
                        "appliesToActivityIds": [
                          "PROs"
                        ],
                        "sourceText": "y PROs should be completed before any other study procedures if the patient is not adversely affecte"
                      },
                      {
                        "id": "268b3837-b00e-4484-a02c-a7404cd6c5ae",
                        "conditionType": "timing_after",
                        "text": "z When the sponsor determines that the study has met the completion criteria, all patients remaining in the study will return to the site for a FTV within approximately 30 days. The safety follow-up visit will be approximately 30 days after the FTV.",
                        "footnoteId": "70407f7f-55d6-4de0-a558-318d3613a9f3",
                        "sourceText": "z When the sponsor determines that the study has met the completion criteria, all patients remaining"
                      },
                      {
                        "id": "321de1f9-bb8b-4d6c-8d73-73aa9f82b23b",
                        "conditionType": "general",
                        "text": "a. Coronary heart disease documented as having any of the following: 1) History of acute myocardial infarction (ST elevation or non-ST elevation) 2) Stenosis of 50% in at least 1 major (left main, left anterior descending, ramus intermedius, left circumflex, right) coronary artery as determined by cardiac imaging 3) Coronary calcium score 300 4) Stable angina pectoris treated with anti-anginal medication 5) Asymptomatic cardiac ischemia documented by cardiac imaging on exercise or pharmacological stress test 6) History of coronary revascularization (percutaneous coronary intervention or coronary artery bypass surgery) OR",
                        "footnoteId": "83a5cb55-ebc5-428c-921b-3d868d1eff40",
                        "sourceText": "a. Coronary heart disease documented as having any of the following: 1) History of acute myocardial "
                      },
                      {
                        "id": "d826f506-e28d-4ba8-8eea-6ecb5d134c6e",
                        "conditionType": "general",
                        "text": "b. Peripheral arterial disease presumed to be of atherosclerotic origin documented as a history of any of the following: 1) Current or intermittent claudication 2) Resting limb ischemia 3) Stenosis of >50% in an iliac, femoral, popliteal, or subclavian artery 4) An ankle-brachial index 0.90 5) Peripheral arterial revascularization or amputation due to atherosclerotic vascular disease 6) Asymptomatic carotid artery stenosis 70% 7) Carotid artery revascularization",
                        "footnoteId": "46d619dd-ae51-4764-980a-97f205687866",
                        "sourceText": "b. Peripheral arterial disease presumed to be of atherosclerotic origin documented as a history of a"
                      },
                      {
                        "id": "e8fbaa36-403f-45bb-bf27-68e4809b02a9",
                        "conditionType": "procedure_timepoints",
                        "text": "4. based solely on history of chronic kidney disease and eGFR <60 mL/min/1.73m2, the eGFR value must be confirmed to be <60 mL/min/1.73m2 at Visit 2. u This sample is required only for patients who meet inclusion criterion",
                        "footnoteId": "e26e3395-a366-4a8f-8642-43a6c003c4b6",
                        "sourceText": "4. based solely on history of chronic kidney disease and eGFR <60 mL/min/1.73m2, the eGFR value must"
                      },
                      {
                        "id": "8831876e-6ece-4cc4-ad6d-e4d7f1fb0f2c",
                        "conditionType": "general",
                        "text": "1. Have been diagnosed with T2DM based on the World Health Organization classification or other locally applicable diagnostic standards Patient Characteristics",
                        "footnoteId": "eee0d99b-76f9-4895-bdf2-d449d65759eb",
                        "sourceText": "1. Have been diagnosed with T2DM based on the World Health Organization classification or other loca"
                      },
                      {
                        "id": "0813dd21-c5ef-42f9-ac90-7a47625ffd47",
                        "conditionType": "procedure_timepoints",
                        "text": "2. Have HbA1c between 7.5% (58 mmol/mol) and 10.5% (91 mmol/mol) at screening as determined by the central laboratory at Visit 1",
                        "footnoteId": "45931c68-6838-4861-90cf-83f1042bc5c6",
                        "sourceText": "2. Have HbA1c between 7.5% (58 mmol/mol) and 10.5% (91 mmol/mol) at screening as determined by the"
                      },
                      {
                        "id": "75cf12d5-7ea4-46d7-a78c-8df7edf4a881",
                        "conditionType": "timing_before",
                        "text": "3. On stable treatment with unchanged dose of at least 1 and no more than 3 oral antihyperglycemic drugs, which may only include metformin, SGLT-2i, and/or sulfonylurea for at least 3 months before Visit 1",
                        "footnoteId": "6220c92c-1490-45d7-a457-38fee11fc4e9",
                        "sourceText": "3. On stable treatment with unchanged dose of at least 1 and no more than 3 oral antihyperglycemic d"
                      },
                      {
                        "id": "5e4e36bf-dec8-46ac-9db6-eb1acb3e17fc",
                        "conditionType": "general",
                        "text": "6. Study Population Prospective approval of protocol deviations to recruitment and enrollment criteria, also known as protocol waivers or exemptions, are not permitted.",
                        "footnoteId": "721c9fe8-a09f-41c1-bfc0-9195228c95f9",
                        "sourceText": "6. Study Population Prospective approval of protocol deviations to recruitment and enrollment criter"
                      }
                    ],
                    "endpointAlgorithms": [
                      {
                        "id": "c2751c57-26e3-44b6-81e4-c3b30f83f411",
                        "name": "Primary: Mean change in HbA1c",
                        "endpointType": "Primary",
                        "inputs": [
                          "HbA1c_baseline",
                          "HbA1c_week52"
                        ],
                        "timeWindow": {
                          "reference": "baseline",
                          "duration": "P52W"
                        },
                        "algorithm": "HbA1c_week52 - HbA1c_baseline",
                        "successCriteria": "Noninferiority of LY3298176 10 mg and/or 15 mg to insulin glargine (2-sided 0.05 level)",
                        "sourceText": "The primary endpoint will be the mean change in hemoglobin A1c (HbA1c) levels from baseline to 52 weeks."
                      },
                      {
                        "id": "dd354d38-6065-4f10-951c-c3e42b57949d",
                        "name": "Key Secondary: Mean change in HbA1c (5 mg)",
                        "endpointType": "Secondary",
                        "inputs": [
                          "HbA1c_baseline",
                          "HbA1c_week52"
                        ],
                        "timeWindow": {
                          "reference": "baseline",
                          "duration": "P52W"
                        },
                        "algorithm": "HbA1c_week52 - HbA1c_baseline",
                        "successCriteria": "Noninferiority of LY3298176 5 mg to insulin glargine",
                        "sourceText": "To demonstrate that QW LY3298176 5 mg is noninferior to insulin glargine for change from baseline in HbA1c at 52 weeks"
                      },
                      {
                        "id": "2a91e2be-9449-4a30-8ee6-1ee722e06307",
                        "name": "Key Secondary: Superiority in HbA1c",
                        "endpointType": "Secondary",
                        "inputs": [
                          "HbA1c_baseline",
                          "HbA1c_week52"
                        ],
                        "timeWindow": {
                          "reference": "baseline",
                          "duration": "P52W"
                        },
                        "algorithm": "HbA1c_week52 - HbA1c_baseline",
                        "successCriteria": "Superiority of LY3298176 5 mg, 10 mg, and/or 15 mg to insulin glargine",
                        "sourceText": "To demonstrate that QW LY3298176 5 mg, 10 mg, and/or 15 mg is superior to insulin glargine for change from baseline in HbA1c at 52 weeks"
                      },
                      {
                        "id": "b19a9dc5-c807-4cbc-a87e-cd9adff9f7b2",
                        "name": "Key Secondary: Mean change in body weight",
                        "endpointType": "Secondary",
                        "inputs": [
                          "weight_baseline",
                          "weight_week52"
                        ],
                        "timeWindow": {
                          "reference": "baseline",
                          "duration": "P52W"
                        },
                        "algorithm": "weight_week52 - weight_baseline",
                        "successCriteria": "Superiority of LY3298176 5 mg, 10 mg, and/or 15 mg to insulin glargine",
                        "sourceText": "To demonstrate that QW LY3298176 5 mg, 10 mg, and/or 15 mg is superior to insulin glargine for change from baseline in weight at 52 weeks"
                      }
                    ],
                    "derivedVariables": [
                      {
                        "id": "222df0f1-51b6-4568-b6c6-fa29af822087",
                        "name": "Change from baseline in HbA1c",
                        "variableType": "ChangeFromBaseline",
                        "sourceVariables": [
                          "HbA1c"
                        ],
                        "derivationRule": "Value at 52 weeks - Baseline value",
                        "baselineDefinition": "Value at randomization/Day 1",
                        "baselineVisit": "Baseline",
                        "analysisWindow": "52 weeks",
                        "imputationRule": "Modified Intention-to-Treat (mITT) / MMRM (implied by Phase 3 standard)",
                        "unit": "%"
                      },
                      {
                        "id": "df73bdf9-7ce6-4462-8492-95d977bb5d48",
                        "name": "Change from baseline in body weight",
                        "variableType": "ChangeFromBaseline",
                        "sourceVariables": [
                          "Body weight"
                        ],
                        "derivationRule": "Value at 52 weeks - Baseline value",
                        "baselineDefinition": "Value at randomization/Day 1",
                        "baselineVisit": "Baseline",
                        "analysisWindow": "52 weeks",
                        "imputationRule": "mITT",
                        "unit": "kg"
                      },
                      {
                        "id": "1c64e53f-854f-426d-a7ba-f2f4134e4cf6",
                        "name": "Proportion of patients with HbA1c <7.0%",
                        "variableType": "Categorical",
                        "sourceVariables": [
                          "HbA1c"
                        ],
                        "derivationRule": "1 if HbA1c < 7.0% (53 mmol/mol) at 52 weeks, else 0",
                        "baselineDefinition": "Not applicable for status at 52 weeks",
                        "baselineVisit": "Baseline",
                        "analysisWindow": "52 weeks",
                        "imputationRule": "mITT",
                        "unit": "proportion"
                      },
                      {
                        "id": "0b3274e9-b94f-4f84-a15d-07157b4da086",
                        "name": "Change from baseline in fasting serum glucose",
                        "variableType": "ChangeFromBaseline",
                        "sourceVariables": [
                          "Fasting serum glucose"
                        ],
                        "derivationRule": "Value at 52 weeks - Baseline value",
                        "baselineDefinition": "Value at randomization/Day 1",
                        "baselineVisit": "Baseline",
                        "analysisWindow": "52 weeks",
                        "imputationRule": "mITT",
                        "unit": "mg/dL or mmol/L"
                      },
                      {
                        "id": "2395f390-90b0-4b14-a816-6e7d2928f351",
                        "name": "Proportion of patients with HbA1c <=6.5%",
                        "variableType": "Categorical",
                        "sourceVariables": [
                          "HbA1c"
                        ],
                        "derivationRule": "1 if HbA1c <= 6.5% (48 mmol/mol) at 52 weeks, else 0",
                        "baselineDefinition": "Not applicable",
                        "baselineVisit": "Baseline",
                        "analysisWindow": "52 weeks",
                        "imputationRule": "mITT",
                        "unit": "proportion"
                      },
                      {
                        "id": "c82c64f8-6438-459c-bfe1-20a364b9477f",
                        "name": "Proportion of patients with HbA1c <5.7%",
                        "variableType": "Categorical",
                        "sourceVariables": [
                          "HbA1c"
                        ],
                        "derivationRule": "1 if HbA1c < 5.7% (39 mmol/mol) at 52 weeks, else 0",
                        "baselineDefinition": "Not applicable",
                        "baselineVisit": "Baseline",
                        "analysisWindow": "52 weeks",
                        "imputationRule": "mITT",
                        "unit": "proportion"
                      },
                      {
                        "id": "0a8017ab-d88c-4184-a182-ccbbb0159d5b",
                        "name": "Weight loss categories (>=5%, >10%, >15%)",
                        "variableType": "PercentChange",
                        "sourceVariables": [
                          "Body weight"
                        ],
                        "derivationRule": "((Value at 52 weeks - Baseline value) / Baseline value) * 100",
                        "baselineDefinition": "Value at randomization/Day 1",
                        "baselineVisit": "Baseline",
                        "analysisWindow": "52 weeks",
                        "imputationRule": "mITT",
                        "unit": "%"
                      },
                      {
                        "id": "9376008c-c599-4264-bf48-3f959414b6f3",
                        "name": "Time to initiation of rescue therapy",
                        "variableType": "TimeToEvent",
                        "sourceVariables": [
                          "Rescue therapy start date",
                          "Randomization date"
                        ],
                        "derivationRule": "Rescue therapy start date - Randomization date",
                        "baselineDefinition": "Date of randomization",
                        "baselineVisit": "Day 1",
                        "analysisWindow": "From randomization to end of study",
                        "imputationRule": "Censoring at last contact if no rescue therapy",
                        "unit": "days"
                      },
                      {
                        "id": "e4283ba6-f5a9-4750-b83b-4d535406c6c5",
                        "name": "Composite CV endpoint",
                        "variableType": "Composite",
                        "sourceVariables": [
                          "Cardiovascular death",
                          "Myocardial infarction",
                          "Stroke",
                          "Hospitalization for unstable angina"
                        ],
                        "derivationRule": "Occurrence of any of the four component events",
                        "baselineDefinition": "Post-randomization occurrence",
                        "baselineVisit": "Baseline",
                        "analysisWindow": "Duration of study",
                        "imputationRule": "Adjudicated events",
                        "unit": "count/incidence"
                      }
                    ],
                    "stateMachine": {
                      "id": "cb1dd7e0-07c1-4981-9474-f55947cf7a40",
                      "initialState": "Screening",
                      "terminalStates": [
                        "Early Termination",
                        "Completed"
                      ],
                      "states": [
                        "Screening",
                        "Lead In",
                        "Treatment",
                        "Safety Follow Up",
                        "End Of Study",
                        "Early Termination"
                      ],
                      "transitions": [
                        {
                          "fromState": "Screening",
                          "toState": "Lead In",
                          "trigger": "Progress to Lead In"
                        },
                        {
                          "fromState": "Lead In",
                          "toState": "Treatment",
                          "trigger": "Progress to Treatment"
                        },
                        {
                          "fromState": "Treatment",
                          "toState": "Safety Follow Up",
                          "trigger": "Progress to Safety Follow Up"
                        },
                        {
                          "fromState": "Safety Follow Up",
                          "toState": "End Of Study",
                          "trigger": "Progress to End Of Study"
                        },
                        {
                          "fromState": "Treatment",
                          "toState": "Early Termination",
                          "trigger": "Subject exits to Early Termination"
                        }
                      ],
                      "epochIds": {
                        "Screening": "SCREENING",
                        "Lead In": "LEAD_IN",
                        "Treatment": "TREATMENT",
                        "Safety Follow Up": "SAFETY_FOLLOW_UP",
                        "End Of Study": "END_OF_STUDY",
                        "Early Termination": "EARLY_TERMINATION"
                      }
                    },
                    "dosingRegimens": [
                      {
                        "id": "e441ab77-003e-4336-8f7e-aab28b1d17ff",
                        "treatmentName": "QW LY3298176",
                        "frequency": "QW",
                        "route": "Oral",
                        "startDay": 1,
                        "doseLevels": [
                          {
                            "amount": 10.0,
                            "unit": "mg"
                          },
                          {
                            "amount": 15.0,
                            "unit": "mg"
                          }
                        ],
                        "durationDescription": "52 weeks",
                        "sourceText": "ascular (CV) risk. The primary endpoint will be the mean change in hemoglobin A1c (HbA1c) levels from baseline to 52 weeks. Objective(s)/Endpoints: Objectives Endpoints Primary  To demonstrate that Q"
                      },
                      {
                        "id": "31c01fc3-7672-418d-9c8c-3bf8999c7dfa",
                        "treatmentName": "with LY3298176",
                        "frequency": "QD",
                        "route": "Oral",
                        "startDay": 1,
                        "doseLevels": [
                          {
                            "amount": 5.0,
                            "unit": "mg"
                          },
                          {
                            "amount": 10.0,
                            "unit": "mg"
                          },
                          {
                            "amount": 15.0,
                            "unit": "mg"
                          }
                        ],
                        "sourceText": "uate the relationship between LY3298176 exposure and safety, tolerability, and efficacy measures  Population PK and PD parameters Tertiary/Exploratory  To characterize long-term glycemic control wit"
                      },
                      {
                        "id": "0b7ed4ce-23b8-4913-bfec-35fbd2abaeb4",
                        "treatmentName": "compare LY3298176",
                        "frequency": "QD",
                        "route": "Oral",
                        "startDay": 1,
                        "doseLevels": [
                          {
                            "amount": 5.0,
                            "unit": "mg"
                          },
                          {
                            "amount": 10.0,
                            "unit": "mg"
                          },
                          {
                            "amount": 15.0,
                            "unit": "mg"
                          }
                        ],
                        "sourceText": "posure and safety, tolerability, and efficacy measures  Population PK and PD parameters Tertiary/Exploratory  To characterize long-term glycemic control with LY3298176 5 mg, 10 mg, and 15 mg  To co"
                      },
                      {
                        "id": "a4b559af-8298-4990-9423-8393eed1b6d3",
                        "treatmentName": "LY3298176",
                        "frequency": "QW",
                        "route": "SC",
                        "startDay": 1,
                        "durationDescription": "Not specified in provided text",
                        "titrationSchedule": "Mentioned in Section 7.4.1 'Study Drugs' and 7.2.1.1, though specific increments are not in this excerpt.",
                        "doseModifications": [
                          "Dosage modification details located in Section 7.4"
                        ]
                      },
                      {
                        "id": "6a23d129-f248-4bec-9c42-d84d0dfb04c8",
                        "treatmentName": "Insulin Glargine",
                        "frequency": "QD",
                        "route": "SC",
                        "startDay": 1,
                        "durationDescription": "Not specified in provided text",
                        "titrationSchedule": "Mentioned in Section 7.2.1.2 and 7.4.1.",
                        "doseModifications": [
                          "Reduction and/or Discontinuation of Concomitant Antihyperglycemic Medications (Section 7.4.2)"
                        ]
                      }
                    ],
                    "visitWindows": [
                      {
                        "id": "ed1490c3-b955-4fa6-8d00-764f2f6de4ad",
                        "visitName": "Screening",
                        "targetDay": -14,
                        "windowBefore": 7,
                        "windowAfter": 3,
                        "isRequired": true,
                        "visitNumber": 1,
                        "epoch": "Study Period I: Screening",
                        "sourceText": "Screening Lead in Treatment Period"
                      },
                      {
                        "id": "aae0c112-ab58-4510-a21b-d894d2e6dafd",
                        "visitName": "Early Termination",
                        "targetDay": null,
                        "windowBefore": 0,
                        "windowAfter": 0,
                        "isRequired": true,
                        "visitNumber": 2,
                        "sourceText": "HbA1c target values of <7.0% (53 mmol/mol) at 52 weeks "
                      },
                      {
                        "id": "5b308f19-e154-4ac8-a114-50c36a026472",
                        "visitName": "baseline",
                        "targetDay": 0,
                        "windowBefore": 1,
                        "windowAfter": 1,
                        "isRequired": true,
                        "visitNumber": 3,
                        "sourceText": "(central laboratory) from baseline  The proportion of patients achieving an HbA1c"
                      },
                      {
                        "id": "8be8a907-4ca8-4174-a45a-d105ce938fe8",
                        "visitName": "Visit 801",
                        "targetDay": null,
                        "windowBefore": 3,
                        "windowAfter": 3,
                        "isRequired": true,
                        "visitNumber": 4,
                        "sourceText": "Visit 801 (safety follow-up visit) should be performed 4 weeks after the ET visit as the final study visit. c The visit date is determined in relation to the date of the randomization visit ( the all"
                      },
                      {
                        "id": "e04ad0ee-a656-4573-b154-aca81119cf2c",
                        "visitName": "Visit 2",
                        "targetDay": null,
                        "windowBefore": 3,
                        "windowAfter": 3,
                        "isRequired": true,
                        "visitNumber": 5,
                        "sourceText": "Dilated fundoscopic exam will be performed by an eye care professional (ophthalmologist or optometrist) for all patients between Visit 2 and Visit 3 to exclude patients with proliferative retinopathy "
                      },
                      {
                        "id": "c02c671e-73c3-4a94-b32e-01767c853e0f",
                        "visitName": "Visit 1",
                        "targetDay": null,
                        "windowBefore": 3,
                        "windowAfter": 3,
                        "isRequired": true,
                        "visitNumber": 6,
                        "sourceText": "A serum pregnancy test will be performed at Visit 1 for women of childbearing potential only. q A urine pregnancy test must be performed at Visit 3 with the result available prior to randomization and"
                      },
                      {
                        "id": "23695061-8e73-4bb1-b8be-4b089c283e12",
                        "visitName": "Visit 3",
                        "targetDay": null,
                        "windowBefore": 3,
                        "windowAfter": 3,
                        "isRequired": true,
                        "visitNumber": 7,
                        "sourceText": "A urine pregnancy test must be performed at Visit 3 with the result available prior to randomization and first injection of study drug(s) for women of childbearing potential only. Additional pregnancy"
                      },
                      {
                        "id": "9417e5e1-e000-4564-b8a6-69889cc64fe7",
                        "visitName": "Visit 25",
                        "targetDay": null,
                        "windowBefore": 3,
                        "windowAfter": 3,
                        "isRequired": true,
                        "visitNumber": 8,
                        "sourceText": "Long-term safety period (Visit 25 to Visit 29): Some patients will continue to receive LY3298176 or insulin glargine for up to, but not longer than, 24 months, as determined by the sponsor."
                      },
                      {
                        "id": "c339e2cb-a125-4d9c-aa0d-d26fccb90c9c",
                        "visitName": "Visit 29",
                        "targetDay": null,
                        "windowBefore": 3,
                        "windowAfter": 3,
                        "isRequired": true,
                        "visitNumber": 9,
                        "sourceText": "attend Visit 29 (24 months) or the FTV are considered to have completed the treatment period. Study Period IV (safety follow-up period) Safety follow-up (Visit 801) visits:"
                      },
                      {
                        "id": "100330a4-29fe-4ede-85a8-b1e66072fbcb",
                        "visitName": "End of Study",
                        "targetDay": null,
                        "windowBefore": 3,
                        "windowAfter": 7,
                        "isRequired": true,
                        "visitNumber": 10,
                        "sourceText": "End of Study Definition End of the study is the date of the last visit or last scheduled procedure shown in the Schedule of Activities (Section 2) for the last patient."
                      },
                      {
                        "id": "91d69a1f-ded6-4e2a-802f-81e172afcc5b",
                        "visitName": "Visit 13",
                        "targetDay": null,
                        "windowBefore": 3,
                        "windowAfter": 3,
                        "isRequired": false,
                        "visitNumber": 11,
                        "sourceText": "scheduled visits, the IWRS will have unscheduled visits (for example, Visit 13a) dedicated to provide dispensing information for patients whose dose has been de-escalated. Those patients who have thei"
                      },
                      {
                        "id": "d25a4fbb-43eb-4d03-a588-e4d3fc9a39c5",
                        "visitName": "randomization",
                        "targetDay": 1,
                        "windowBefore": 7,
                        "windowAfter": 7,
                        "isRequired": true,
                        "visitNumber": 12,
                        "epoch": "Study Period II: Treatment Period",
                        "sourceText": "or insulin glargine. The randomization will be stratified by country, baseline HbA1c concentration (8.5%, 8.5% [69, 69 mmol/mol]), and sodium-glucose co-transporter-2 inhibitors (SGLT-2i) use (Yes"
                      },
                      {
                        "id": "1f3bc91a-8fde-4814-be6d-ba64d70d6a52",
                        "visitName": "Week 1",
                        "targetDay": 8,
                        "windowBefore": 3,
                        "windowAfter": 3,
                        "isRequired": true,
                        "visitNumber": 4,
                        "targetWeek": 1,
                        "epoch": "Study Period II: Treatment Period"
                      },
                      {
                        "id": "592976ea-bff4-404c-805e-08aac31845c8",
                        "visitName": "Week 2",
                        "targetDay": 15,
                        "windowBefore": 3,
                        "windowAfter": 3,
                        "isRequired": true,
                        "visitNumber": 5,
                        "targetWeek": 2,
                        "epoch": "Study Period II: Treatment Period"
                      },
                      {
                        "id": "7d0ebdab-ca9f-4697-b68f-7b22eae5377c",
                        "visitName": "Week 3",
                        "targetDay": 22,
                        "windowBefore": 3,
                        "windowAfter": 3,
                        "isRequired": true,
                        "visitNumber": 6,
                        "targetWeek": 3,
                        "epoch": "Study Period II: Treatment Period"
                      },
                      {
                        "id": "2f317ffa-ed84-469f-a15c-65f9640c2bae",
                        "visitName": "Week 4",
                        "targetDay": 29,
                        "windowBefore": 3,
                        "windowAfter": 3,
                        "isRequired": true,
                        "visitNumber": 7,
                        "targetWeek": 4,
                        "epoch": "Study Period II: Treatment Period"
                      },
                      {
                        "id": "55698f8d-cf26-4213-9359-5b8064558b31",
                        "visitName": "Week 5",
                        "targetDay": 36,
                        "windowBefore": 3,
                        "windowAfter": 3,
                        "isRequired": true,
                        "visitNumber": 8,
                        "targetWeek": 5,
                        "epoch": "Study Period II: Treatment Period"
                      },
                      {
                        "id": "e0861992-9215-4467-9f13-15e351be2222",
                        "visitName": "Week 6",
                        "targetDay": 43,
                        "windowBefore": 3,
                        "windowAfter": 3,
                        "isRequired": true,
                        "visitNumber": 9,
                        "targetWeek": 6,
                        "epoch": "Study Period II: Treatment Period"
                      },
                      {
                        "id": "5b760fea-56e9-4eb4-98fd-62937a1a1d2d",
                        "visitName": "Week 8",
                        "targetDay": 50,
                        "windowBefore": 3,
                        "windowAfter": 3,
                        "isRequired": true,
                        "visitNumber": 19,
                        "targetWeek": 8,
                        "epoch": "Study Period II: Treatment Period",
                        "sourceText": "Week 8, the dose adjustment will be determined by the patient in a weekly manner and will be reviewed by the investigator at each office visit. Patient will have weekly visits (clinic or phone) in the"
                      },
                      {
                        "id": "905e2fcd-c9c5-4cb2-b249-75c8e62be12c",
                        "visitName": "Week 10",
                        "targetDay": 71,
                        "windowBefore": 3,
                        "windowAfter": 3,
                        "isRequired": true,
                        "visitNumber": 12,
                        "targetWeek": 10,
                        "epoch": "Study Period II: Treatment Period"
                      },
                      {
                        "id": "8d8967b5-d0f0-4ea8-aeee-f998bd16c276",
                        "visitName": "Week 12",
                        "targetDay": 85,
                        "windowBefore": 3,
                        "windowAfter": 3,
                        "isRequired": true,
                        "visitNumber": 13,
                        "targetWeek": 12,
                        "epoch": "Study Period II: Treatment Period"
                      },
                      {
                        "id": "1e28e39b-ff4b-44a4-bf2e-b3313f1137fb",
                        "visitName": "Week 16",
                        "targetDay": 106,
                        "windowBefore": 3,
                        "windowAfter": 3,
                        "isRequired": true,
                        "visitNumber": 22,
                        "targetWeek": 16,
                        "epoch": "Study Period II: Treatment Period",
                        "sourceText": "have weekly visits (clinic or phone) in the first 8 weeks and then visits every 2-3 weeks (clinic or phone) until Week 16 in order to improve compliance with the TTT algorithm. o"
                      },
                      {
                        "id": "e3d9f690-591e-425a-81c3-06fd6265d9c1",
                        "visitName": "Week 20",
                        "targetDay": 141,
                        "windowBefore": 3,
                        "windowAfter": 3,
                        "isRequired": true,
                        "visitNumber": 16,
                        "targetWeek": 20,
                        "epoch": "Study Period II: Treatment Period"
                      },
                      {
                        "id": "c27e366e-5b94-42a6-897e-78be1ec17c72",
                        "visitName": "Week 24",
                        "targetDay": 162,
                        "windowBefore": 3,
                        "windowAfter": 3,
                        "isRequired": true,
                        "visitNumber": 24,
                        "targetWeek": 24,
                        "epoch": "Study Period II: Treatment Period",
                        "sourceText": "(Week 24), dose decreases will not be permitted. 7.8. Treatment after the End of the Study"
                      },
                      {
                        "id": "b40123a7-82a8-4b7b-b3d1-c3047c544500",
                        "visitName": "Week 28",
                        "targetDay": 197,
                        "windowBefore": 3,
                        "windowAfter": 3,
                        "isRequired": true,
                        "visitNumber": 19,
                        "targetWeek": 28,
                        "epoch": "Study Period II: Treatment Period"
                      },
                      {
                        "id": "4d19b5a1-0eab-4646-a8a6-84af0b2746a4",
                        "visitName": "Week 32",
                        "targetDay": 225,
                        "windowBefore": 3,
                        "windowAfter": 3,
                        "isRequired": true,
                        "visitNumber": 20,
                        "targetWeek": 32,
                        "epoch": "Study Period II: Treatment Period"
                      },
                      {
                        "id": "3de90fcc-32fc-4ea6-a4a9-8370b96a8b08",
                        "visitName": "Week 35",
                        "targetDay": 239,
                        "windowBefore": 3,
                        "windowAfter": 3,
                        "isRequired": true,
                        "visitNumber": 27,
                        "targetWeek": 35,
                        "epoch": "Study Period II: Treatment Period",
                        "sourceText": "patient gets assigned, they may be required to come to site for PK-specific visits. Draw PK at ET visit only if patient discontinues study prior to Week 35. Visits 10 and 14 are for all patients, but "
                      },
                      {
                        "id": "4eb93fd3-1fd2-4a9c-80df-dd91e4148b54",
                        "visitName": "Week 36",
                        "targetDay": 253,
                        "windowBefore": 3,
                        "windowAfter": 3,
                        "isRequired": true,
                        "visitNumber": 22,
                        "targetWeek": 36,
                        "epoch": "Study Period II: Treatment Period"
                      },
                      {
                        "id": "d0ddda02-4dc2-43e6-934b-eba00c6f7f21",
                        "visitName": "Week 42",
                        "targetDay": 295,
                        "windowBefore": 7,
                        "windowAfter": 7,
                        "isRequired": true,
                        "visitNumber": 23,
                        "targetWeek": 42,
                        "epoch": "Study Period II: Treatment Period"
                      },
                      {
                        "id": "18e6bd58-cfbd-46fb-8720-0d0fe72244c3",
                        "visitName": "Week 52",
                        "targetDay": 358,
                        "windowBefore": 3,
                        "windowAfter": 3,
                        "isRequired": true,
                        "visitNumber": 30,
                        "targetWeek": 52,
                        "epoch": "Study Period II: Treatment Period",
                        "sourceText": "same treatment arm who had their efficacy measure at the Week 52 visit assessed after early discontinuation of study drug and/or initiation of rescue medication (retrieved dropouts). Analysis will be "
                      },
                      {
                        "id": "e6d208bf-95b2-407b-9f33-af4de44cf414",
                        "visitName": "Follow-up",
                        "targetDay": 365,
                        "windowBefore": 7,
                        "windowAfter": 7,
                        "isRequired": true,
                        "visitNumber": 31,
                        "sourceText": "safety follow-up period, with respect to the following outcomes "
                      },
                      {
                        "id": "ee00941b-0ca8-4f03-b4b1-98f0b4a4f96c",
                        "visitName": "Week 62",
                        "targetDay": 435,
                        "windowBefore": 7,
                        "windowAfter": 7,
                        "isRequired": true,
                        "visitNumber": 25,
                        "targetWeek": 62,
                        "epoch": "Study Period III: Treatment Period"
                      },
                      {
                        "id": "0addec05-b578-47c5-8a59-d57dd9576b54",
                        "visitName": "Week 72",
                        "targetDay": 505,
                        "windowBefore": 7,
                        "windowAfter": 7,
                        "isRequired": true,
                        "visitNumber": 26,
                        "targetWeek": 72,
                        "epoch": "Study Period III: Treatment Period"
                      },
                      {
                        "id": "0f089e19-9d86-4af8-ab71-0476f7945b69",
                        "visitName": "Week 78",
                        "targetDay": 547,
                        "windowBefore": 7,
                        "windowAfter": 7,
                        "isRequired": true,
                        "visitNumber": 27,
                        "targetWeek": 78,
                        "epoch": "Study Period III: Treatment Period"
                      },
                      {
                        "id": "95b5cc74-0b69-4241-9af6-062bc3ea2ec6",
                        "visitName": "Week 88",
                        "targetDay": 617,
                        "windowBefore": 7,
                        "windowAfter": 7,
                        "isRequired": true,
                        "visitNumber": 28,
                        "targetWeek": 88,
                        "epoch": "Study Period III: Treatment Period"
                      },
                      {
                        "id": "c92f42c7-9e9a-4ada-a4ec-2bf41448a43d",
                        "visitName": "Week 104",
                        "targetDay": 729,
                        "windowBefore": 7,
                        "windowAfter": 7,
                        "isRequired": true,
                        "visitNumber": 29,
                        "targetWeek": 104,
                        "epoch": "Study Period III: Treatment Period"
                      },
                      {
                        "id": "2a0e92f1-4e7c-453c-9a1e-fd3520086060",
                        "visitName": "Safety Follow-Up",
                        "targetDay": 757,
                        "windowBefore": 3,
                        "windowAfter": 3,
                        "isRequired": true,
                        "visitNumber": 801,
                        "targetWeek": 108,
                        "epoch": "Study Period IV: Safety F/U"
                      }
                    ],
                    "randomizationScheme": {
                      "id": "b06e7130-58f7-4e85-9a81-21401629dfae",
                      "ratio": "1:1:1:3",
                      "method": "Stratified randomization",
                      "centralRandomization": true,
                      "stratificationFactors": [
                        {
                          "id": "5d10c26f-a80f-40b4-b014-a5c724683322",
                          "name": "Country",
                          "categories": [
                            "Category 1",
                            "Category 2"
                          ],
                          "isBlocking": false,
                          "sourceText": "country, baseline hba1c concentration (8"
                        },
                        {
                          "id": "e5dfcf33-ef6c-40ab-bfb2-9724dd01576b",
                          "name": "Baseline",
                          "categories": [
                            "Category 1",
                            "Category 2"
                          ],
                          "isBlocking": false,
                          "sourceText": "country, baseline hba1c concentration (8"
                        },
                        {
                          "id": "5be24278-7bf7-44f4-b58b-62d824dd6704",
                          "name": "Baseline HbA1c concentration",
                          "categories": [
                            "8.5% (69 mmol/mol)",
                            "8.5% (69 mmol/mol)"
                          ],
                          "isBlocking": false
                        },
                        {
                          "id": "566f1f21-fceb-4f3e-835f-f492be30c18d",
                          "name": "Sodium-glucose co-transporter-2 inhibitors (SGLT-2i) use",
                          "categories": [
                            "Yes",
                            "No"
                          ],
                          "isBlocking": false
                        }
                      ],
                      "sourceText": "I8F-MC-GPGM(b) Clinical Protocol\nPage 11\nLY3298176\nSummary of Study Design:  \nStudy GPGM is a Phase 3, open-label comparator, multicenter, parallel-arm, randomized study to compare the \nsafety and eff"
                    },
                    "analysisWindows": [
                      {
                        "id": "d453421e-2133-46db-80a0-9d094a185d11",
                        "windowType": "treatment",
                        "name": "Treatment Period",
                        "startDay": 3,
                        "endDay": 2,
                        "description": "Active treatment from Day 3 to Day 2",
                        "sourceText": "Treatment\n-3\n-2"
                      }
                    ]
                  }
                }
              },
              {
                "id": "84cd7a41-3bf2-4c32-ab30-a9a865e19ddb",
                "url": "https://protocol2usdm.io/extensions/x-soaFootnotes",
                "valueString": "[\"a Baseline assessments must be completed before processing in the interactive web-response system (IWRS).\", \"b Patients who are unable or unwilling to continue in the study for any reason will perform an ET visit. If the patient is discontinuing during an unscheduled visit, that visit should be performed as the ET visit. If the patient is discontinuing during a scheduled visit, that visit should be performed as an ET visit. Visit 801 (safety follow-up visit) should be performed 4 weeks after the ET visit as the final study visit.\", \"c The visit date is determined in relation to the date of the randomization visit (\\u00b1 the allowed visit window).\", \"d On visits 3, 5, 7, 11, 13, 15, 16, 18, 23, 24, 27, 29, ET, and at follow-up (801), patients should be reminded to report to the site in a fasting condition, after a period of approximately 8 hours without eating, drinking (except water), or any significant physical activity and before taking study drug(s), metformin (if used), SGLT-2i (if used), SU (if used).\", \"e Medical history includes assessment of preexisting conditions (including history of gall bladder disease, cardiovascular disease, and medullary thyroid carcinoma) and substance usage (such as, alcohol and tobacco).\", \"f Weight measurements should be obtained per the detailed guidance in the Manual of Operations.\", \"g Vital sign measurements should be taken before obtaining an ECG tracing and before collection of blood samples for laboratory testing, at visits where required. The participant should sit quietly for 5 minutes before vital sign measurements are taken. For each parameter, 2 measurements will be taken using the same arm; the recordings should be taken at least 1 minute apart. BP must be taken with an automated blood pressure machine.\", \"h Dilated fundoscopic exam will be performed by an eye care professional (ophthalmologist or optometrist) for all patients between Visit 2 and Visit 3 to exclude patients with proliferative retinopathy and/or maculopathy. The results from this exam will be recorded on a specific retinopathy eCRF as a baseline measure of retinopathy. A follow-up dilated fundoscopic exam should be performed when clinically indicated by any adverse event suspected of worsening retinopathy, and the findings should be recorded on the retinopathy eCRF.\", \"i Includes counseling on diet and exercise, management of hypoglycemia and hyperglycemia, etc.\", \"j All training should be repeated as needed to ensure patient compliance.\", \"k Patient is required to collect two 7-point SMBGs on nonconsecutive days prior to the next visit. A 7-point SMBG consists of measurements before and 2 hours after each of 3 main meals within the same day and at bedtime. These SMBG profiles will be collected by the patient within 2 weeks prior to the assigned visits. If 7-point SMBG is not performed, then data from the most recent nonconsecutive 4-point SMBG profiles can be used. If more than 2 SMBG profiles are available, the 2 most recent nonconsecutive profiles should be used.\", \"l Patients should administer their first dose of LY3298176 at the end of this visit, after other study procedures and randomization.\", \"m LY3298176 patients only.\", \"n During the first 8 weeks, the dose adjustment will be determined by the investigator in discussion with the patient by following a TTT algorithm. After Week 8, the dose adjustment will be determined by the patient in a weekly manner and will be reviewed by the investigator at each office visit. Patient will have weekly visits (clinic or phone) in the first 8 weeks and then visits every 2-3 weeks (clinic or phone) until Week 16 in order to improve compliance with the TTT algorithm.\", \"o Insulin glargine patients only. A review of the patient\\u2019s compliance to the TTT algorithm will still be conducted during the telephone Visits 6, 8, 9, and 12, but the patient\\u2019s compliance for these visits will be collected in the eCRF at Visits 7, 10 and 13 for the period since the previous visit.\", \"p A serum pregnancy test will be performed at Visit 1 for women of childbearing potential only.\", \"q A urine pregnancy test must be performed at Visit 3 with the result available prior to randomization and first injection of study drug(s) for women of childbearing potential only. Additional pregnancy tests may be performed at the investigator\\u2019s discretion during the study. If required per local regulations and/or institutional guidelines, pregnancy testing can also occur at other times during the study treatment period.\", \"r Follicle-stimulating hormone test performed at Visit 1 for postmenopausal women at least 50 years of age with an intact uterus, without a history of oophorectomy or bilateral tubal ligation, not on hormone therapy, and who have had spontaneous amenorrhea for more than 6 months and less than 12 months.\", \"s Screening visit assessment will serve as baseline.\", \"t The CKD-EPI equation will be used by the central lab to estimate and report eGFR. For patients who meet inclusion criterion [4] based solely on history of chronic kidney disease and eGFR <60 mL/min/1.73m\\u00b2, the eGFR value must be confirmed to be <60 mL/min/1.73m\\u00b2 at Visit 2.\", \"u This sample is required only for patients who meet inclusion criterion [4] based solely on history of chronic kidney disease and eGFR <60 mL/min/1.73m\\u00b2.\", \"v In the event of systemic drug hypersensitivity reactions (immediate or nonimmediate), additional blood samples will be collected including ADA, PK, and, exploratory biomarker sample.\", \"w PK sample for immunogenicity must be collected prior to drug administration.\", \"x PK samples will not be collected from patients who were randomized to insulin glargine since it is an open-label study. PK samples will be collected at these visits at time windows of 1 to 24 hours, 24 to 96 hours, OR 120 to 168 hours post dose, as assigned by IWRS. Dependent on the time-windows to which a patient gets assigned, they may be required to come to site for PK-specific visits. Draw PK at ET visit only if patient discontinues study prior to Week 35. Visits 10 and 14 are for all patients, but only those patients assigned to PK will get a PK blood draw. Visits 17 and 21 are for patients assigned to a PK blood draw only.\", \"y PROs should be completed before any other study procedures if the patient is not adversely affected by the fasting condition or completed after the patient has sufficiently recovered from the preceding visit procedures.\", \"z When the sponsor determines that the study has met the completion criteria, all patients remaining in the study will return to the site for a FTV within approximately 30 days. The safety follow-up visit will be approximately 30 days after the FTV.\", \"a. Coronary heart disease documented as having any of the following: 1) History of acute myocardial infarction (ST elevation or non-ST elevation) 2) Stenosis of \\u226550% in at least 1 major (left main, left anterior descending, ramus intermedius, left circumflex, right) coronary artery as determined by cardiac imaging 3) Coronary calcium score \\u2265300 4) Stable angina pectoris treated with anti-anginal medication 5) Asymptomatic cardiac ischemia documented by cardiac imaging on exercise or pharmacological stress test 6) History of coronary revascularization (percutaneous coronary intervention or coronary artery bypass surgery) OR\", \"b. Peripheral arterial disease presumed to be of atherosclerotic origin documented as a history of any of the following: 1) Current or intermittent claudication 2) Resting limb ischemia 3) Stenosis of >50% in an iliac, femoral, popliteal, or subclavian artery 4) An ankle-brachial index \\u22640.90 5) Peripheral arterial revascularization or amputation due to atherosclerotic vascular disease 6) Asymptomatic carotid artery stenosis \\u226570% 7) Carotid artery revascularization\", \"4. based solely on history of chronic kidney disease and eGFR <60 mL/min/1.73m2, the eGFR value must be confirmed to be <60 mL/min/1.73m2 at Visit 2. u This sample is required only for patients who meet inclusion criterion\", \"1. Have been diagnosed with T2DM based on the World Health Organization classification or other locally applicable diagnostic standards Patient Characteristics\", \"2. Have HbA1c between \\u22657.5% (58 mmol/mol) and \\u226410.5% (91 mmol/mol) at screening as determined by the central laboratory at Visit 1\", \"3. On stable treatment with unchanged dose of at least 1 and no more than 3 oral antihyperglycemic drugs, which may only include metformin, SGLT-2i, and/or sulfonylurea for at least 3 months before Visit 1\", \"6. Study Population Prospective approval of protocol deviations to recruitment and enrollment criteria, also known as protocol waivers or exemptions, are not permitted.\", \"5. Asymptomatic cardiac ischemia documented by cardiac imaging on exercise or pharmacological stress test\", \"7. Carotid artery revascularization\"]",
                "instanceType": "ExtensionAttribute"
              }
            ],
            "administrations": [
              {
                "id": "5cdae1b3-316b-4023-9cbd-837ef4b8d816",
                "name": "QW LY3298176 Administration",
                "instanceType": "Administration",
                "dose": "10.0 mg / 15.0 mg",
                "doseFrequency": "QW",
                "route": {
                  "id": "bf6dad66-3e91-42cb-be6c-71871fcc5001",
                  "code": "Oral",
                  "codeSystem": "USDM",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Oral",
                  "instanceType": "Code"
                },
                "duration": "52 weeks",
                "description": "ascular (CV) risk. The primary endpoint will be the mean change in hemoglobin A1c (HbA1c) levels from baseline to 52 weeks. Objective(s)/Endpoints: Objectives Endpoints Primary  To demonstrate that Q"
              },
              {
                "id": "f4f6484b-b753-4bf3-ace5-5ef5e297fff4",
                "name": "with LY3298176 Administration",
                "instanceType": "Administration",
                "dose": "5.0 mg / 10.0 mg / 15.0 mg",
                "doseFrequency": "QD",
                "route": {
                  "id": "91b2e5da-18e3-4fbf-943f-0842a8218712",
                  "code": "Oral",
                  "codeSystem": "USDM",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Oral",
                  "instanceType": "Code"
                },
                "description": "uate the relationship between LY3298176 exposure and safety, tolerability, and efficacy measures  Population PK and PD parameters Tertiary/Exploratory  To characterize long-term glycemic control wit"
              },
              {
                "id": "b6200133-884c-4e9f-bc5f-d7a57937a73d",
                "name": "compare LY3298176 Administration",
                "instanceType": "Administration",
                "dose": "5.0 mg / 10.0 mg / 15.0 mg",
                "doseFrequency": "QD",
                "route": {
                  "id": "3e935292-cc13-4a83-b229-349201459faf",
                  "code": "Oral",
                  "codeSystem": "USDM",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Oral",
                  "instanceType": "Code"
                },
                "description": "posure and safety, tolerability, and efficacy measures  Population PK and PD parameters Tertiary/Exploratory  To characterize long-term glycemic control with LY3298176 5 mg, 10 mg, and 15 mg  To co"
              },
              {
                "id": "349155f4-e99c-4e48-9733-659b4c50964b",
                "name": "LY3298176 Administration",
                "instanceType": "Administration",
                "doseFrequency": "QW",
                "route": {
                  "id": "9b438141-cac3-440c-9937-def97548bb18",
                  "code": "SC",
                  "codeSystem": "USDM",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "SC",
                  "instanceType": "Code"
                },
                "duration": "Not specified in provided text"
              },
              {
                "id": "6508c50a-c046-4366-91a2-f5f9372a2213",
                "name": "Insulin Glargine Administration",
                "instanceType": "Administration",
                "doseFrequency": "QD",
                "route": {
                  "id": "8101968a-6e80-4432-8fd5-c91fcfdc7663",
                  "code": "SC",
                  "codeSystem": "USDM",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "SC",
                  "instanceType": "Code"
                },
                "duration": "Not specified in provided text"
              }
            ]
          }
        ],
        "titles": [
          {
            "id": "8cd2e0af-30db-42f4-9a0b-5b592b557d96",
            "text": "Efficacy and Safety of LY3298176 Once Weekly versus Insulin Glargine in Patients with Type 2 Diabetes and Increased Cardiovascular Risk (SURPASS-4)",
            "type": {
              "id": "f1d1cce0-22e0-47e8-8e1c-dbb7f7053157",
              "code": "Official Study Title",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Official Study Title",
              "instanceType": "Code"
            },
            "instanceType": "StudyTitle"
          },
          {
            "id": "5cfc1974-91c8-4b55-9f2f-04b669ac1649",
            "text": "SURPASS-4",
            "type": {
              "id": "4b81ffa3-a0d7-4de8-b19f-bda235528706",
              "code": "Study Acronym",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Study Acronym",
              "instanceType": "Code"
            },
            "instanceType": "StudyTitle"
          }
        ],
        "studyIdentifiers": [
          {
            "id": "3c11dded-4f0a-4a99-9534-835710314703",
            "text": "NCT03730662",
            "instanceType": "StudyIdentifier",
            "scopeId": "432d83b8-e43d-4105-9f5e-b818c4049ddf",
            "type": {
              "code": "C172240",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-09-27",
              "decode": "Clinicaltrials.gov Identifier",
              "instanceType": "Code"
            }
          },
          {
            "id": "c3e196c9-043c-447a-9709-f58e0bca8bd3",
            "text": "I8F-MC-GPGM(b)",
            "instanceType": "StudyIdentifier",
            "scopeId": "3e7e8941-64db-4509-812f-1097e7e4b2bf",
            "type": {
              "code": "C132351",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-09-27",
              "decode": "Sponsor Protocol Identifier",
              "instanceType": "Code"
            }
          },
          {
            "id": "baef7706-cbb3-432b-a26d-9d8cf7b409fb",
            "text": "2018-002618-11",
            "instanceType": "StudyIdentifier",
            "scopeId": "9d434344-994b-4ebc-9dd5-fd49fb9559a3",
            "type": {
              "code": "C98714",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-09-27",
              "decode": "Clinical Trial Registry Identifier",
              "instanceType": "Code"
            }
          }
        ],
        "organizations": [
          {
            "id": "3e7e8941-64db-4509-812f-1097e7e4b2bf",
            "name": "Eli Lilly and Company",
            "type": {
              "id": "42836093-0714-4e11-9329-19f545c394f1",
              "code": "C54086",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Pharmaceutical Company",
              "instanceType": "Code"
            },
            "identifier": "Eli Lilly and Company",
            "identifierScheme": "DUNS",
            "instanceType": "Organization"
          },
          {
            "id": "432d83b8-e43d-4105-9f5e-b818c4049ddf",
            "name": "ClinicalTrials.gov",
            "type": {
              "id": "8d89ca62-a52d-48c2-9f23-a34c74548b05",
              "code": "C19326",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Healthcare Facility",
              "instanceType": "Code"
            },
            "identifier": "ClinicalTrials.gov",
            "identifierScheme": "DUNS",
            "instanceType": "Organization"
          },
          {
            "id": "3e7e8941-64db-4509-812f-1097e7e4b2bf",
            "name": "Advanced Research Center",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "1",
            "type": {
              "id": "756dd40f-6a48-47bd-9bf6-7bfab7ff4d98",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "432d83b8-e43d-4105-9f5e-b818c4049ddf",
            "name": "Valley Clinical Trials Inc.",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "2",
            "type": {
              "id": "72a1d66e-4f86-4527-bbe4-408215057e1b",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "f3476dca-f398-434c-9f0c-7ea552a8d1a0",
            "name": "Marin Endocrine Associates",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "3",
            "type": {
              "id": "22f1683b-926a-44c3-bd50-23500f946ad8",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "4315dc29-f022-449b-8d06-d1476a3cd0f9",
            "name": "National Research Institute",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "4",
            "type": {
              "id": "a639c327-4d58-4089-9dfd-b807822bb106",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "4c07bfa8-dd98-4af4-8e14-6c65515aabe8",
            "name": "Scripps Whittier Diabetes Institute",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "5",
            "type": {
              "id": "d52b6eb9-1f96-4751-a127-e8de601641fc",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "75553364-daf1-42f3-8d97-5552ee849662",
            "name": "First Valley Medical Group",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "6",
            "type": {
              "id": "514b261b-c967-4eba-8268-3915b9213c8e",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "f2a8ae8a-be0c-4bd8-be32-b338851b57c1",
            "name": "National Research Institute",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "7",
            "type": {
              "id": "d35a8bab-aa33-45f0-82d0-0f07e488a93c",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "91356692-11bd-499f-bda8-0a0bab0eeea0",
            "name": "Catalina Research Institute LLC",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "8",
            "type": {
              "id": "4e573751-9deb-4aff-91d3-3f05dc8bc0f1",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "3f0b4ef4-566d-4e1c-a3d7-ca39e17f1f87",
            "name": "Monterey Endocrine & Diabetes Institute Inc.",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "9",
            "type": {
              "id": "f400f206-ed40-4734-9162-808adfc53cf3",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "def5df2c-5143-4708-a4b8-6118cb7a6f8a",
            "name": "Valley Clinical Trials Inc.",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "10",
            "type": {
              "id": "002f26ba-1b86-42b8-bbe3-c09f13d934bc",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "983c7cc5-2ec9-4b1a-b203-4e0814540614",
            "name": "Desert Medical Group Inc",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "11",
            "type": {
              "id": "f5816e7b-b165-41ae-94ec-00b562faa299",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "d6f1ddd7-c620-4273-b3dd-2c807c0d1156",
            "name": "Havana Research Institute",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "12",
            "type": {
              "id": "76db98ef-6e76-4f0d-b910-b790810a2d21",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "ff4ee464-2a81-4830-9f44-88d9ccfdb54d",
            "name": "Western University of Health Sciences",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "13",
            "type": {
              "id": "9f2e3980-03ea-42b7-8013-b312c2e6125d",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "c4238f1d-55f4-4e1c-9f92-a05fd70021a2",
            "name": "LCGK Research",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "14",
            "type": {
              "id": "6aa52a97-9bf2-4aaf-960c-a71b857f2255",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "3f48097d-93be-43a0-aa63-7fa6c8854962",
            "name": "Olive View Medical Center",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "15",
            "type": {
              "id": "38722a99-ec0b-4cb1-827a-5c42c1b99f4a",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "9aebef68-5adc-4167-9fad-34831aa1cf31",
            "name": "University Clinical Investigators Inc.",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "16",
            "type": {
              "id": "71488497-5d1b-4b53-9b07-1d2f07e67170",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "2081e0a7-39ee-4982-8b2b-ac430dfbd2f4",
            "name": "Touro University",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "17",
            "type": {
              "id": "c781f570-35f9-4ef9-ba25-04145ddc0502",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "dbb77255-d728-46a4-a29a-d04c1552337f",
            "name": "Coastal Metabolic Research Centre",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "18",
            "type": {
              "id": "6a3c7e2f-c7ad-4b86-bfdc-ae0ac818a37c",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "201ce61c-8324-44fc-a7f3-ab3cce62b90f",
            "name": "Diablo Clinical Research",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "19",
            "type": {
              "id": "5d3fe394-4ddb-4286-9a35-4766374ac86b",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "93a6db7d-d41a-4a7a-bcb2-4fe21452300b",
            "name": "Chase Medical Research LLC",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "20",
            "type": {
              "id": "9e637bf3-25a9-4c98-b7f0-8da7bbf45809",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "7ed2a80a-31ea-4f17-95c8-ba9699f03221",
            "name": "ALL Medical Research LLC",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "21",
            "type": {
              "id": "424b1751-9a75-4295-b31c-4f1a7c45a4d6",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "54e3427d-4e6f-426e-98ca-d5fcee0d0677",
            "name": "Advanced Pharma Research",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "22",
            "type": {
              "id": "da76e2ab-8f65-40f4-94e4-3af3853f10e8",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "0dd2c1be-1d2d-4a40-8424-8594c2d9c3b4",
            "name": "South Florida Wellness & Clinical Research Institute",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "23",
            "type": {
              "id": "42928428-8ed2-4cd4-847e-243cde80aa1f",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "eb59da8f-6465-4559-9fb6-c7716a297274",
            "name": "Suncoast Research Group LLC",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "24",
            "type": {
              "id": "52596421-84c0-4396-8ddb-720baebe6197",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "4843c895-cf58-456b-ac26-94d2b0bc912b",
            "name": "New Horizon Research Center",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "25",
            "type": {
              "id": "c1d926e8-d09a-4673-b42c-aeeb2de7ae9c",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "8cbda60e-873e-4983-964c-0112dff5bf21",
            "name": "Clinical Neuroscience Solutions Inc",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "26",
            "type": {
              "id": "f64ac177-0eb4-492a-9d34-90b46e37335b",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "5aa6cbfd-37f5-4f24-8051-b797921dfd0c",
            "name": "Progressive Medical Research",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "27",
            "type": {
              "id": "ca3ba178-27fb-4701-833d-e982ff84b57f",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "ce3ab11a-3d86-41bf-8baa-75e96f5243d2",
            "name": "Primary Care Specialists LLC",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "28",
            "type": {
              "id": "eaf06879-d7d5-45bf-b747-50b7548644be",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "446d5b1b-24ca-400a-ad54-2b5342b7b262",
            "name": "Rocky Mountain Diabetes and Osteoporosis Center",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "29",
            "type": {
              "id": "d0cde2b4-d14c-40cb-b7ad-55df8e5c5f47",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "eb28356a-7f1c-4f3b-bdca-2835a0f19caa",
            "name": "Solaris Clinical Research",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "30",
            "type": {
              "id": "ce9d33ae-d003-4028-b87a-d13ef7aa83e3",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "eb2d57d3-8889-4627-96cc-46053bfd75b2",
            "name": "Saltzer Medical Group P.A.",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "31",
            "type": {
              "id": "2ac17778-8105-4ba3-a744-743cfd2b0e18",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "3af61329-0404-4b8b-a06b-011913dc3a93",
            "name": "Northwestern Feinberg School of Medicine",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "32",
            "type": {
              "id": "2f3142ba-ee5f-46e3-9967-51ff17474f46",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "970fc12b-60b3-44e8-b8cb-932cc6fd83b9",
            "name": "NorthShore University HealthSystem",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "33",
            "type": {
              "id": "4368b5ea-be99-42ca-af79-bdbb2ca75f6c",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "ea9168e9-afb7-4372-ac9c-417680da4f5a",
            "name": "University of Iowa Hospital & Clinic",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "34",
            "type": {
              "id": "ae1564f0-92d9-4bd4-a886-a1f6a7de08b9",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "4f039ccd-48a6-47d5-85a2-165838cda489",
            "name": "Iowa Diabetes Research",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "35",
            "type": {
              "id": "6607be14-7431-40bc-9c36-6c4b14eba499",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "ba937122-1058-4055-ae43-f38c16751ed1",
            "name": "Cotton O'Neil Diabetes and Endocrinology Center",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "36",
            "type": {
              "id": "20917402-ce21-465d-a485-6e62e39643b9",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "80e72af6-16e8-4eee-a3ff-c0b560ddae06",
            "name": "Robley Rex VAMC",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "37",
            "type": {
              "id": "69da838f-1879-4c1b-a8d3-3bf43754e6e7",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "c259bc7c-8de5-4c52-8b74-2f429df56fec",
            "name": "NECCR PrimaCare Research LLC",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "38",
            "type": {
              "id": "25b97dcc-f09c-4e98-927e-3b646e5aecac",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "d86cf1b5-a25d-4885-8ec3-356287fdd50a",
            "name": "AA Medical Research Center",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "39",
            "type": {
              "id": "5140349b-984d-47d2-bee8-0e7941154db0",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "b6c33843-9520-4976-8c3c-830f54776d60",
            "name": "Troy Internal Medicine PC",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "40",
            "type": {
              "id": "ca301c0b-1987-4f78-a7e3-4e9d2493c02a",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "0ac67cf5-d375-442f-b04d-f5228a94712e",
            "name": "Centro de Investigaciones Metabolicas (CINME)",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "41",
            "type": {
              "id": "e2cda013-79ec-4b3a-a872-c9a1862df25c",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "13f9e76a-78b8-4187-97ab-db6b2b138262",
            "name": "Mautalen Salud e Investigacion",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "42",
            "type": {
              "id": "65ef9b97-0649-4a96-9a6b-50eb25032ae2",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "88881a6d-d60d-45f9-8d94-226144296ce1",
            "name": "Investigaciones Medicas IMOBA S.R.L.",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "43",
            "type": {
              "id": "39b3b9a2-01b9-44d2-a07f-cd62407dcfd3",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "1054a7a8-3a6d-4145-bffa-880366c87c36",
            "name": "CEDIC-Centro de Investigaciones Clinicas",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "44",
            "type": {
              "id": "103248dc-1a51-46ed-ac7a-27fd901c3746",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "16f3adb7-21c2-4fa4-85c2-2778de2efafc",
            "name": "CEMEDIC",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "45",
            "type": {
              "id": "c1873932-4e5a-4077-81c8-639f56f7014b",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "b7eb447a-afde-4271-88c5-597edb8a862b",
            "name": "Centro Medico Dr Laura Maffei",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "46",
            "type": {
              "id": "e0441fd5-26b2-4889-be7a-3c3b4cc8d66c",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "240b2ac9-3a36-4c25-99e6-81e175f14dd0",
            "name": "Paratus Clinical Blacktown Clinic",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "47",
            "type": {
              "id": "e125366a-bf32-4dfb-9b06-92e0fce04491",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "90a92f11-a668-4368-ae1f-9108d92cfc62",
            "name": "Campbelltown Medical & Dental Centre",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "48",
            "type": {
              "id": "02481303-f937-46af-8c54-a6d0401159db",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "a398663e-068a-43ac-9f04-da6012cebe2f",
            "name": "Paratus Clinical Kanwal Clinic",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "49",
            "type": {
              "id": "1b6e6218-8fc5-4c9d-b80d-ae56c94dff6e",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "e88c01dc-437e-4750-af87-9e154b1d2836",
            "name": "The AIM Centre",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "50",
            "type": {
              "id": "f28c4dc5-a915-4bcb-9bf1-fea645a496b5",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          }
        ],
        "studyPhase": {
          "id": "f37117cc-82fa-4ccf-9ea8-99594be190ae",
          "code": "Phase3",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Phase3",
          "instanceType": "Code"
        },
        "eligibilityCriterionItems": [
          {
            "id": "58cce86d-0d0d-4f25-b3fe-040e65804d5c",
            "name": "T2DM Diagnosis",
            "text": "Have been diagnosed with T2DM based on the World Health Organization classification or other locally applicable diagnostic standards",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "e760185b-8629-43cc-b6c5-9e76eba2b158",
            "name": "HbA1c Range",
            "text": "Have HbA1c between 7.5% (58 mmol/mol) and 10.5% (91 mmol/mol) at screening as determined by the central laboratory at Visit 1",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "1388a367-9835-4502-bf2c-ae7abe53453b",
            "name": "Stable Oral Antihyperglycemic Treatment",
            "text": "On stable treatment with unchanged dose of at least 1 and no more than 3 oral antihyperglycemic drugs, which may only include metformin, SGLT-2i, and/or sulfonylurea for at least 3 months before Visit 1",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "71e9f429-c7d3-4eb5-95dd-168e71f044f8",
            "name": "Increased CV Risk",
            "text": "Increased risk of CV events as defined by at least 1 of the following (a  e): a) Coronary heart disease documented as having any of the following: 1) History of acute myocardial infarction (ST elevation or non-ST elevation) 2) Stenosis of 50% in at least 1 major (left main, left anterior descending, ramus intermedius, left circumflex, right) coronary artery as determined by cardiac imaging 3) Coronary calcium score 300 4) Stable angina pectoris treated with anti-anginal medication 5) Asymptomatic cardiac ischemia documented by cardiac imaging on exercise or pharmacological stress test 6) History of coronary revascularization (percutaneous coronary intervention or coronary artery bypass surgery) OR b) Peripheral arterial disease presumed to be of atherosclerotic origin documented as a history of any of the following: 1) Current or intermittent claudication 2) Resting limb ischemia 3) Stenosis of >50% in an iliac, femoral, popliteal, or subclavian artery 4) An ankle-brachial index 0.90 5) Peripheral arterial revascularization or amputation due to atherosclerotic vascular disease 6) Asymptomatic carotid artery stenosis 70% 7) Carotid artery revascularization 8) Abdominal aortic aneurysm OR c) Cerebrovascular disease presumed to be of atherosclerotic origin documented as a history of ischemic stroke or transient ischemic attack (TIA). Patients with a history of TIA must be age 50 years. NOTE: Does not include stroke or TIA due to nonatherosclerotic causes, for example, hypertension, embolism, or hemorrhagic stroke OR d) Age 50 years, history of CKD, and an estimated glomerular filtration rate <60 mL/min/1.73m2 (CKD-Epidemiology[CKD-EPI]) on consecutive measurements (Visit 1 and Visit 2) OR e) Age 50 years and congestive heart failure (CHF) documented as a history of CHF by the New York Heart Association Functional Classification II to III",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "84b43ed5-e1f7-4787-8bbb-ac509ec7a4ed",
            "name": "Stable Weight",
            "text": "Are of stable weight ( 5%) 3 months prior to Visit 1 and agree to not initiate an intensive diet and/or exercise program during the study with the intent of reducing body weight other than the lifestyle and dietary measures for diabetes treatment",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "1a0e26db-a667-4f66-9c62-ab090639aaa7",
            "name": "BMI Requirement",
            "text": "Have a BMI 25 kg/m2 at Visit 1",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "171265aa-1314-4d2a-8f04-968c18666e51",
            "name": "Age and Contraception",
            "text": "Eighteen years or older at the time of signing informed consent. Male patients: Male patients should be willing to use reliable contraceptive methods throughout the study and for at least 3 months after last injection. Female patients: Female patients not of childbearing potential due to surgical sterilization (hysterectomy, bilateral oophorectomy, or tubal ligation) or menopause. Women with an intact uterus are deemed postmenopausal if they are 45 years old, and have not taken hormones or oral contraceptives within the last year and had cessation of menses for at least 1 year OR have had at least 6 months of amenorrhea with follicle-stimulating hormone (FSH) and estradiol levels consistent with a postmenopausal state (FSH 40 mIU/mL and estradiol <30 pg/mL). Female patients of childbearing potential (not surgically sterilized and between menarche and 1-year postmenopausal) must test negative for pregnancy at Visit 1 based on a serum pregnancy test AND if sexually active, agree to use 2 forms of effective contraception, where at least 1 form is highly effective for the duration of the trial and for 30 days thereafter, not be breastfeeding",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "62df65e3-64c4-4172-b670-8a07d9240f11",
            "name": "Motivation and Capability",
            "text": "In the investigators opinion, are well motivated, capable, and willing to perform SMBG (up to 7 measures in a day), learn how to self-inject treatment (LY3298176 or insulin glargine), as required for this protocol (visually impaired persons who are not able to perform the injections must have the assistance of a sighted individual trained to inject the study drug; persons with physical limitations who are not able to perform the injections must have the assistance of an individual trained to inject the study drug), are willing and able to inject study drug QW/once daily, maintain a study diary, as required for this protocol, have a sufficient understanding of one of the provided languages of the country such that they will be able to complete the patient questionnaires",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "14f04edb-492f-47e3-987c-af24d8a5a9e4",
            "name": "Informed Consent",
            "text": "Have given written informed consent to participate in this study in accordance with local regulations and the Ethical Review Board (ERB) governing the study site",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "24eb1727-a242-44d4-840f-8c22153d028a",
            "name": "Type 1 Diabetes",
            "text": "Have type 1 diabetes mellitus (T1DM)",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "ba70b236-862b-4423-9636-8f2a683ec588",
            "name": "Pancreatitis History",
            "text": "Had chronic or acute pancreatitis any time prior to study entry (Visit 1)",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "c5d36a39-be5c-438c-8436-1d9f218a0ab9",
            "name": "Diabetic Retinopathy",
            "text": "Have a history of proliferative diabetic retinopathy or diabetic maculopathy (a dilated fundoscopic exam, performed by an ophthalmologist or optometrist between Visit 2 and Visit 3, is required to confirm eligibility) or nonproliferative diabetic retinopathy that requires acute treatment",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "ea949626-9d26-4daa-9cf6-f6e51ccc1e8e",
            "name": "Ketoacidosis History",
            "text": "Have a history of ketoacidosis or hyperosmolar state/coma",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "4bae81cf-13ba-4cdd-b0fb-c90c6e51bdfe",
            "name": "Severe Hypoglycemia",
            "text": "Have had 1 or more episode of severe hypoglycemia and/or 1 or more episode of hypoglycemia unawareness within the 6 months prior to Visit 1",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "2b590e10-8e33-487d-92d2-6110f3119c72",
            "name": "Gastric Emptying Abnormality",
            "text": "Have a known clinically significant gastric emptying abnormality (for example, severe diabetic gastroparesis or gastric outlet obstruction), have undergone gastric bypass (bariatric) surgery or restrictive bariatric surgery (for example, Lap-Band), or chronically take drugs that directly affect GI motility",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "66ce6876-09c0-451b-895a-ba4863db6b76",
            "name": "NYHA Class IV CHF",
            "text": "New York Heart Association Functional Classification IV congestive heart failure",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "8d62c56a-3ef5-4368-8f41-8be06879d19b",
            "name": "Recent CV Conditions",
            "text": "Have any of the following CV conditions within 2 months prior to Visit 1: acute myocardial infarction, cerebrovascular accident (stroke), or hospitalization for CHF",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "40f6f06b-bbab-4ba3-aeae-97abd274f3f4",
            "name": "Liver Disease",
            "text": "Have acute or chronic hepatitis, signs or symptoms of any other liver disease, or an alanine aminotransferase (ALT) level >3.0 the upper limit of normal (ULN) for the reference range, as determined by the central laboratory. Patients with nonalcoholic fatty liver disease are eligible to participate only if their ALT level is 3.0 the ULN for the reference range",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "91363638-3d45-4f70-ae3f-859737a37b6b",
            "name": "Endocrine Abnormality",
            "text": "Have evidence of a significant, uncontrolled endocrine abnormality (for example, thyrotoxicosis or adrenal crises), in the opinion of the investigator",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "dfe93147-ca4a-4a70-ab96-644f3f9e9e38",
            "name": "Thyroid Carcinoma History",
            "text": "Have family or personal history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "80db5d26-57f8-49cf-b599-54febea34e52",
            "name": "Serum Calcitonin Level",
            "text": "Have a serum calcitonin level of (a) 20 ng/L at Visit 1, if eGFR 60 mL/min/1.73m2 (b) 35 ng/L at Visit 1, if eGFR <60 mL/min/1.73m2",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "3f80df5d-91b1-4f7f-9068-03888ad8fb33",
            "name": "Autoimmune Abnormality",
            "text": "Have evidence of significant, active autoimmune abnormality (for example, lupus, rheumatoid arthritis) that, in the opinion of the investigator, is likely to require concurrent treatment with systemic glucocorticoids in the next 12 months.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "53e409dd-812a-47a1-9152-c0f9d3bdc1d2",
            "name": "Product Hypersensitivity",
            "text": "Known or suspected hypersensitivity to trial product(s) or related products",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "9acfd639-ad05-4e5e-a7bc-a865b88e65c1",
            "name": "Insulin Glargine Hypersensitivity",
            "text": "History of hypersensitivity to insulin glargine",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "d1b31a4d-37e9-42c8-b5f9-3fd7af3e38e0",
            "name": "Organ Transplant",
            "text": "Have had a transplanted organ (corneal transplants [keratoplasty] allowed) or awaiting an organ transplant",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "03987741-4427-4da6-b663-1d7fe36a6343",
            "name": "Malignancy History",
            "text": "Have a history of an active or untreated malignancy or are in remission from a clinically significant malignancy (other than basal or squamous cell skin cancer, in situ carcinomas of the cervix, or in situ prostate cancer) for less than 5 years",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "15b7bc28-dd0e-41b0-bee7-fe19fa9cdece",
            "name": "Other Conditions",
            "text": "Have a history of any other condition (such as known drug, alcohol abuse, or psychiatric disorder) that, in the opinion of the investigator, may preclude the patient from following and completing the protocol",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "293a802c-815e-47e2-bc60-92b49372d398",
            "name": "Hematological Condition",
            "text": "Have any hematological condition that may interfere with HbA1c measurement (for example, hemolytic anemias, sickle cell disease)",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "ed396ee4-4e6f-4d04-b8bb-bed6d6df2dc6",
            "name": "Insulin Therapy History",
            "text": "Have a history of insulin therapy except for the use of insulin for treatment of gestational diabetes or acute, temporary use of insulin (14 days), for example, for acute illness, hospitalization, elective surgery",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "0010d932-dc87-4058-847c-e692e492bc10",
            "name": "Other Glucose-Lowering Agents",
            "text": "Treatment with any glucose-lowering agent(s) other than stated in the inclusion criteria (including DPP-4 inhibitors and GLP-1 receptor agonists) in a period of 3 months before screening prior to Visit 1",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "4609541e-379e-41f2-b236-ba8b58c84761",
            "name": "Glucocorticoid Therapy",
            "text": "Are receiving chronic (>2 weeks or 14 days) systemic glucocorticoid therapy (excluding topical, intra-ocular, intranasal, or inhaled preparations) or have received such therapy within 1 month of Visit 1",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "881f84c1-0f7e-4338-9f0a-1760bc422c91",
            "name": "Weight Loss Drugs",
            "text": "Have been treated with drugs that promote weight loss (for example, Saxenda [liraglutide 3.0 mg], Xenical [orlistat], Meridia [sibutramine], Acutrim [phenylpropanolamine], Sanorex [mazindol], Apidex [phentermine], BELVIQ [lorcaserin], Qsymia[phentermine/topiramate combination], Contrave [naltrexone/bupropion], or similar other body weight loss medications including over-the-counter [OTC] medications [for example, all]) within 3 months prior to Visit 1 and/or between study entry (Visit 1) and randomization (Visit 3)",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "793e55c4-952e-4be9-adde-d90a83b09459",
            "name": "Concurrent Clinical Study",
            "text": "Are currently enrolled in any other clinical study involving an investigational product or any other type of medical research judged not to be scientifically or medically compatible with this study",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "3ec2019c-611f-43bb-a113-ea40a44da437",
            "name": "Recent Investigational Product",
            "text": "Have participated, within the last 30 days, in a clinical study involving an investigational product. If the previous investigational product has a long half-life, 5 half-lives or 30 days (whichever is longer) should have passed",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "67fe5218-1fca-4dbe-8a74-7642030f89e0",
            "name": "Previous LY3298176 Study",
            "text": "Have previously completed or withdrawn from this study or any other study investigating LY3298176",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "9921029b-36c6-4e21-ae4d-5cecd7268b07",
            "name": "Site Personnel",
            "text": "Are investigator site personnel directly affiliated with this study and/or their immediate families. Immediate family is defined as a spouse, parent, child, or sibling, whether biological or legally adopted",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "b8d8b132-cb97-4319-a8b9-273a52c63e4d",
            "name": "Lilly Employees",
            "text": "Are Lilly employees",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "cb2e8f2c-fb96-4e30-9e58-fba5cf08a7ec",
            "name": "Diary Compliance",
            "text": "Are unwilling or unable to comply with completing a diary to record data from the subject",
            "instanceType": "EligibilityCriterionItem"
          }
        ],
        "studyInterventions": [
          {
            "id": "90ceb7ef-df96-45f3-88cb-7623927464fe",
            "name": "LY3298176",
            "type": {
              "id": "63c31c50-86bf-4520-b1a7-a2fdd9067f2f",
              "code": "C54121",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Investigational Product",
              "instanceType": "Code"
            },
            "role": {
              "id": "16b2dea7-b1d1-4eb7-8381-0fd2041f1a2d",
              "code": "C54121",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Investigational Product",
              "instanceType": "Code"
            },
            "instanceType": "StudyIntervention",
            "description": "A 39-amino acid synthetic peptide with agonist activity at both the GIP and GLP-1 receptors, administered once weekly.",
            "productIds": [
              "35ddc8d8-cf15-46a9-8c34-b89d7b2e2f94"
            ],
            "administrationIds": [
              "bb3c4fcf-0dc2-4a22-b475-1725faaa9680",
              "d82639b1-3260-45cd-9503-bf1173e80cb7",
              "2617e15b-459a-4ef8-aa4f-26c2a47e70f1",
              "3adea541-ab38-4aef-ba9a-d9872127ef53"
            ]
          },
          {
            "id": "ef7ddc48-d72e-4f43-b9bd-4854f728d597",
            "name": "Insulin Glargine",
            "type": {
              "id": "c24846d4-27a3-40ca-a22f-2cc9d6dcb4a3",
              "code": "C54129",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Comparator",
              "instanceType": "Code"
            },
            "role": {
              "id": "288acd4f-8596-4502-b188-09e62ccdfccf",
              "code": "C54129",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Comparator",
              "instanceType": "Code"
            },
            "instanceType": "StudyIntervention",
            "description": "Basal insulin used as an active comparator, titrated following a treat-to-target algorithm.",
            "productIds": [
              "33b28042-3952-45a4-bd2d-8555568cf17f"
            ],
            "administrationIds": [
              "cb283838-ac3e-44c7-93fc-e3e7a18b71a3",
              "a2039a1e-5f3d-46fb-af7e-efb0e310314e"
            ]
          },
          {
            "id": "6e9c48dd-40dd-4c9d-acb5-65520cb421f1",
            "name": "Metformin",
            "type": {
              "id": "5a1b7ff1-8d76-43f7-9048-51fab8c5ecc2",
              "code": "C54127",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Background Therapy",
              "instanceType": "Code"
            },
            "role": {
              "id": "efaa21f8-f4fb-4846-923f-d7b593261de6",
              "code": "C54127",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Background Therapy",
              "instanceType": "Code"
            },
            "instanceType": "StudyIntervention",
            "description": "Oral antihyperglycemic medication; patients must be on a stable dose for at least 90 days prior to screening.",
            "administrationIds": [
              "1b92f65e-87fa-4aa7-976e-8bc012a0c521"
            ]
          },
          {
            "id": "91c4ae3e-9303-469d-a141-ba92cfc7b036",
            "name": "SGLT-2 inhibitors",
            "type": {
              "id": "2c343f59-aa43-4481-a317-253ced97eea9",
              "code": "C54127",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Background Therapy",
              "instanceType": "Code"
            },
            "role": {
              "id": "80ad66f4-a39a-47e5-a31c-899cdf1b8aef",
              "code": "C54127",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Background Therapy",
              "instanceType": "Code"
            },
            "instanceType": "StudyIntervention",
            "description": "Sodium-glucose co-transporter-2 inhibitors; oral antihyperglycemic medication.",
            "administrationIds": [
              "5a576fef-2621-48ff-a9f5-44fd24ea1f6e"
            ]
          },
          {
            "id": "9e36d3f4-cf97-4be3-bae8-f5f0c1509c75",
            "name": "Sulfonylureas",
            "type": {
              "id": "121a6901-ab1d-4096-9638-f37b29c2c5a6",
              "code": "C54127",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Background Therapy",
              "instanceType": "Code"
            },
            "role": {
              "id": "dea2b5d7-f86d-46e5-96b5-2f5eb3f40181",
              "code": "C54127",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Background Therapy",
              "instanceType": "Code"
            },
            "instanceType": "StudyIntervention",
            "description": "Oral antihyperglycemic medication."
          },
          {
            "id": "d77a9204-c738-4ce6-b958-9bf7c236d9dc",
            "name": "GLP-1 receptor agonists",
            "type": {
              "id": "d1e85771-c8f1-484f-b523-2667db8461d8",
              "code": "C54126",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Concomitant Medication",
              "instanceType": "Code"
            },
            "role": {
              "id": "29da5854-e3de-460c-8f81-56737ef503d3",
              "code": "C54126",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Concomitant Medication",
              "instanceType": "Code"
            },
            "instanceType": "StudyIntervention",
            "description": "Prohibited medication during the study."
          },
          {
            "id": "0f7cae25-1af6-4cde-a663-5ac7444720ab",
            "name": "DPP-4 inhibitors",
            "type": {
              "id": "8c4d7de1-29cd-4d1f-b64d-0cff83b7ae82",
              "code": "C54126",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Concomitant Medication",
              "instanceType": "Code"
            },
            "role": {
              "id": "dca8099a-c0fe-42fd-98d4-27218b5833e4",
              "code": "C54126",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Concomitant Medication",
              "instanceType": "Code"
            },
            "instanceType": "StudyIntervention",
            "description": "Prohibited medication during the study."
          },
          {
            "id": "77bd3db8-7bee-4ec4-84a2-3f8d8de9f21a",
            "name": "Amylin analogs",
            "type": {
              "id": "84d6b19d-fda0-4df0-a84b-f1c42007a33d",
              "code": "C54126",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Concomitant Medication",
              "instanceType": "Code"
            },
            "role": {
              "id": "ce7c0497-99f5-434c-941d-9897056c5d15",
              "code": "C54126",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Concomitant Medication",
              "instanceType": "Code"
            },
            "instanceType": "StudyIntervention",
            "description": "Prohibited medication during the study."
          },
          {
            "id": "a626a651-3e11-448e-b0cc-75bfb2aad083",
            "name": "Weight loss medications",
            "type": {
              "id": "1faef4ed-1430-4812-ab73-3ff39a8b1f7d",
              "code": "C54126",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Concomitant Medication",
              "instanceType": "Code"
            },
            "role": {
              "id": "43489e5e-e3b6-4170-a9d7-70d1fc8eac81",
              "code": "C54126",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Concomitant Medication",
              "instanceType": "Code"
            },
            "instanceType": "StudyIntervention",
            "description": "Prohibited medications including Saxenda, Xenical, Meridia, etc., within 3 months prior to screening."
          },
          {
            "id": "c7ef24f0-9053-4ca0-b800-c90f8c9d25ff",
            "name": "Paracetamol/aspirin",
            "type": {
              "id": "a61912ea-cbc3-4d3e-976a-eb15af97833b",
              "code": "C54126",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Concomitant Medication",
              "instanceType": "Code"
            },
            "role": {
              "id": "bd43b6d1-2969-40f3-bc92-ec414406306e",
              "code": "C54126",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Concomitant Medication",
              "instanceType": "Code"
            },
            "instanceType": "StudyIntervention",
            "description": "Permitted over-the-counter drugs for symptomatic relief."
          },
          {
            "id": "b6ad3955-c25f-4fd0-a94c-6261018a90ba",
            "name": "Rescue therapy",
            "type": {
              "id": "fce6e514-2656-4756-9457-eaa956e1cea7",
              "code": "C54125",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Rescue Medication",
              "instanceType": "Code"
            },
            "role": {
              "id": "94103b1a-0d1d-4c56-8651-095f5db87132",
              "code": "C54125",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Rescue Medication",
              "instanceType": "Code"
            },
            "instanceType": "StudyIntervention",
            "description": "New glucose-lowering intervention for patients with severe, persistent hyperglycemia."
          }
        ],
        "administrableProducts": [
          {
            "id": "35ddc8d8-cf15-46a9-8c34-b89d7b2e2f94",
            "name": "LY3298176 prefilled syringe",
            "administrableDoseForm": {
              "id": "d3466b05-2182-4dcb-95a2-ecb2a1f0fc14",
              "code": "C42945",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Injection",
              "instanceType": "Code",
              "standardCode": {
                "id": "b0af4209-dbbe-4e22-8e8a-41b879df3d73",
                "code": "C42945",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "25.01d",
                "decode": "Injection",
                "instanceType": "Code"
              }
            },
            "productDesignation": {
              "id": "f5a8cc8d-df1d-48a2-a170-971a37a4c3ce",
              "code": "C54121",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Investigational Product",
              "instanceType": "Code"
            },
            "instanceType": "AdministrableProduct",
            "strength": "2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg",
            "substanceIds": [
              "affa98fc-28e2-496d-b97a-60b8622d5629"
            ],
            "manufacturer": "Eli Lilly and Company"
          },
          {
            "id": "33b28042-3952-45a4-bd2d-8555568cf17f",
            "name": "Insulin glargine prefilled pen",
            "administrableDoseForm": {
              "id": "f404bc43-c6ed-4660-b0e6-ae09ad66fa08",
              "code": "C42945",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Injection",
              "instanceType": "Code",
              "standardCode": {
                "id": "5314bdaf-732d-4a9e-9d1f-c61cbfb4156d",
                "code": "C42945",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "25.01d",
                "decode": "Injection",
                "instanceType": "Code"
              }
            },
            "productDesignation": {
              "id": "89f8fe35-9728-482c-8a57-c46cead382a4",
              "code": "C54121",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Investigational Product",
              "instanceType": "Code"
            },
            "instanceType": "AdministrableProduct",
            "strength": "100 units/mL (implied by standard pen)",
            "substanceIds": [
              "678104bf-d45e-4f54-895f-b436f6c9336b"
            ],
            "manufacturer": "Marketed product (e.g., Basaglar)"
          }
        ],
        "narrativeContents": [
          {
            "id": "95b4ca49-0b70-4077-8309-f5640ce50e27",
            "name": "Synopsis",
            "text": "Synopsis",
            "order": 0,
            "instanceType": "NarrativeContent",
            "sectionNumber": "1",
            "sectionTitle": "Synopsis",
            "sectionType": {
              "id": "0ded3299-1d2a-405c-80d0-a63376bbb894",
              "code": "Synopsis",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Synopsis",
              "instanceType": "Code"
            }
          },
          {
            "id": "40686c50-2e7d-4310-be00-bd17d1e95258",
            "name": "Schedule of Activities",
            "text": "Schedule of Activities",
            "order": 1,
            "instanceType": "NarrativeContent",
            "sectionNumber": "2",
            "sectionTitle": "Schedule of Activities",
            "sectionType": {
              "id": "a6da99e4-5f4f-470e-be4a-ee32ab7c2724",
              "code": "Study Procedures",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Study Procedures",
              "instanceType": "Code"
            }
          },
          {
            "id": "93e39a1a-8cea-44dc-a7c2-1ccba58c82cd",
            "name": "Introduction",
            "text": "Introduction",
            "order": 2,
            "instanceType": "NarrativeContent",
            "sectionNumber": "3",
            "sectionTitle": "Introduction",
            "sectionType": {
              "id": "a60a78b6-3c30-4b12-b05c-56c82097894b",
              "code": "Introduction",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Introduction",
              "instanceType": "Code"
            },
            "childIds": [
              "9a06e24a-1a3c-4de1-bc6c-72392b8b09b7",
              "18832188-7919-44bc-9dee-084519309739",
              "e7c710a8-49ba-4063-afd7-e733bfd72edd"
            ]
          },
          {
            "id": "85988114-70c6-4365-83c3-b46c8eba3e27",
            "name": "Objectives and Endpoints",
            "text": "Objectives and Endpoints",
            "order": 3,
            "instanceType": "NarrativeContent",
            "sectionNumber": "4",
            "sectionTitle": "Objectives and Endpoints",
            "sectionType": {
              "id": "ed2354b3-7a6d-4010-af10-d2559a398dfd",
              "code": "Objectives",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Objectives",
              "instanceType": "Code"
            }
          },
          {
            "id": "874e14d0-72f4-4bb8-a1ef-97a14ee94f6a",
            "name": "Study Design",
            "text": "Study Design",
            "order": 4,
            "instanceType": "NarrativeContent",
            "sectionNumber": "5",
            "sectionTitle": "Study Design",
            "sectionType": {
              "id": "68671c03-f300-48d5-b383-122305fe63df",
              "code": "Study Design",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Study Design",
              "instanceType": "Code"
            },
            "childIds": [
              "7275a98e-a245-43e7-847e-3e002763e8a0",
              "4b416480-b3ac-4525-8c1a-abaa8acbf939",
              "4f71b511-f23b-4202-8d8d-b5c0dde34915",
              "8a16471f-24a1-499e-aaaf-ecb94dc42847",
              "5856005e-88c3-419e-90c5-a5b35080d415"
            ]
          },
          {
            "id": "efdd26fb-c642-4609-b29f-a867e58a43bf",
            "name": "Study Population",
            "text": "Study Population",
            "order": 5,
            "instanceType": "NarrativeContent",
            "sectionNumber": "6",
            "sectionTitle": "Study Population",
            "sectionType": {
              "id": "5bbef832-bace-43b0-812e-6d1cacc0e5d0",
              "code": "Study Population",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Study Population",
              "instanceType": "Code"
            },
            "childIds": [
              "87df9210-4da7-4956-ae99-a28797963182",
              "b59b5f05-2f68-46f3-8766-d073bb172fd9",
              "3c0520c5-3c02-471f-8243-a3896366af8a",
              "d793d8df-9c18-4bca-9fa5-f94ea76be8b1"
            ]
          },
          {
            "id": "14019373-8f22-4056-b3c1-992cb5c135d0",
            "name": "Treatments",
            "text": "Treatments",
            "order": 6,
            "instanceType": "NarrativeContent",
            "sectionNumber": "7",
            "sectionTitle": "Treatments",
            "sectionType": {
              "id": "cf7f074a-0933-4727-986f-dcad2b9e2663",
              "code": "Treatment",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Treatment",
              "instanceType": "Code"
            },
            "childIds": [
              "0c924901-345f-4cec-a300-ee8f74d2e1f6",
              "da7b8f54-c986-4578-b82e-811093c96b8a",
              "0d490476-4db7-4c1e-b380-b8678918e17b",
              "e1da79e1-41a8-4d83-b060-0195b96662ad",
              "77c7560a-2915-4630-bb4e-a05d219fa81e",
              "1461dbea-3c79-43f8-accf-49d8d900b4ef",
              "ce1017d5-0674-4656-ae94-ee9719d38a88",
              "b0162f84-5e84-4181-aaca-e588be101bab",
              "4ac87722-f879-4bb6-a4b6-42e2e2db4758",
              "b0e1aab1-fc25-460e-8ddc-8d1a6a33f8d8"
            ]
          },
          {
            "id": "632f84cb-9280-4ba9-bf7a-4b7009f30657",
            "name": "Abbreviations and Definitions",
            "text": "Abbreviations and Definitions",
            "order": 7,
            "instanceType": "NarrativeContent",
            "sectionNumber": "Appendix 1",
            "sectionTitle": "Abbreviations and Definitions",
            "sectionType": {
              "id": "251232dc-c78b-4b7a-81c6-f51cebd8a69b",
              "code": "Appendix",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Appendix",
              "instanceType": "Code"
            }
          },
          {
            "id": "ad032dea-63e4-4ca3-93dc-6c8676aacfc9",
            "name": "Clinical Laboratory Tests",
            "text": "Clinical Laboratory Tests",
            "order": 8,
            "instanceType": "NarrativeContent",
            "sectionNumber": "Appendix 2",
            "sectionTitle": "Clinical Laboratory Tests",
            "sectionType": {
              "id": "9c2eed8d-9f3f-4445-adfb-716fc5bda008",
              "code": "Appendix",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Appendix",
              "instanceType": "Code"
            }
          },
          {
            "id": "87358456-5c66-42a8-be4a-414447420d33",
            "name": "Study Governance Considerations",
            "text": "Study Governance Considerations",
            "order": 9,
            "instanceType": "NarrativeContent",
            "sectionNumber": "Appendix 3",
            "sectionTitle": "Study Governance Considerations",
            "sectionType": {
              "id": "58d5c25d-c8bf-43df-a6ea-0a37aa01c71b",
              "code": "Appendix",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Appendix",
              "instanceType": "Code"
            }
          },
          {
            "id": "eeee66ec-b0c7-464e-9d32-f5d852531a87",
            "name": "Hepatic Monitoring Tests for Treatment-Emergent Abnormality",
            "text": "Hepatic Monitoring Tests for Treatment-Emergent Abnormality",
            "order": 10,
            "instanceType": "NarrativeContent",
            "sectionNumber": "Appendix 4",
            "sectionTitle": "Hepatic Monitoring Tests for Treatment-Emergent Abnormality",
            "sectionType": {
              "id": "061438ba-3a03-46e9-bcac-7e927fa73c50",
              "code": "Appendix",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Appendix",
              "instanceType": "Code"
            }
          },
          {
            "id": "84cae3eb-bdcf-45c9-866c-b4fedc22c71e",
            "name": "World Health Organization Classification of Diabetes and Diagnostic Criteria",
            "text": "World Health Organization Classification of Diabetes and Diagnostic Criteria",
            "order": 11,
            "instanceType": "NarrativeContent",
            "sectionNumber": "Appendix 5",
            "sectionTitle": "World Health Organization Classification of Diabetes and Diagnostic Criteria",
            "sectionType": {
              "id": "f36928b7-ee18-433b-ba66-2c7243554637",
              "code": "Appendix",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Appendix",
              "instanceType": "Code"
            }
          },
          {
            "id": "f322d5fa-304f-4c34-abf9-64e8cc2d2f33",
            "name": "Classification of Contraceptive Methods",
            "text": "Classification of Contraceptive Methods",
            "order": 12,
            "instanceType": "NarrativeContent",
            "sectionNumber": "Appendix 6",
            "sectionTitle": "Classification of Contraceptive Methods",
            "sectionType": {
              "id": "990c9b8c-306b-411d-b09b-aff5cf44facc",
              "code": "Appendix",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Appendix",
              "instanceType": "Code"
            }
          },
          {
            "id": "a7511da2-db8c-40cb-9d6d-8b0aee054edc",
            "name": "Management of Patients with Severe, Persistent Hyperglycemia during the Treatment Period",
            "text": "Management of Patients with Severe, Persistent Hyperglycemia during the Treatment Period",
            "order": 13,
            "instanceType": "NarrativeContent",
            "sectionNumber": "Appendix 7",
            "sectionTitle": "Management of Patients with Severe, Persistent Hyperglycemia during the Treatment Period",
            "sectionType": {
              "id": "443e3a95-9abe-4efe-8271-0c2cf7fcd775",
              "code": "Appendix",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Appendix",
              "instanceType": "Code"
            }
          },
          {
            "id": "5312fad4-9e2d-4ab6-87e9-4da6f843c3b5",
            "name": "Changes to Study Procedures due to the COVID-19 Pandemic",
            "text": "Changes to Study Procedures due to the COVID-19 Pandemic",
            "order": 14,
            "instanceType": "NarrativeContent",
            "sectionNumber": "Appendix 8",
            "sectionTitle": "Changes to Study Procedures due to the COVID-19 Pandemic",
            "sectionType": {
              "id": "74840104-44a6-43cd-8ad9-35c3588bbf9c",
              "code": "Appendix",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Appendix",
              "instanceType": "Code"
            }
          },
          {
            "id": "9a11f073-de9c-4d14-81dc-7198eb8f085e",
            "name": "Protocol Amendment I8F-MC-GPGM(b)",
            "text": "Protocol Amendment I8F-MC-GPGM(b)",
            "order": 15,
            "instanceType": "NarrativeContent",
            "sectionNumber": "Appendix 9",
            "sectionTitle": "Protocol Amendment I8F-MC-GPGM(b)",
            "sectionType": {
              "id": "5ed12b5d-8323-4c57-94c8-3a7f1d6542ff",
              "code": "Appendix",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Appendix",
              "instanceType": "Code"
            }
          }
        ],
        "narrativeContentItems": [
          {
            "id": "9a06e24a-1a3c-4de1-bc6c-72392b8b09b7",
            "name": "Study Rationale",
            "text": "",
            "order": 0,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "3.1",
            "sectionTitle": "Study Rationale"
          },
          {
            "id": "18832188-7919-44bc-9dee-084519309739",
            "name": "Background",
            "text": "",
            "order": 1,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "3.2",
            "sectionTitle": "Background"
          },
          {
            "id": "e7c710a8-49ba-4063-afd7-e733bfd72edd",
            "name": "Benefit/Risk Assessment",
            "text": "",
            "order": 2,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "3.3",
            "sectionTitle": "Benefit/Risk Assessment"
          },
          {
            "id": "7275a98e-a245-43e7-847e-3e002763e8a0",
            "name": "Overall Design",
            "text": "",
            "order": 0,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "5.1",
            "sectionTitle": "Overall Design"
          },
          {
            "id": "4b416480-b3ac-4525-8c1a-abaa8acbf939",
            "name": "Number of Participants",
            "text": "",
            "order": 1,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "5.2",
            "sectionTitle": "Number of Participants"
          },
          {
            "id": "4f71b511-f23b-4202-8d8d-b5c0dde34915",
            "name": "End of Study Definition",
            "text": "",
            "order": 2,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "5.3",
            "sectionTitle": "End of Study Definition"
          },
          {
            "id": "8a16471f-24a1-499e-aaaf-ecb94dc42847",
            "name": "Scientific Rationale for Study Design",
            "text": "",
            "order": 3,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "5.4",
            "sectionTitle": "Scientific Rationale for Study Design"
          },
          {
            "id": "5856005e-88c3-419e-90c5-a5b35080d415",
            "name": "Justification for Dose",
            "text": "",
            "order": 4,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "5.5",
            "sectionTitle": "Justification for Dose"
          },
          {
            "id": "87df9210-4da7-4956-ae99-a28797963182",
            "name": "Inclusion Criteria",
            "text": "",
            "order": 0,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "6.1",
            "sectionTitle": "Inclusion Criteria"
          },
          {
            "id": "b59b5f05-2f68-46f3-8766-d073bb172fd9",
            "name": "Exclusion Criteria",
            "text": "",
            "order": 1,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "6.2",
            "sectionTitle": "Exclusion Criteria"
          },
          {
            "id": "3c0520c5-3c02-471f-8243-a3896366af8a",
            "name": "Lifestyle Restrictions",
            "text": "",
            "order": 2,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "6.3",
            "sectionTitle": "Lifestyle Restrictions"
          },
          {
            "id": "d793d8df-9c18-4bca-9fa5-f94ea76be8b1",
            "name": "Screen Failures",
            "text": "",
            "order": 3,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "6.4",
            "sectionTitle": "Screen Failures"
          },
          {
            "id": "0c924901-345f-4cec-a300-ee8f74d2e1f6",
            "name": "Treatments Administered",
            "text": "",
            "order": 0,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "7.1",
            "sectionTitle": "Treatments Administered"
          },
          {
            "id": "da7b8f54-c986-4578-b82e-811093c96b8a",
            "name": "Packaging and Labeling",
            "text": "",
            "order": 1,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "7.1.1",
            "sectionTitle": "Packaging and Labeling"
          },
          {
            "id": "0d490476-4db7-4c1e-b380-b8678918e17b",
            "name": "Medical Devices",
            "text": "",
            "order": 2,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "7.1.2",
            "sectionTitle": "Medical Devices"
          },
          {
            "id": "e1da79e1-41a8-4d83-b060-0195b96662ad",
            "name": "Method of Treatment Assignment",
            "text": "",
            "order": 3,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "7.2",
            "sectionTitle": "Method of Treatment Assignment"
          },
          {
            "id": "77c7560a-2915-4630-bb4e-a05d219fa81e",
            "name": "Selection and Timing of Doses",
            "text": "",
            "order": 4,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "7.2.1",
            "sectionTitle": "Selection and Timing of Doses"
          },
          {
            "id": "1461dbea-3c79-43f8-accf-49d8d900b4ef",
            "name": "LY3298176",
            "text": "",
            "order": 5,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "7.2.1.1",
            "sectionTitle": "LY3298176"
          },
          {
            "id": "ce1017d5-0674-4656-ae94-ee9719d38a88",
            "name": "Insulin Glargine",
            "text": "",
            "order": 6,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "7.2.1.2",
            "sectionTitle": "Insulin Glargine"
          },
          {
            "id": "b0162f84-5e84-4181-aaca-e588be101bab",
            "name": "Blinding",
            "text": "",
            "order": 7,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "7.3",
            "sectionTitle": "Blinding"
          },
          {
            "id": "4ac87722-f879-4bb6-a4b6-42e2e2db4758",
            "name": "Dosage Modification",
            "text": "",
            "order": 8,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "7.4",
            "sectionTitle": "Dosage Modification"
          },
          {
            "id": "b0e1aab1-fc25-460e-8ddc-8d1a6a33f8d8",
            "name": "Study Drugs",
            "text": "",
            "order": 9,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "7.4.1",
            "sectionTitle": "Study Drugs"
          }
        ],
        "abbreviations": [
          {
            "id": "f9865c79-2abb-406e-8a60-fe7b3eb3d6c0",
            "abbreviatedText": "T2DM",
            "expandedText": "type 2 diabetes mellitus",
            "instanceType": "Abbreviation"
          },
          {
            "id": "2e1d8f95-a477-4912-8071-390e7cba02b9",
            "abbreviatedText": "GIP",
            "expandedText": "glucose-dependent insulinotropic polypeptide",
            "instanceType": "Abbreviation"
          },
          {
            "id": "9ef7b86c-7c60-4b66-99dc-1abdd1ac9b39",
            "abbreviatedText": "GLP-1",
            "expandedText": "glucagon-like peptide-1",
            "instanceType": "Abbreviation"
          },
          {
            "id": "8f7e6dc7-a4c3-49b7-9670-4e712887651b",
            "abbreviatedText": "QW",
            "expandedText": "once weekly",
            "instanceType": "Abbreviation"
          },
          {
            "id": "e70b4a46-1b0e-40eb-bea3-20e661ea0e3a",
            "abbreviatedText": "CV",
            "expandedText": "cardiovascular",
            "instanceType": "Abbreviation"
          },
          {
            "id": "6b4503ba-4da6-4f05-bcac-b350481ace2b",
            "abbreviatedText": "HbA1c",
            "expandedText": "hemoglobin A1c",
            "instanceType": "Abbreviation"
          },
          {
            "id": "472acf9c-c1b2-4a22-b380-37cc25c007b0",
            "abbreviatedText": "SARS-CoV-2",
            "expandedText": "severe acute respiratory syndrome coronavirus 2",
            "instanceType": "Abbreviation"
          },
          {
            "id": "21ffbb06-88bd-4085-90cc-b61bf95af495",
            "abbreviatedText": "COVID-19",
            "expandedText": "Coronavirus Disease 2019",
            "instanceType": "Abbreviation"
          },
          {
            "id": "b29d8d4a-e5d8-44e5-9b5b-8a519a15da1b",
            "abbreviatedText": "ADA",
            "expandedText": "anti-drug antibodies",
            "instanceType": "Abbreviation"
          },
          {
            "id": "5281e743-b210-4e1c-a546-3f972386831a",
            "abbreviatedText": "APPADL",
            "expandedText": "Ability to Perform Physical Activities of Daily Living",
            "instanceType": "Abbreviation"
          },
          {
            "id": "9830b168-8d26-4625-9d7b-aaeddede832b",
            "abbreviatedText": "BG",
            "expandedText": "blood glucose",
            "instanceType": "Abbreviation"
          },
          {
            "id": "1d219110-63bf-49d5-a924-6b24aa7febf4",
            "abbreviatedText": "BP",
            "expandedText": "blood pressure",
            "instanceType": "Abbreviation"
          },
          {
            "id": "1308491c-65d9-43da-8944-6ff1d7181df1",
            "abbreviatedText": "CKD-EPI",
            "expandedText": "Chronic Kidney Disease-Epidemiology",
            "instanceType": "Abbreviation"
          },
          {
            "id": "66abd382-2411-4a90-911a-d9e1eebccf03",
            "abbreviatedText": "DTSQc",
            "expandedText": "Diabetes Treatment Satisfaction Questionnaire change",
            "instanceType": "Abbreviation"
          },
          {
            "id": "2e261850-d527-4e89-965c-803a847953ef",
            "abbreviatedText": "DTSQs",
            "expandedText": "Diabetes Treatment Satisfaction Questionnaire status",
            "instanceType": "Abbreviation"
          },
          {
            "id": "3aaf93c0-3ced-4fbe-8290-00d426f7f45f",
            "abbreviatedText": "ECG",
            "expandedText": "electrocardiogram",
            "instanceType": "Abbreviation"
          },
          {
            "id": "e313969d-cd67-40d5-9b10-52b8ba5021b6",
            "abbreviatedText": "eGFR",
            "expandedText": "estimated glomerular filtration rate",
            "instanceType": "Abbreviation"
          },
          {
            "id": "01b1a694-1ec6-437f-b88d-f5ce4aa103a8",
            "abbreviatedText": "EQ-5D-5L",
            "expandedText": "European Qualtiy of Life-dimensions",
            "instanceType": "Abbreviation"
          },
          {
            "id": "79173e93-e30a-4ef0-b3d5-da13d928e093",
            "abbreviatedText": "ET",
            "expandedText": "early termination",
            "instanceType": "Abbreviation"
          },
          {
            "id": "3e4f7bd2-b067-4f0e-926d-7b4836f0cee5",
            "abbreviatedText": "FTV",
            "expandedText": "final treatment visit",
            "instanceType": "Abbreviation"
          },
          {
            "id": "2c9bb542-5514-48ef-a525-8b7547a98517",
            "abbreviatedText": "F/U",
            "expandedText": "follow-up",
            "instanceType": "Abbreviation"
          },
          {
            "id": "a84ca061-902c-401b-a954-9576307fd11e",
            "abbreviatedText": "GAD",
            "expandedText": "glutamic acid decarboxylase",
            "instanceType": "Abbreviation"
          },
          {
            "id": "35b55db4-9373-4d4f-a987-08841de13e97",
            "abbreviatedText": "HR",
            "expandedText": "heart rate",
            "instanceType": "Abbreviation"
          },
          {
            "id": "832ae881-f47d-4e09-9e51-4392e083da09",
            "abbreviatedText": "IW-SP",
            "expandedText": "Impact of Weight on Self Perception",
            "instanceType": "Abbreviation"
          },
          {
            "id": "41b31b9d-9933-4e18-ab52-3fbb8e123e45",
            "abbreviatedText": "LY",
            "expandedText": "LY3298176",
            "instanceType": "Abbreviation"
          },
          {
            "id": "7e9501c0-3ed4-4d3f-8bf9-2ee34ac18da6",
            "abbreviatedText": "PK",
            "expandedText": "pharmacokinetics",
            "instanceType": "Abbreviation"
          },
          {
            "id": "fcec876b-1303-4f1c-9023-0e4f651a46b4",
            "abbreviatedText": "PRO",
            "expandedText": "patient-reported outcome",
            "instanceType": "Abbreviation"
          },
          {
            "id": "39d4f10c-979f-48ef-a618-ab0286c45d72",
            "abbreviatedText": "SGLT-2i",
            "expandedText": "sodium-glucose co-transporter-2 inhibitor",
            "instanceType": "Abbreviation"
          },
          {
            "id": "260606f5-06a4-4e38-9bc2-8d67989ef44f",
            "abbreviatedText": "SMBG",
            "expandedText": "self-monitored blood glucose",
            "instanceType": "Abbreviation"
          },
          {
            "id": "126bca86-9dfb-4fa8-b117-f40bb63a0e42",
            "abbreviatedText": "SU",
            "expandedText": "sulfonylurea",
            "instanceType": "Abbreviation"
          },
          {
            "id": "eacca0db-ce2f-4263-bcfd-808245a497ad",
            "abbreviatedText": "TTT",
            "expandedText": "treat-to-target",
            "instanceType": "Abbreviation"
          },
          {
            "id": "92b94287-936e-4410-a52d-f92408c80056",
            "abbreviatedText": "Tx",
            "expandedText": "treatment",
            "instanceType": "Abbreviation"
          },
          {
            "id": "081965f7-4ca5-4f92-b4bb-973f5f19f84d",
            "abbreviatedText": "QD",
            "expandedText": "once daily",
            "instanceType": "Abbreviation"
          }
        ],
        "amendments": [
          {
            "id": "9a183ac2-fe68-4238-82e3-974c092b6de8",
            "number": "a",
            "name": "Amendment a",
            "scope": {
              "id": "cb11f0fb-dc0c-432f-b4a0-7fdb14281910",
              "code": "Global",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Global",
              "instanceType": "Code"
            },
            "primaryReason": {
              "id": "63acbf7c-39e1-45eb-9a40-071024c57774",
              "code": {
                "id": "7d4304fd-c2fd-40ac-a9dc-62904d2a2886",
                "code": "C98782",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "25.01d",
                "decode": "Protocol Amendment",
                "instanceType": "Code"
              },
              "otherReason": "Protocol Amendment",
              "instanceType": "StudyAmendmentReason"
            },
            "geographicScopes": [
              {
                "id": "71ad52d8-393c-4b1c-b39b-5cddd971acb4",
                "type": {
                  "id": "c5e43952-94d0-441e-895e-0e01333bc12e",
                  "code": "Global",
                  "codeSystem": "USDM",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Global",
                  "instanceType": "Code"
                },
                "instanceType": "GeographicScope"
              }
            ],
            "instanceType": "StudyAmendment",
            "summary": "Amendment (a) was electronically signed and approved by Lilly on 28 Sep 2018.",
            "effectiveDate": "2018-09-28",
            "reasonIds": [
              "6507da2b-023b-4693-a4cf-05b7d1fd4100"
            ],
            "previousVersion": "Original Protocol",
            "newVersion": "a"
          },
          {
            "id": "025b85c2-5d71-4248-ba16-44d96f6e95c6",
            "number": "b",
            "name": "Amendment b",
            "scope": {
              "id": "d1888e7d-13e0-48f1-87ec-3a31213a886d",
              "code": "Global",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Global",
              "instanceType": "Code"
            },
            "primaryReason": {
              "id": "7fb6618f-c7d6-4a86-9c5c-c64d24f7ab1c",
              "code": {
                "id": "f5cb6796-c5f4-45dc-ad6f-a2d143ee2c25",
                "code": "C98782",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "25.01d",
                "decode": "Protocol Amendment",
                "instanceType": "Code"
              },
              "otherReason": "Protocol Amendment",
              "instanceType": "StudyAmendmentReason"
            },
            "geographicScopes": [
              {
                "id": "85356530-8275-409f-b88a-ea7685694b18",
                "type": {
                  "id": "f21afe6f-f1f2-4952-99ce-b9afe72a70ad",
                  "code": "Global",
                  "codeSystem": "USDM",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Global",
                  "instanceType": "Code"
                },
                "instanceType": "GeographicScope"
              }
            ],
            "instanceType": "StudyAmendment",
            "summary": "The main reason for preparation of this amendment was to incorporate changes to study procedures due to the COVID-19 pandemic, as detailed in Appendix 8, and to update the protocol for continued efficacy and safety assessment of LY3298176.",
            "effectiveDate": "2020-07-10",
            "reasonIds": [
              "ffe20ab2-0f42-4f01-b894-098d226623eb",
              "9bc74f9f-703b-49c4-8393-a158220bb75f",
              "a5e0cd9e-a619-42ac-8e9c-dcfaf8692a45"
            ],
            "previousVersion": "a",
            "newVersion": "b"
          }
        ],
        "medicalDevices": [
          {
            "id": "91bdfce7-4055-448a-8ab5-d1b19f88c17c",
            "name": "Investigational Prefilled Syringe",
            "instanceType": "MedicalDevice",
            "label": "LY3298176 PFS",
            "description": "Single-dose prefilled syringe for subcutaneous injection of LY3298176",
            "deviceType": {
              "id": "851a5e8f-febc-479d-b4de-315e912e5482",
              "code": "Drug Delivery Device",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Drug Delivery Device",
              "instanceType": "Code"
            },
            "manufacturer": "Eli Lilly and Company"
          },
          {
            "id": "a4ca71c6-a90b-488c-8bf7-4d7708054f31",
            "name": "Marketed Insulin Glargine Prefilled Pen",
            "instanceType": "MedicalDevice",
            "label": "Insulin Pen",
            "description": "Prefilled pen for daily administration of insulin glargine",
            "deviceType": {
              "id": "9ce4669a-5212-42d2-a13e-2d906981005f",
              "code": "Drug Delivery Device",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Drug Delivery Device",
              "instanceType": "Code"
            }
          },
          {
            "id": "08ff01fb-ca12-4573-ba11-0975d5f5ffc8",
            "name": "Automated Blood Pressure Machine",
            "instanceType": "MedicalDevice",
            "label": "BP Monitor",
            "description": "Device used for taking automated blood pressure measurements",
            "deviceType": {
              "id": "0c7fa8c1-1356-44ee-bcf6-6ab60bad1899",
              "code": "Monitoring Device",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Monitoring Device",
              "instanceType": "Code"
            }
          },
          {
            "id": "7d1f4411-a4a0-464f-aab8-ca73a23ee82c",
            "name": "Glucose Monitor",
            "instanceType": "MedicalDevice",
            "label": "Glucometer",
            "description": "Device used by patients for self-monitored blood glucose (SMBG)",
            "deviceType": {
              "id": "1c5e2c93-1c8f-45fa-994c-e77df742cb3c",
              "code": "Monitoring Device",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Monitoring Device",
              "instanceType": "Code"
            }
          }
        ],
        "studySites": [
          {
            "id": "41d43ef8-9977-4f24-8c0d-829803a9199c",
            "name": "Advanced Research Center",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "1",
            "organizationId": "3e7e8941-64db-4509-812f-1097e7e4b2bf",
            "country": "United States"
          },
          {
            "id": "c0ebf24b-5be4-42f9-a49d-8a84d6d93373",
            "name": "Valley Clinical Trials Inc.",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "2",
            "organizationId": "432d83b8-e43d-4105-9f5e-b818c4049ddf",
            "country": "United States"
          },
          {
            "id": "92b10a5b-2471-4f2f-afbd-3979d70776a6",
            "name": "Marin Endocrine Associates",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "3",
            "organizationId": "f3476dca-f398-434c-9f0c-7ea552a8d1a0",
            "country": "United States"
          },
          {
            "id": "905ba93c-43da-4d32-9270-0893e213bd5c",
            "name": "National Research Institute",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "4",
            "organizationId": "4315dc29-f022-449b-8d06-d1476a3cd0f9",
            "country": "United States"
          },
          {
            "id": "5b03efb1-befb-48f8-800f-f00abffab133",
            "name": "Scripps Whittier Diabetes Institute",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "5",
            "organizationId": "4c07bfa8-dd98-4af4-8e14-6c65515aabe8",
            "country": "United States"
          },
          {
            "id": "372ff645-eff2-4052-90ce-2ea2e12b11fc",
            "name": "First Valley Medical Group",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "6",
            "organizationId": "75553364-daf1-42f3-8d97-5552ee849662",
            "country": "United States"
          },
          {
            "id": "fc00d18f-b711-4034-9cb1-c623164c2b2f",
            "name": "National Research Institute",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "7",
            "organizationId": "f2a8ae8a-be0c-4bd8-be32-b338851b57c1",
            "country": "United States"
          },
          {
            "id": "d15887a2-4e6b-4b36-aea9-d2623ed0c98d",
            "name": "Catalina Research Institute LLC",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "8",
            "organizationId": "91356692-11bd-499f-bda8-0a0bab0eeea0",
            "country": "United States"
          },
          {
            "id": "53c97646-0b14-49dc-8ce2-66ea1a0648bb",
            "name": "Monterey Endocrine & Diabetes Institute Inc.",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "9",
            "organizationId": "3f0b4ef4-566d-4e1c-a3d7-ca39e17f1f87",
            "country": "United States"
          },
          {
            "id": "21cc2d2e-5b42-4a32-a6a3-e652ce24ef9e",
            "name": "Valley Clinical Trials Inc.",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "10",
            "organizationId": "def5df2c-5143-4708-a4b8-6118cb7a6f8a",
            "country": "United States"
          },
          {
            "id": "3d6cc9cc-b7fb-450a-aa96-31f1c01970b6",
            "name": "Desert Medical Group Inc",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "11",
            "organizationId": "983c7cc5-2ec9-4b1a-b203-4e0814540614",
            "country": "United States"
          },
          {
            "id": "8b0f3d33-874b-43c9-bb22-dc3d96d80c5b",
            "name": "Havana Research Institute",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "12",
            "organizationId": "d6f1ddd7-c620-4273-b3dd-2c807c0d1156",
            "country": "United States"
          },
          {
            "id": "95cdcdf2-353d-4ebe-83f6-d54eece183ea",
            "name": "Western University of Health Sciences",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "13",
            "organizationId": "ff4ee464-2a81-4830-9f44-88d9ccfdb54d",
            "country": "United States"
          },
          {
            "id": "2bec5371-42a6-4a35-bf0a-87ef7f6c650f",
            "name": "LCGK Research",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "14",
            "organizationId": "c4238f1d-55f4-4e1c-9f92-a05fd70021a2",
            "country": "United States"
          },
          {
            "id": "e9914089-eff4-4312-baa7-d502ffb792fb",
            "name": "Olive View Medical Center",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "15",
            "organizationId": "3f48097d-93be-43a0-aa63-7fa6c8854962",
            "country": "United States"
          },
          {
            "id": "4efa2da9-7044-47b4-8bf8-0984156b9843",
            "name": "University Clinical Investigators Inc.",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "16",
            "organizationId": "9aebef68-5adc-4167-9fad-34831aa1cf31",
            "country": "United States"
          },
          {
            "id": "7e437663-d2de-40c9-b1eb-8f1f518ca777",
            "name": "Touro University",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "17",
            "organizationId": "2081e0a7-39ee-4982-8b2b-ac430dfbd2f4",
            "country": "United States"
          },
          {
            "id": "0ddf34da-e878-4ed7-b818-136072bf399a",
            "name": "Coastal Metabolic Research Centre",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "18",
            "organizationId": "dbb77255-d728-46a4-a29a-d04c1552337f",
            "country": "United States"
          },
          {
            "id": "9fe2c942-c59a-484b-8bdb-f5ad1215b226",
            "name": "Diablo Clinical Research",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "19",
            "organizationId": "201ce61c-8324-44fc-a7f3-ab3cce62b90f",
            "country": "United States"
          },
          {
            "id": "4645a8ad-f548-440f-87fe-788dc45a7475",
            "name": "Chase Medical Research LLC",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "20",
            "organizationId": "93a6db7d-d41a-4a7a-bcb2-4fe21452300b",
            "country": "United States"
          },
          {
            "id": "6ecb0e37-425b-418e-961e-fb494b838d6b",
            "name": "ALL Medical Research LLC",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "21",
            "organizationId": "7ed2a80a-31ea-4f17-95c8-ba9699f03221",
            "country": "United States"
          },
          {
            "id": "032d79d3-5045-4647-bd0d-f38871cb909d",
            "name": "Advanced Pharma Research",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "22",
            "organizationId": "54e3427d-4e6f-426e-98ca-d5fcee0d0677",
            "country": "United States"
          },
          {
            "id": "dfb5e4c0-0868-4457-a668-1d4d9905a77f",
            "name": "South Florida Wellness & Clinical Research Institute",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "23",
            "organizationId": "0dd2c1be-1d2d-4a40-8424-8594c2d9c3b4",
            "country": "United States"
          },
          {
            "id": "052d4996-fb53-4b9c-9a73-300e43f03171",
            "name": "Suncoast Research Group LLC",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "24",
            "organizationId": "eb59da8f-6465-4559-9fb6-c7716a297274",
            "country": "United States"
          },
          {
            "id": "b24ce863-239b-4dd6-a28c-472b8558f65f",
            "name": "New Horizon Research Center",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "25",
            "organizationId": "4843c895-cf58-456b-ac26-94d2b0bc912b",
            "country": "United States"
          },
          {
            "id": "8f7c970f-5a8e-4852-94a9-93ae00a79581",
            "name": "Clinical Neuroscience Solutions Inc",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "26",
            "organizationId": "8cbda60e-873e-4983-964c-0112dff5bf21",
            "country": "United States"
          },
          {
            "id": "eb2ba156-7ffc-428d-8960-4d5ded81a14d",
            "name": "Progressive Medical Research",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "27",
            "organizationId": "5aa6cbfd-37f5-4f24-8051-b797921dfd0c",
            "country": "United States"
          },
          {
            "id": "e4047da1-29b8-45be-953c-72607156cedc",
            "name": "Primary Care Specialists LLC",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "28",
            "organizationId": "ce3ab11a-3d86-41bf-8baa-75e96f5243d2",
            "country": "United States"
          },
          {
            "id": "e2eef4c6-79f7-4093-85c9-dd15e06c152b",
            "name": "Rocky Mountain Diabetes and Osteoporosis Center",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "29",
            "organizationId": "446d5b1b-24ca-400a-ad54-2b5342b7b262",
            "country": "United States"
          },
          {
            "id": "7391a51e-afb1-4888-b550-3b7a4c908acf",
            "name": "Solaris Clinical Research",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "30",
            "organizationId": "eb28356a-7f1c-4f3b-bdca-2835a0f19caa",
            "country": "United States"
          },
          {
            "id": "3938ae83-45eb-434c-ac29-4f719242827a",
            "name": "Saltzer Medical Group P.A.",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "31",
            "organizationId": "eb2d57d3-8889-4627-96cc-46053bfd75b2",
            "country": "United States"
          },
          {
            "id": "07ebd65b-76c6-4475-bb74-5590bbe491d9",
            "name": "Northwestern Feinberg School of Medicine",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "32",
            "organizationId": "3af61329-0404-4b8b-a06b-011913dc3a93",
            "country": "United States"
          },
          {
            "id": "520bef49-cbdb-4485-8571-308d1ffe5bc1",
            "name": "NorthShore University HealthSystem",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "33",
            "organizationId": "970fc12b-60b3-44e8-b8cb-932cc6fd83b9",
            "country": "United States"
          },
          {
            "id": "b9654511-d043-4c41-889b-6375e9cd12f5",
            "name": "University of Iowa Hospital & Clinic",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "34",
            "organizationId": "ea9168e9-afb7-4372-ac9c-417680da4f5a",
            "country": "United States"
          },
          {
            "id": "bcaebc76-36a0-4412-804c-969a2e37efec",
            "name": "Iowa Diabetes Research",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "35",
            "organizationId": "4f039ccd-48a6-47d5-85a2-165838cda489",
            "country": "United States"
          },
          {
            "id": "ba593863-c412-4ffd-8a46-3ebc1684dbf5",
            "name": "Cotton O'Neil Diabetes and Endocrinology Center",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "36",
            "organizationId": "ba937122-1058-4055-ae43-f38c16751ed1",
            "country": "United States"
          },
          {
            "id": "1f1814f9-9757-466c-93cf-3ce62d021be2",
            "name": "Robley Rex VAMC",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "37",
            "organizationId": "80e72af6-16e8-4eee-a3ff-c0b560ddae06",
            "country": "United States"
          },
          {
            "id": "dfa1232c-5711-428e-9c72-4b1755ce0c9d",
            "name": "NECCR PrimaCare Research LLC",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "38",
            "organizationId": "c259bc7c-8de5-4c52-8b74-2f429df56fec",
            "country": "United States"
          },
          {
            "id": "74b98fc9-8215-417a-8945-08f7bfdb66d9",
            "name": "AA Medical Research Center",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "39",
            "organizationId": "d86cf1b5-a25d-4885-8ec3-356287fdd50a",
            "country": "United States"
          },
          {
            "id": "3b87b93a-5caa-4510-99c4-53ea37a9a392",
            "name": "Troy Internal Medicine PC",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "40",
            "organizationId": "b6c33843-9520-4976-8c3c-830f54776d60",
            "country": "United States"
          },
          {
            "id": "e2477532-41d8-4ced-a2bf-b5f71073b56c",
            "name": "Centro de Investigaciones Metabolicas (CINME)",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "41",
            "organizationId": "0ac67cf5-d375-442f-b04d-f5228a94712e",
            "country": "Argentina"
          },
          {
            "id": "986ae7d5-d3c8-45fb-b312-331d3e88cc1b",
            "name": "Mautalen Salud e Investigacion",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "42",
            "organizationId": "13f9e76a-78b8-4187-97ab-db6b2b138262",
            "country": "Argentina"
          },
          {
            "id": "b9c88c48-6ab9-4ca0-aa1e-f33b70fcf53d",
            "name": "Investigaciones Medicas IMOBA S.R.L.",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "43",
            "organizationId": "88881a6d-d60d-45f9-8d94-226144296ce1",
            "country": "Argentina"
          },
          {
            "id": "562e43c3-4e96-4484-86b4-844cda6d4cc8",
            "name": "CEDIC-Centro de Investigaciones Clinicas",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "44",
            "organizationId": "1054a7a8-3a6d-4145-bffa-880366c87c36",
            "country": "Argentina"
          },
          {
            "id": "bb9969d5-8592-434a-8b87-21d1839b1fbf",
            "name": "CEMEDIC",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "45",
            "organizationId": "16f3adb7-21c2-4fa4-85c2-2778de2efafc",
            "country": "Argentina"
          },
          {
            "id": "e4108c6d-64ec-460e-975c-f55de30521f8",
            "name": "Centro Medico Dr Laura Maffei",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "46",
            "organizationId": "b7eb447a-afde-4271-88c5-597edb8a862b",
            "country": "Argentina"
          },
          {
            "id": "7df14cc0-ea0c-4ef9-a9d7-43b11b466e99",
            "name": "Paratus Clinical Blacktown Clinic",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "47",
            "organizationId": "240b2ac9-3a36-4c25-99e6-81e175f14dd0",
            "country": "Australia"
          },
          {
            "id": "60e50eda-f52f-43a6-aa9e-d69b1e990bc0",
            "name": "Campbelltown Medical & Dental Centre",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "48",
            "organizationId": "90a92f11-a668-4368-ae1f-9108d92cfc62",
            "country": "Australia"
          },
          {
            "id": "eb58f36d-0b03-4cf1-9c73-a354a345e585",
            "name": "Paratus Clinical Kanwal Clinic",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "49",
            "organizationId": "a398663e-068a-43ac-9f04-da6012cebe2f",
            "country": "Australia"
          },
          {
            "id": "c2d9c170-de19-4535-afe9-bf0393c3a023",
            "name": "The AIM Centre",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "50",
            "organizationId": "e88c01dc-437e-4750-af87-9e154b1d2836",
            "country": "Australia"
          }
        ],
        "administrations": [
          {
            "id": "d82639b1-3260-45cd-9503-bf1173e80cb7",
            "name": "Administration of QW LY3298176",
            "description": "RouteOfAdministration.ORAL DosingFrequency.WEEKLY",
            "instanceType": "Administration",
            "route": {
              "id": "697ba8b2-cd5e-45e4-a9f6-4a7599b9a2cf",
              "code": "C38288",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "2024-09-27",
              "decode": "Oral",
              "instanceType": "Code"
            }
          },
          {
            "id": "2617e15b-459a-4ef8-aa4f-26c2a47e70f1",
            "name": "Administration of compare LY3298176",
            "description": "RouteOfAdministration.ORAL DosingFrequency.ONCE_DAILY",
            "instanceType": "Administration",
            "route": {
              "id": "b973cf61-bc74-4d98-81ee-90f5b98513a9",
              "code": "C38288",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "2024-09-27",
              "decode": "Oral",
              "instanceType": "Code"
            }
          },
          {
            "id": "3adea541-ab38-4aef-ba9a-d9872127ef53",
            "name": "Administration of LY3298176",
            "description": "RouteOfAdministration.SUBCUTANEOUS DosingFrequency.WEEKLY",
            "instanceType": "Administration",
            "route": {
              "id": "886eceba-f812-4f39-93fd-ae5cd0df64dd",
              "code": "C38288",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "2024-09-27",
              "decode": "SC",
              "instanceType": "Code"
            }
          },
          {
            "id": "a2039a1e-5f3d-46fb-af7e-efb0e310314e",
            "name": "Administration of Insulin Glargine",
            "description": "RouteOfAdministration.SUBCUTANEOUS DosingFrequency.ONCE_DAILY",
            "instanceType": "Administration",
            "route": {
              "id": "f1fe2904-1efa-4fe4-9fac-38a8b01b6bf4",
              "code": "C38288",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "2024-09-27",
              "decode": "SC",
              "instanceType": "Code"
            }
          }
        ],
        "rationale": "Protocol version"
      }
    ],
    "name": "Efficacy and Safety of LY3298176 Once Weekly versus Insulin Glargine in Patients with Type 2 Diabetes and Increased Cardiovascular Risk (SURPASS-4)"
  },
  "administrations": [
    {
      "id": "bb3c4fcf-0dc2-4a22-b475-1725faaa9680",
      "name": "LY3298176 5 mg regimen",
      "instanceType": "Administration",
      "dose": "5 mg",
      "doseFrequency": "once weekly",
      "route": {
        "id": "53cbe313-b5d6-4917-8277-87e6f619ecc6",
        "code": "Subcutaneous",
        "codeSystem": "USDM",
        "codeSystemVersion": "2024-09-27",
        "decode": "Subcutaneous",
        "instanceType": "Code"
      },
      "duration": "Up to 104 weeks (titration starts at 2.5 mg for 4 weeks)"
    },
    {
      "id": "cb283838-ac3e-44c7-93fc-e3e7a18b71a3",
      "name": "LY3298176 10 mg regimen",
      "instanceType": "Administration",
      "dose": "10 mg",
      "doseFrequency": "once weekly",
      "route": {
        "id": "d4b74a8f-288d-4a63-a003-2d5fbae95181",
        "code": "Subcutaneous",
        "codeSystem": "USDM",
        "codeSystemVersion": "2024-09-27",
        "decode": "Subcutaneous",
        "instanceType": "Code"
      },
      "duration": "Up to 104 weeks (titrated 2.5 mg every 4 weeks)"
    },
    {
      "id": "1b92f65e-87fa-4aa7-976e-8bc012a0c521",
      "name": "LY3298176 15 mg regimen",
      "instanceType": "Administration",
      "dose": "15 mg",
      "doseFrequency": "once weekly",
      "route": {
        "id": "1563f9f8-5434-452f-85ec-edf9fc38e0e5",
        "code": "Subcutaneous",
        "codeSystem": "USDM",
        "codeSystemVersion": "2024-09-27",
        "decode": "Subcutaneous",
        "instanceType": "Code"
      },
      "duration": "Up to 104 weeks (titrated 2.5 mg every 4 weeks)"
    },
    {
      "id": "5a576fef-2621-48ff-a9f5-44fd24ea1f6e",
      "name": "Insulin glargine titration",
      "instanceType": "Administration",
      "dose": "Starting 10 IU/day, adjusted based on FBG",
      "doseFrequency": "once daily",
      "route": {
        "id": "475aca64-9128-4160-ab14-8493a9ffe87f",
        "code": "Subcutaneous",
        "codeSystem": "USDM",
        "codeSystemVersion": "2024-09-27",
        "decode": "Subcutaneous",
        "instanceType": "Code"
      },
      "duration": "Up to 104 weeks"
    }
  ],
  "substances": [
    {
      "id": "affa98fc-28e2-496d-b97a-60b8622d5629",
      "name": "LY3298176",
      "instanceType": "Substance",
      "description": "GIP and GLP-1 receptor agonist; tirzepatide"
    },
    {
      "id": "678104bf-d45e-4f54-895f-b436f6c9336b",
      "name": "Insulin glargine",
      "instanceType": "Substance",
      "description": "Long-acting basal insulin analogue"
    }
  ],
  "studyDefinitionDocument": {
    "id": "e3eb50f2-1746-4364-87ec-31e9ca41af15",
    "name": "Efficacy and Safety of LY3298176 Once Weekly versus Insulin Glargine in Patients with Type 2 Diabetes and Increased Cardiovascular Risk (SURPASS-4)",
    "documentType": "Protocol",
    "language": "en",
    "instanceType": "StudyDefinitionDocument",
    "version": "I8F-MC-GPGM(b)",
    "versionDate": "Not explicitly provided in text",
    "contentIds": [
      "95b4ca49-0b70-4077-8309-f5640ce50e27",
      "40686c50-2e7d-4310-be00-bd17d1e95258",
      "93e39a1a-8cea-44dc-a7c2-1ccba58c82cd",
      "85988114-70c6-4365-83c3-b46c8eba3e27",
      "874e14d0-72f4-4bb8-a1ef-97a14ee94f6a",
      "efdd26fb-c642-4609-b29f-a867e58a43bf",
      "14019373-8f22-4056-b3c1-992cb5c135d0",
      "632f84cb-9280-4ba9-bf7a-4b7009f30657",
      "ad032dea-63e4-4ca3-93dc-6c8676aacfc9",
      "87358456-5c66-42a8-be4a-414447420d33",
      "eeee66ec-b0c7-464e-9d32-f5d852531a87",
      "84cae3eb-bdcf-45c9-866c-b4fedc22c71e",
      "f322d5fa-304f-4c34-abf9-64e8cc2d2f33",
      "a7511da2-db8c-40cb-9d6d-8b0aee054edc",
      "5312fad4-9e2d-4ab6-87e9-4da6f843c3b5",
      "9a11f073-de9c-4d14-81dc-7198eb8f085e"
    ]
  },
  "geographicScope": {
    "id": "9190762f-b99e-49f0-b8d7-93f8229337b0",
    "name": "Study Geographic Scope",
    "scopeType": "Global",
    "instanceType": "GeographicScope"
  },
  "ingredients": [
    {
      "id": "e4497ad6-cad5-454a-896e-91fdb7b597fb",
      "name": "LY3298176",
      "role": "Active",
      "instanceType": "Ingredient",
      "substanceId": "Tirzepatide"
    },
    {
      "id": "d8292ddc-65c4-42fa-aef3-41b82b91bb19",
      "name": "Insulin Glargine",
      "role": "Active",
      "instanceType": "Ingredient",
      "substanceId": "Insulin Glargine"
    },
    {
      "id": "4e31f069-280c-4a55-8475-2a5d5d57adb1",
      "name": "Metformin",
      "role": "Active",
      "instanceType": "Ingredient",
      "substanceId": "Metformin"
    }
  ],
  "strengths": [
    {
      "id": "5222869a-9814-43d6-97b7-e4e935dcec6c",
      "instanceType": "Strength",
      "value": 2.5,
      "unit": "mg",
      "numerator": {
        "value": 2.5,
        "unit": "mg"
      },
      "denominator": {
        "value": 1,
        "unit": "dose"
      }
    },
    {
      "id": "fc389af6-faca-42e0-af59-6e3fdba72e47",
      "instanceType": "Strength",
      "value": 5,
      "unit": "mg",
      "numerator": {
        "value": 5,
        "unit": "mg"
      },
      "denominator": {
        "value": 1,
        "unit": "dose"
      }
    },
    {
      "id": "8a5ceb66-4c21-4eab-94bb-1b0752e2720e",
      "instanceType": "Strength",
      "value": 7.5,
      "unit": "mg",
      "numerator": {
        "value": 7.5,
        "unit": "mg"
      },
      "denominator": {
        "value": 1,
        "unit": "dose"
      }
    },
    {
      "id": "f806cbf1-c372-4803-8f7b-bded4d2ea233",
      "instanceType": "Strength",
      "value": 10,
      "unit": "mg",
      "numerator": {
        "value": 10,
        "unit": "mg"
      },
      "denominator": {
        "value": 1,
        "unit": "dose"
      }
    },
    {
      "id": "af0c3977-2a11-46e4-93b7-ccdb0e1c7e6b",
      "instanceType": "Strength",
      "value": 12.5,
      "unit": "mg",
      "numerator": {
        "value": 12.5,
        "unit": "mg"
      },
      "denominator": {
        "value": 1,
        "unit": "dose"
      }
    },
    {
      "id": "84610f97-2f4d-4fa9-9cdf-c6c168360edf",
      "instanceType": "Strength",
      "value": 15,
      "unit": "mg",
      "numerator": {
        "value": 15,
        "unit": "mg"
      },
      "denominator": {
        "value": 1,
        "unit": "dose"
      }
    },
    {
      "id": "670faade-7ed0-4531-9e15-718ce14e3e80",
      "instanceType": "Strength",
      "value": 10,
      "unit": "IU",
      "numerator": {
        "value": 10,
        "unit": "IU"
      },
      "denominator": {
        "value": 1,
        "unit": "day"
      }
    }
  ],
  "documentContentReferences": [
    {
      "id": "77212d33-76e7-49de-aa5b-cddac695f7ea",
      "name": "Schedule of Activities Reference",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "2",
      "sectionTitle": "Schedule of Activities",
      "description": "Reference to study procedures listed in the Schedule of Activities"
    },
    {
      "id": "5d1685a3-2a8e-4417-878d-e5f5c6c0d26d",
      "name": "Prohibited Medications Reference",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "7.7",
      "sectionTitle": "Concomitant Therapy",
      "description": "Reference to prohibited medications including GLP-1 receptor agonists and DPP-4 inhibitors"
    },
    {
      "id": "e907547e-45e4-483d-94e9-bce68d56223f",
      "name": "Pharmacokinetics Reference",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "9.5",
      "sectionTitle": "Pharmacokinetics",
      "description": "Reference to PK sample collection criteria"
    },
    {
      "id": "bba529ba-5bae-42ff-bae0-e2736b40d6e9",
      "name": "Rescue Therapy Thresholds Reference",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "7.2.1.2",
      "sectionTitle": "Insulin Glargine",
      "description": "Reference to prespecified thresholds for severe, persistent hyperglycemia"
    },
    {
      "id": "ffba3f00-7276-4fdc-bc0e-feaa76710add",
      "name": "Hyperglycemia Management Reference",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "9.2.2.2",
      "sectionTitle": "Severe, Persistent Hyperglycemia",
      "description": "Reference to rescue therapy and hyperglycemia management"
    },
    {
      "id": "71f6c54a-475a-402a-b858-478726f7f79e",
      "name": "Study Governance Reference",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "Appendix 3",
      "sectionTitle": "Study Governance Considerations",
      "description": "Reference to detailed study governance considerations"
    },
    {
      "id": "6487bdbb-cef4-4544-b9b5-c5b7a47145ca",
      "name": "Hypoglycemia Management Reference",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "9.2.2.1",
      "sectionTitle": "Hypoglycemia",
      "description": "Reference for further information on hypoglycemia management"
    },
    {
      "id": "bdf61b2b-f89a-4126-8512-33b323fdd82e",
      "name": "Hepatic Monitoring Reference",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "9.4.5.1",
      "sectionTitle": "Hepatic Safety Monitoring",
      "description": "Reference to hepatic monitoring protocols"
    },
    {
      "id": "12ac2f7d-29e7-423d-b7c3-c7603b29f201",
      "name": "Hepatic Monitoring Appendix Reference",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "Appendix 4",
      "sectionTitle": "Hepatic Monitoring Tests for Treatment-Emergent Abnormality",
      "description": "Reference to hepatic monitoring tests appendix"
    },
    {
      "id": "d043b029-5fd6-4335-b7f1-d31823c50566",
      "name": "GI Management Reference",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "7.7.1",
      "sectionTitle": "Management of Patients with Gastrointestinal Symptoms",
      "description": "Reference for detailed information concerning the management of GI AEs"
    },
    {
      "id": "23dd3afb-ffbf-49a8-95e6-c7bf4573cb73",
      "name": "COVID-19 Instructions Reference",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "Appendix 8",
      "sectionTitle": "Changes to Study Procedures due to the COVID-19 Pandemic",
      "description": "Reference for additional instructions for patients affected by COVID-19"
    }
  ],
  "commentAnnotations": [
    {
      "id": "e19997c4-4e7f-442e-a68b-b77f581949fb",
      "text": "This document may contain protected personal data and/or commercially confidential information exempt from public disclosure.",
      "annotationType": "Note",
      "instanceType": "CommentAnnotation",
      "sourceSection": "Confidential Information",
      "pageNumber": 2
    },
    {
      "id": "e224090c-9fd1-45bc-904a-3253f4ffd619",
      "text": "In the United States, this document is subject to Freedom of Information Act (FOIA) Exemption 4.",
      "annotationType": "Note",
      "instanceType": "CommentAnnotation",
      "sourceSection": "Confidential Information",
      "pageNumber": 2
    },
    {
      "id": "d25c9cc5-c4da-43ca-8f5f-971e20f56f37",
      "text": "56 mg/dL",
      "annotationType": "Clarification",
      "instanceType": "CommentAnnotation",
      "sourceSection": "7.4.2",
      "pageNumber": 43
    }
  ],
  "studyDefinitionDocumentVersions": [
    {
      "id": "1efe4527-1439-44e5-afa3-4bf1aa620f79",
      "versionNumber": "Initial",
      "status": "Approved",
      "instanceType": "StudyDefinitionDocumentVersion",
      "versionDate": "2018-07-18",
      "description": "Protocol Electronically Signed and Approved by Lilly",
      "amendmentNumber": "Original"
    },
    {
      "id": "934dfb89-545b-44fd-b407-21945914c344",
      "versionNumber": "Amendment (a)",
      "status": "Approved",
      "instanceType": "StudyDefinitionDocumentVersion",
      "versionDate": "2018-09-28",
      "description": "Amendment (a) Electronically Signed and Approved by Lilly",
      "amendmentNumber": "a"
    },
    {
      "id": "a42a818e-4ac7-4c41-821d-67bc64342bbb",
      "versionNumber": "Amendment (b)",
      "status": "Approved",
      "instanceType": "StudyDefinitionDocumentVersion",
      "versionDate": "2020-07-10",
      "description": "Amendment (b) incorporating changes up to July 2020",
      "amendmentNumber": "b"
    }
  ],
  "studyAmendmentImpacts": [
    {
      "id": "2a845e77-9597-4b94-a924-da06967c9b28",
      "amendmentId": "5e5707b1-7b45-4f2d-a6f3-5e27ac3d59d7",
      "affectedSection": "Protocol Header",
      "impactLevel": "Administrative",
      "instanceType": "StudyAmendmentImpact",
      "description": "Updated protocol version from (a) to (b) and revised approval date."
    },
    {
      "id": "b779088b-6e03-4739-81e4-9f81655ff48d",
      "amendmentId": "5e5707b1-7b45-4f2d-a6f3-5e27ac3d59d7",
      "affectedSection": "Section 1 - Synopsis",
      "impactLevel": "Minor",
      "instanceType": "StudyAmendmentImpact",
      "description": "Updated synopsis to reflect changes in study design and endpoints consistent with the full protocol body."
    }
  ],
  "studyAmendmentReasons": [
    {
      "id": "65185e18-43e5-415b-ab84-9ee4002174eb",
      "amendmentId": "5e5707b1-7b45-4f2d-a6f3-5e27ac3d59d7",
      "reasonText": "Implementation of Amendment (b) to update study procedures and administrative details.",
      "category": "Administrative",
      "isPrimary": true,
      "instanceType": "StudyAmendmentReason"
    }
  ],
  "studyChanges": [
    {
      "id": "66defbdc-138d-4544-b47d-c423efda3cf7",
      "amendmentId": "5e5707b1-7b45-4f2d-a6f3-5e27ac3d59d7",
      "changeType": "Modification",
      "instanceType": "StudyChange",
      "sectionNumber": "Title Page",
      "beforeText": "Protocol I8F-MC-GPGM (a)",
      "afterText": "Protocol I8F-MC-GPGM (b)",
      "summary": "Updated protocol version identifier."
    },
    {
      "id": "1d3a2d9c-cdb6-4ca0-ac3d-75adc97b5383",
      "amendmentId": "5e5707b1-7b45-4f2d-a6f3-5e27ac3d59d7",
      "changeType": "Modification",
      "instanceType": "StudyChange",
      "sectionNumber": "Title Page",
      "beforeText": "28 Sep 2018",
      "afterText": "10-Jul-2020",
      "summary": "Updated approval date for Amendment (b)."
    },
    {
      "id": "fa91ef34-5ba3-445a-bc4a-7df79ea29b94",
      "amendmentId": "5e5707b1-7b45-4f2d-a6f3-5e27ac3d59d7",
      "changeType": "Modification",
      "instanceType": "StudyChange",
      "sectionNumber": "Table of Contents",
      "beforeText": "I8F-MC-GPGM(a) Clinical Protocol",
      "afterText": "I8F-MC-GPGM(b) Clinical Protocol",
      "summary": "Updated header reference to the current amendment version."
    }
  ],
  "computationalExecution": {
    "ready": true,
    "supportedSystems": [
      "EDC",
      "ePRO",
      "CTMS",
      "RTSM"
    ],
    "validationStatus": "complete"
  }
}